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Abstract 
Introduction 
Chronic HIV-1 infection is driven by inflammation and immune activation which ultimately 
induces T lymphocyte exhaustion. Co-infection with TB is problematic as the HIV-impaired 
immune system is unable to effectively contain the TB, and in turn the TB disease promotes 
further immune activation and exhaustion through additional antigenic burden.  
In the current two component study, a total of 101 HIV-1 infected, 25 HIV-1-TB co-infected 
and 52 uninfected control individuals were included from the Cape Town peri-urban region.   
A cross sectional investigation of expression of markers of immune activation (CD38 and 
HLA-DR), exhaustion/inhibition (PD-1, Tim-3, LAG-3, 2B4) and apoptosis (CD95) was 
investigated on both CD4+ and CD8+ T cells. Functional proliferative responsiveness of T 
cells was also assessed.  
Materials and Methods 
Flow cytometry (both 4–colour and 10-colour) was used to determine expression of 
phenotypic markers using both fresh whole blood (pilot study) and PBMC (main study). CD4+ 
and CD8+ T lymphocyte populations of all study groups were stained for all the markers and 
evaluated for positive expression or co-expression.  
A functional proliferation assay (αCD3 and αCD28 stimulation) was conducted using CFSE-
staining on the HIV-1+ samples. Impact of blocking Tim-3 and PD-1 pathways was 
evaluated.   
Results 
Chronic HIV-1 infection was accompanied by a significant increase in CD38 (p<0.0001), 
CD95 (p<0.01), PD-1 (p<0.01) and Tim-3 (p<0.01) expression on CD8+ T cells (pilot study). 
TB co-infection led to significantly elevated expression of CD38, CD95 and Tim-3, but not 
PD-1 (all p<0.05). CD4+ T cells displayed decreased expression of all of these markers in 
the infected groups, except for Tim-3, which was consistently <5%. 
In the main study CD8+ T cell-associated CD38, CD95, and PD-1 displayed a similar trend, 
with significant higher expression in the infected groups (p<0.0001, p<0.05, and p<0.0001, 
respectively), In contrast to the pilot study, Tim-3 expression was consistently <10%, with no 
difference between the groups. The novel marker 2B4 showed high level baseline 
expression (median 59.2%) which was significantly increased in the HIV and HIV/TB groups 
(69.6% and 75.1% respectively, p=0.025). LAG-3 was poorly expressed. Co-expression of 
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PD-1 and 2B4 as well as CD95 and CD38 was also significantly increased (p<0.0001 for 
both). 
Discussion 
Increased immune activation and exhaustion was evident in the infected groups in both 
studies. PD-1 and 2B4 were both strongly expressed on CD8+ T cells and were significantly 
up-regulated in infected groups. PD-1 correlated positively with Tim-3 and LAG-3, and 2B4 
with LAG-3, (both p<0.01) indicating that they are useful as biomarkers of exhaustion.  
Although significantly elevated exhaustion markers were observed in the TB co-infected 
setting in the pilot study, this did not reflect in the main study (except for CD95, 2B4). This 
suggests that immune dysfunction is mainly driven by HIV-1 infection alone. Short-term anti-
TB therapy may also have had a restorative impact on the exhaustive marker expression. 
Differences in expression patterns using fresh whole blood vs. PBMC (especially Tim-3) 
warrant further investigation. Blocking Tim-3 and PD-1 expression on CD4+ and CD8+ T cells 
did not appear to have beneficial effects on T cell proliferation.  
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Opsomming  
Inleiding 
Kroniese MIV-1 infeksie word gedryf deur inflammasie en immuun-aktivering wat lei tot T 
limfosiet uitputting. Mede-infeksie met TB  is veral problematies omdat die immuunstelsel nie 
die infeksie kan oorkom nie, wat lei tot die verdere aftakeling van die immuun stelsel.  
Tydens die tweeledige studie ‘n totaal van 178 individue was ondersoek wat bestaan het uit 
die volgende: 101 MIV-1 positiewe individue, 25 MIV-1-TB mede-geïnfekteerde individue en 
52 kontrole individue. Individue wat deel gevorm het van die studie groep was afkomstig van 
Kaapstad se buitestedelike areas. Die studie het die uitdrukking van merkers van immuun- 
aktivering (CD38 en HLA-DR), onderdrukking/uitputting (PD-1, Tim-3, LAG-3, 2B4) en 
seldood (CD95) ondersoek op CD 4+ en CD8+ selle. Die proliferatiewe reaksie van T selle 
was ook geassesseer.  
Materiale en Metodes 
Vloeisitometrie (4-kleur en 10-kleur) was gebruik om die uitdrukking van fenotipiese merkers 
te ondersoek in beide vars heelbloed en PBMS. CD4+ en CD8+ T limfosiet populasies was 
ondersoek deur immuun merkers te kleur en daarna te evalueer vir positiewe uitdrukking of 
ko-uitdrukking.  
‘n Funksionele proliferasie toets (αCD3 en αCD28 stimulasie) was uitgevoer op die HIV-1+ 
monsters deur middel van CFSE-kleuring. Die impak van Tim-3 en PD-1 paaie was 
geëvalueer.  
Resultate 
Kroniese MIV-1 infeksie het gepaard gegaan met ‘n verhoogde- CD38 (p<0.0001), CD95 
(p<0.01), PD-1 (p<0.01) en Tim-3 (p<0.01) uitdrukking op CD8+ T selle. TB mede-infeksie 
het gelei tot ‘n verhoogde uitdrukking van CD38, CD95 en Tim-3, maar nie PD-1 (p<0.05) 
nie. CD4+ T selle in geïnfekteerde groepe het ‘n verlaagde uitdrukking van alle immuun-
merkers getoon, behalwe vir Tim-3 (<5%).  
Die hoof studie het bevind at CD8+ T sel-geassosieerde CD38, CD95, en PD-1 ‘n 
soortgelyke patroon vertoon het, met verhoogde uitdrukking in geïnfekteerde groepe 
(p<0.0001, p<0.05, en p<0.0001, onderskeidelik). In kontras met die loodsstudie was 
uitdrukking van Tim-3 konstant <10%, met geen verskille tussen studie groepe.  
Die nuwe merker 2B4 het ‘n verhoogde basislyn uitdrukking getoon (mediaan 59.2%) wat 
beduidend verhoog was in die HIV-1+ en HIV-TB groepe (69.6% en 75.1% onderskeidelik, 
p=0.025). LAG-3 was swak uitgedruk. Ko-uitdrukking van PD-1 en 2B4 sowel as CD95 en 
CD38 was beduidend verhoog (p<0.0001). 
Bespreking 
Verhoogde immuun-aktivering en uitputting was opmerklik in geïnfekteerde groepe in beide 
studies. PD-1 en 2B4 was albei sterk uitgedruk op CD8+ T selle en was beduidend 
opgereguleer in geïnfekteerde groepe. PD-1 is positief gekorreleer met Tim-3 en LAG-3, en 
2B4 met LAG-3, (beide p<0.01), wat toon dat hul gebruik kan word as biomerkers van 
uitputting.  
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Alhoewel uitputting merkers beduidend verhoog was in die TB ko-geinfekteerde individue in 
die loodsstudie, was dit nie gereflekteer in die hoof studie nie (behalwe vir CD95 en 2B4). Dit 
kan ‘n indikasie wees dat immuunstelsel aftakeling gedryf word deur MIV-1 infeksie. 
Korttermyn anti-TB medikasie mag ook ‘n restoratiewe impak tot gevolg gehad het. Verskille 
in die uitdrukking van merkers tussen vars bloed en PBMS dui daarop dat verdere navorsing 
benodig word. Onderdrukking van  Tim-3 en PD-1 uitdrukking op CD4+ en CD8+ T selle het 
geen voordelige effek gehad op T sel proliferering nie. 
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CHAPTER 1: INTRODUCTION 
The human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) 
epidemic has had a global impact on millions of lives worldwide since the early 1980s when 
the first official reports appeared. Over 30 years later, the disease has spread to all countries 
in the world and has had devastating implications on human health, social wellbeing and 
economic resources (Mayosi and Benatar, 2014). The virus targets CD4+ T lymphocytes (or 
T cells) weakening the human immune system against infection. Currently there is neither a 
vaccine nor a cure (Sharp and Hahn, 2011; Shapiro 2013; Walker et al., 2013; Levy et al., 
2014; Liu et al., 2015). It is estimated that 36.9 million people globally are living with HIV-1 
and that 25.3 million people have died due to AIDS related diseases since 2000. This 
number of AIDS related deaths has decreased by 42% with 1.2 million recorded deaths in 
2014 compared to 2 million deaths in 2005 (UNAIDS, 2015). It is encouraging that the 
number of new infections globally has decreased by 35% since 2000. Furthermore, the 
number of children newly infected worldwide has also decreased by 58% between 2000 and 
2014. These numbers equate to 220 000 children newly infected in 2014, compared to 
520 000 children newly infected in 2000 (UNAIDS, 2015).  
The burden of HIV-1 is amplified by co-infection with tuberculosis (TB). TB is the number 
one cause of death in people with HIV-1/AIDS. At present, one in three people worldwide are 
infected with the bacillus, which remains dormant (latent), and kept under control primarily by 
the CD4+ T helper (Th) lymphocytes cells (Valadas and Antunes, 2005). Once the immune 
system is compromised (such as in HIV-1), it often fails to contain TB, and the disease 
transforms into a state of active disease. The target cell for HIV-1 is also the primary effector 
cell for control of TB.    
Together, HIV-1 and TB drive the immune system to exhaustion and collapse by the on-
going increased levels of immune activation and immune cell dysfunction. Simultaneously, 
these two diseases constitute the main burden of infectious diseases in the developing 
world. Estimates by the World Health Organization (WHO) indicate that there are more than 
nine million new cases of TB every year, which leads to over two million deaths per year. 
Consequently, HIV-1/TB co-infection presents particular diagnostic and therapeutic 
challenges, which burden healthcare systems in developing countries within Africa and 
elsewhere, due to the large number of individuals in need of basic treatment.  
As T cells are the target cells for the virus, and also the effector cells for control, the main 
focus of this study will be the analysis of T cell phenotype in three main groups, namely: an 
HIV-1 positive group; an HIV-1/TB co-infected group, and a healthy HIV-1 uninfected control 
group. T cell markers of activation (CD38 and HLA-DR), exhaustion (PD-1, Tim-3, 2B4 and 
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LAG-3) and apoptosis (Fas) were analysed.  An initial pilot study focused on Tim-3, PD-1, 
CD38 and Fas expression and was analysed by 4-colour flow cytometry (Becton Dicksinson 
FACS Calibur, USA). The subsequent main study expanded the marker repertoire to include 
2B4, LAG-3 and HLA-DR, analysis was performed using a 10-colour Beckman Coulter 
Navios instrument. 
The literature includes extensive reports that markers of T cell activation, such as HLA-DR 
and CD38 on CD8+ T cells, are reliable markers of disease progression in chronic HIV 
infection. More recently, it has been shown that T cell exhaustion occurs in chronic infection, 
most clearly demonstrated by Programmed Death-1 (PD-1) expression on CD8+ T cells. 
According to the literature, blocking of PD-1 has shown encouraging results in improving T 
cell effector function in exhausted T cell phenotypes in several disease settings, including 
chronic HIV. In the current study, (αCD3 and αCD28 induced proliferation assays) T cells 
were monitored by CFSE staining and binary dilution. The PD-1 and Tim-3 inhibitory 
pathways were blocked using functional monoclonal antibodies, in an attempt to ascertain 
whether blocking the expression of these markers did in fact restore proliferation ability in 
both CD4+ and CD8+ T cells. 
The primary aim of this current study was to CD4+ and CD9+ T cell phenotypes with respect 
to activation and inhibition marker expressed in chronic HIV-1 infection with or without co-
infection.  In particular, the relative expression of the well-described PD-1 and Tim-3 markers 
compared to the newer less well described 2B4 and LAG-3 was undertaken. The study 
evaluated the relationship of these markers to standard clinical markers (CD4 count, viral 
load), and to T cell markers of activation and cell death (CD38, HLA-DR and Fas). The final 
component of the study was to ascertain whether function could be restored to “exhausted T 
cells” by blocking PD-1 and Tim-3. This approach could prove beneficial in new treatment 
strategies, as excessive immune activation is known to drive T cells to an exhaustive state 
which accelerates disease progression (Kuchroo et al., 2014).  
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CHAPTER 2 LITERATURE REVIEW 
2.1 HIV epidemic: Eastern and Sub Saharan Africa 
Approximately 1% of the global population is living in Sub Saharan Africa (SSA)1, which is 
home to about 17-20% of the HIV/AIDS burden (Delva and Karim 2014; Mayosi and 
Benatar, 2014). When looking at the possibility of an AIDS-free SSA, the transmission rate 
between sexually active persons is of concern; in 2012 UNAIDS found that a staggering 74% 
of men and 58% of women had never been tested for HIV (UNIADS, 2015). When 
comparing HIV-1 incidence rates in Swaziland, individuals aged 18-19 years were most 
affected. Girls in this age group had an overall prevalence of 14.3% when compared to 0.8% 
for boys (Delva and Karim, 2014). Currently 13 000 Kenyan children become infected with 
HIV-1 every year, and a further 100 000 children die before the age of five due to the virus 
(UNAIDS, 2015). According to the 2015 UNAIDS report for Eastern and Southern Africa 
(ESA2), there was a remarkable increase in the number of HIV-1 positive pregnant women 
on antiretroviral therapy (ART) with approximately 78% in ESA. This resulted in a 50% 
decrease in the number of babies born with HIV-1 by the end of 2013. Furthermore, in 
Ethiopia, mother to child transmission (MTCT) has decreased significantly by 57% between 
2009 and 2013 (UNAIDS, 2015). Of those children who were infected at birth, Botswana 
appeared to have the highest number of children on treatment with 80% ART coverage, 
followed by South Africa, Namibia, Rwanda and Swaziland with 46% in 2013 collectively. It is 
estimated that approximately 2 million children in ESA are currently HIV-1 positive (UNAIDS, 2015). 
 
Figure 2. 1 Adults and children estimated to be living with HIV-1 globally in 2014. Adults and 
children estimated to be living with HIV-1 globally in 2014. SSA has the highest HIV burden in the 
world, with approximately 25.8 million people currently infected (UNAIDS, 2015). 
 
                                                          
1
 Swaziland, Lesotho, Botswana, South Africa, Zimbabwe, Namibia, Zambia, Mozambique, Angola and Malawi. 
2
 Angola, Botswana, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, South Africa, Swaziland, 
Uganda, Tanzania, Zambia and Zambabwe. 
Stellenbosch University  https://scholar.sun.ac.za
4 | P a g e   
 
  
South Africa alone accounts for more than 6.1 million people living with HIV/AIDS and only 
2.1 million of these people have access to ART (Delva and Karim, 2014; Mayosi and 
Benatar, 2014). There has been great improvement in life expectancy and morbidity in 
people who do have access to ART. UNAIDS (2015) global statistics indicate that 35 million 
people worldwide are infected with HIV-1. SSA is the worst affected with approximately 25.8 
million people infected with the virus (Figure 2.1). 
2.1.1 HIV-1 epidemic: South Africa 
South Africa has a population of 54.96 million according to the mid-year population 
estimates for 2015. It has the highest prevalence of HIV-1 compared to the rest of the world, 
with approximately 6.19 million people living with HIV-1 and a prevalence rate of 16.6% 
reported in the 15-49 years age group in 2015. The overall HIV-1 prevalence rate is currently 
11.2%. Although deaths, as a result of AIDS have decreased from 44.6% in 2002 to 30.5% 
in 2015 (Statistics South Africa, 2015), the UNAIDS reported the number of AIDS orphans to 
be 230 0000 with an additional 340 000 children (0-14 aged) living with HIV-1 in 2014 
(UNAIDS, 2015).    
The South African HIV-1 prevalence is higher than other countries which  could be a result of 
many factors including: poverty, the high prevalence of sexually transmitted infections (STI), 
sexual abuse of women, limited access to primary health care and education (Mayosi and 
Benatar, 2014; UNAIDS, 2015; Statistics South Africa, 2015). Women between the ages of 
15-19 years have a three times higher risk of HIV-1 infection compared to men (Fatti et al., 
2014; UNAIDS, 2015). Approximately 1 in 5 young South African female adults will contract 
HIV-1 during their reproductive years. Young adults aged between 15-24 years had a 
prevalence rate of 5.59% in 2015, which shows a 1.16% decrease since 2002. However, the 
2015 prevalence rate of 16.59% in the age group 15-49 years, has increased by 2.09% 
since 2002 (Statistics South Africa, 2015).  
The province with the highest prevalence of HIV-1 is KwaZulu-Natal (KZN) where 27.6% of 
individuals aged 15-49 years are currently infected (Figure 2.2). The Western Cape with a 
prevalence of only 9.2%, which is three times lower than KZN, is the province with the 
overall lowest prevalence (Delva and Karim, 2014). Globally, South Africa has the highest 
incidence of childhood infections via MTCT with approximately 280 000 HIV-1 positive 
pregnant women (Fatti et al., 2014).  
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Figure 2. 2 The percentage of people residing in each South African province 2015. (B) South African 
2012 HIV prevalence per province for the age group 15-49 years. (A) The percentage of people residing in 
each South African province 2015. (B) South African 2012 HIV prevalence per province for the age group 15-49 
years. Gauteng province is an urban area representing 13 million (23.9%) of the total South African population 
with an HIV-1 prevalence of 16.5% (HSRC, 2012). KwaZulu Natal province is a rural area representing 10 million 
(19.8%) of the total South African population (Statistics South Africa, 2015) with an HIV prevalence of 27.6% 
(HSRC, 2012). The Western Cape has a population of 6 million (Statistics South Africa, 2015) and an HIV 
prevalence of 9.2% (HSRC, 2012 HIV Report). Overall prevalence for South Africa is 11.2% (Statistics South 
Africa, 2015).  
KZN= Kwazulu Natal; MP= Mpumalanga; FS= Free State; EC= Eastern Cape; NW= North West; GP= Gauteng; LP= Limpopo; 
NC= Northern Cape; WC= Western Cape 
 
11.3% 
2.2% 
12.6% 
5.2% 
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2.1.2 Antiretroviral Therapy globally and in South Africa  
Access to ART by those living with HIV-1 has increased from 13.6 million in 2014, to 15 
million in 2015 globally (UNAIDS, 2015). While SSA is receiving a high portion of the global 
ART supplies, many more individuals are still waiting for treatment as shown in Figure 2.3. 
The number of adults living with HIV-1 who had access to treatment was 41% in 2014 
compared to 23% in 2010. Similarly, the number of children who had access to treatment in 
2014 was 32% compared to 14% in 2010. Finally in 2014, approximately 73% of all HIV-1 
positive pregnant women had access to treatment globally (UNAIDS, 2015). 
 
Figure 2.3 The number of people receiving ART globally in 2013. SSA had the highest number of people 
receiving ART.  However, these only accounts for approximately 37% of all individuals infected with HIV/AIDS on 
the African region (WHO, 2015). 
The South African government introduced the ART Rollout Programme in 2003 with the help 
of international agencies for funding and support (HIV/AIDS Care & Treatment, 2015). Since 
then, more than two million people have been receiving ART, and as a result there has been 
a drastic decrease in the morbidity and mortality figures (Delva and Karim, 2014). However, 
mortality is higher in the first three months of treatment due to: drug toxicity, added disease 
burden complications, such as pre-existing diseases, malnutrition, low CD4 count, severely 
low haemoglobin and advanced HIV-1 disease (WHO, 2015). Furthermore, according to a 
study by Boulle et al., (2014), mortality while on ART is higher in areas with limited 
resources. This would include areas with limited access to housing and sanitation, limited 
access to primary health care and areas with severe poverty. 
According to the World Health Organization (WHO) 2013 ART drug guidelines for adults, the 
first line drug treatment should consist of two nucleoside reverse-transcriptase inhibitors 
(NRTIs) as well as a non-nucleoside reverse-transcriptase inhibitor (NNRTI) for effective 
viral repression (Table 2.1). Second line drug treatments should include a ritonavir-boosted 
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protease inhibitor (PI) as well as a combination of the previous three drugs from the first line 
drug treatment.  
Table 2. 1 South African Antiretroviral Therapy Guidelines Standardised National ART Regimens 
for Adults and Adolescents 2013 
First line ART regimens 
 
Second line ART regimens  Third line ART regimens 
TDF* 3TC (or FTC)* EFV* AZT 3TC (or FTC) RAL 
DRV 
ETV 
AZT 3TC EVP (or NVP) TDF 3TC (or FTC) 
D4t 3TC EVP (or NVP)   
TDF 3TC (or FTC) NVP  
*Preferred first line ART regimen  
TDF= Tenofovir (NRTI), AZT= Zidovudine (NRTI), NVP= nevirapine (NNRTI), ETV = Etravirine (NNRTI), DRV= 
Darunavir (PI), RAL= Raltegravir (InSTI), 3TC= Lamivudine (NRTI), EFV=Efavirenz (NNRTI), D4T= Stavudine 
(NRTI), FTC=Emtricitabine (NRTI), EVP= Emtricitabine
+
rilpivirine
+
tenofovir (fixed dose combination) (WHO, 
2015).  
In South Africa, when a person is eligible to start ART, the initial regimen from 2003 until 
2004 was zidovudine (ZDV) and lamivudine (3TC), together with either nevirapine (NVP) or 
efavirenz (EFV). Stavudine (d4T) replaced ZDV due to high toxicity in the standard first-line 
regimen in 2004, as stated in the South African national guidelines (Department of Health 
SA, 2014). This regimen was further changed in 2013 to the current preferred first-line 
therapy of tenofovir (TDF), 3TC or emtricitabine (FTC) in combination with EFV. If first line 
therapy fails due to the inability of the drugs to repress viral replication, second line therapy 
would be implemented, which consists of a revised combination of drugs depending on the 
type of resistance to a given first line drug (WHO, 2015). Furthermore, an earlier study by 
Boulle et al., (2010), reported that many people who had been moved to the second-line 
regimen might not have been completely adherent to their first-line regimen. In order to 
move onto second-line ART, the patient’s plasma HIV-1 RNA load must be greater than 
1 000 copies/ml (WHO, 2015). When individuals move onto second-line regimens 
prematurely, it becomes problematic as more drugs are required to be administered, which 
is expensive, complex dosing schedules are required, and the issue of further drug 
resistance becomes apparent. 
While ART prolongs life, it does not fully restore the immune system, in turn leading to 
immune exhaustion as the virus is still able to replicate at a decreased rate. Immune 
activation can continue, leading to immune exhaustion and resulting in the development of 
certain chronic conditions, such as cardiovascular disease. Furthermore, long-term therapy 
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is also associated with drug toxicities, resulting in renal impairment and other complications 
when compared to the general population (Cockerham et al., 2014). 
The current study examined the impact of TB co-infection on immune function in chronic 
HIV-1 infection. For this reason a brief background to the TB epidemic is presented below. 
2.2 TB epidemic world statistics 
According to the WHO, one third of the world’s population is infected with TB and it is the 
second leading cause of death by an infectious disease worldwide (WHO, 2015). The report 
emphasizes the profound impact of TB worldwide with 9 million new active TB cases being 
reported in 2013 and between 1.4 million and 1.5 million TB deaths. Of the 9 million new TB 
cases, 1.1 million (12%) were HIV-1 positive, while 1.1 million of the reported TB deaths 
(73%) were among HIV-1 negative patients and 0.4 million (27%) HIV-TB co-infected 
patients. In 2013, women infected with TB accounted for 3.3 million new and current 
infections with 510 000 deaths, respectively. Similarly, children in the same year accounted 
for approximately 550 000 current infections and 80 000 TB deaths worldwide. While TB is 
still a major global health concern more so in the developing worlds, the total deaths due to 
TB infection have declined greatly (by 45%) since 1990. Furthermore, the number of newly 
infected people worldwide has also declined by 1.5% per year. It has also been estimated 
that the number of lives saved between 2000 and 2013 is in the area of 37 million, which can 
be attributed to medical advances in timely TB detection and adherence to TB treatment 
programs (Claassens et al., 2012; WHO, 2015). However, despite progress, TB still remains 
the leading cause of death for those persons co-infected with HIV-1 (Sullivan et al., 2015). 
It appears that Asia is most highly burdened by the worldwide TB epidemic with 56% of all 
cases recorded globally in 2013. The SSA/African region accounts for 29%, of all TB cases 
followed by the Eastern Mediterranean with 8%, Europe with 4% and the American region 
with 3% (WHO, 2015). The WHO listed the top 10 counties in order of TB burden as: India, 
China, Nigeria, Pakistan, Indonesia, South Africa, Bangladesh, Philippines, Democratic 
Republic of the Congo and finally Ethiopia. 
2.2.1 TB epidemic in South Africa 
According to 2014 global statistics, South Africa has one of the highest TB burdens in the 
world. This can be causally linked to weakened immunity in those with HIV-1, predisposing 
individuals to reactivation of latent TB, followed by a more rapid course with more severe 
disease manifestations. There has been a significant increase in the number of multidrug-
resistant-TB (MDR TB) and extensively drug-resistant TB (XDR TB) cases in recent years in 
the region (Mayosi and Benatar, 2014). In South Africa, TB is responsible for 11% of all 
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recorded deaths (Osman et al., 2015). Osman et al. (2015) used the ETR.net TB database 
in a retrospective study and found that HIV-1 positive individuals between the ages 15-24 
years old were almost 5 times more likely to die from TB than those without HIV-1 due to 
failing immune systems. Cape Town has a TB treatment rate of 83% and the number of TB 
cases has greatly decreased from 8.7% in 2009 to 6.6% in 2013. In high burden areas of TB 
and HIV-1 infection, the risk of death while on treatment was most often due to malnutrition 
and advanced immune suppression; whereas in areas with low TB and HIV-1 disease, the 
risk factors included increased age, excessive alcohol use, IV drug use and homelessness.  
A brief historical background to both diseases will be presented prior to discussing HIV-1 
pathogenesis and immune response in more detail.  
 History of HIV  2.3
HIV-1 was initially called lymphadenopathy-associated virus (LAV) or human T-cell 
lymphotropic virus III (HTLV-3) (Knipe and Howley, 2013). Despite only first being 
recognized in the early 1980s, subsequent studies date the HIV-1 epidemic to a much earlier 
time point. The origin of HIV-1 is via cross species spread from African primates infected 
with simian immunodeficiency virus (SIV). These primates were naturally infected with SIV 
across multiple species where the virus had limited negative effects on the immune system 
and impact on health, while in other species, such as the chimpanzees; the disease 
appeared to display similar immune dysfunction as that of HIV-1 in humans. HIV-1 and HIV-
2 are both lentiviruses and result from the zoonotic transfer between multiple primate 
species to humans (Sharp and Hahn, 2011). It is believed that transmission of SIVcpz from 
chimpanzees in south eastern Cameroon to humans gave rise to HIV-1 group M (major), 
which is regarded as the principal cause of the HIV-1 pandemic (Sharp and Hahn, 2011). 
The time when humans first became infected with HIV-1 is unclear; however, records from 
Bioko Island dates monkeys infected with SIV back to at least 30 000 years ago (Worobey et 
al., 2010). HIV-1, group M is the lineage of the virus which is responsible for the AIDS 
epidemic. Besides group M, groups N, O and P have also been described, but only infect a 
small percentage of the world’s population (Mauclere et al., 1997).         
Stellenbosch University  https://scholar.sun.ac.za
10 | P a g e   
 
  
 
Figure 2.4 Transmission of HIV from African monkeys to humans. HIV-1 is believed to have been 
transferred to humans by the Chimpanzee and the Western Gorilla. HIV-2 is believed to be 
transmitted to humans from the Sooty mangabey (Sharp and Hahn, 2011).  
Phylogenetic analysis and statistical modelling has estimated that HIV-1 group M entered 
the human domain between 1910 and 1930 (Korber et al., 2000; Worobey et al., 2008). 
Molecular virologists believe that the virus went unnoticed in West-Central Africa for 
approximately 50-70 years spreading among the local people and travellers in the area of 
Kinshasa (Vidal et al., 2000). 
HIV-1 infection was first officially recorded in Los Angeles and San Francisco, USA, in 1981. 
A small group of young homosexual men displayed Pneumocystis carinii pneumonia, 
Kaposi’s’s sarcoma and failing immune systems followed by rapid death (Sharp and Hahn, 
2011; Masia et al., 2014). HIV-1 was initially believed to be a disease of the gay community. 
A year after the first description in 1982 the CDC named the disease AIDS, a universally 
accepted nomenclature which superseded the numerous earlier designations (AIDS, 2011).  
In 1984, Gallo, Montaigner and Levy were independently the first to confirm that the causal 
agent of AIDS was a virus (HIV-1) (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Levy et al., 
1985). In the same year, reports from the CDC confirmed that the virus is transmitted via 
sharing needles among the intravenous (IV) drug users, unprotected sex among all sexual 
orientations and via blood transfusions in the hospital setting (Sharp and Hahn, 2011). One 
year later in 1985, the virus had been confirmed to have spread to all continents of the world. 
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In 1986, the official name HIV-1 was given to the causative virus (A Timeline of HIV/AIDS, 
2015).   
 History of TB  2.4
As mentioned above, TB is the second leading cause of death from an infectious disease 
worldwide (Yang et al., 2013; Jiang et al., 2014; Yang et al., 2014). Evidence collected from 
Egyptian mummies suggested that TB has been plaguing humans for around 4 000 years. 
Once referred to as “white plague” or “consumption”, TB has caused one billion human 
deaths in the time spanning 1700 to 1900. Fortunately, in 1882, Robert Koch, a German 
scientist and physician, identified Mycobacterium tuberculosis (M.tb), which is the bacterium 
responsible for TB (Morris et al., 2013; Nunes-Alves et al., 2014; Stanley et al., 2014; 
Stylianou et al., 2014). Koch won the Nobel Prize in 1905 as a result of his research and 
discovery of tuberculosis. Since Koch’s discovery, three other scientists, Paul Ehrlich, 
Gerhard Domagk and Selman Walksman, have been awarded the Nobel Prize for their 
contribution towards compounds that are able to slow down or stop the growth of M.tb. The 
combination of these compounds, which include Isoniazid (INH), Rifampicin (RIF), 
Pyrazinamide (PZA), Ethambutol (EMB) and Streptomycin (STR), still forms the majority of 
the TB medication currently in use today (Department of Health SA, 2014). 
2.4.1 Diagnosing TB in South Africa 
The diagnosis of TB involves clinical examination and radiographic and/or 
mycobacteriological confirmation. A biological specimen (sputum) is obtained and analysed 
using a smear microscopy. Alternatively, M.tb is cultured (in broth or plates) or confirmed 
using molecular techniques (see below) (WHO, 2015). The smear methodology refers to two 
staining procedures for acid-fast bacilli, known as either Ziehl-Neelsen or fluorescent 
auramine staining. These tests depend on the ability of the bacterium to retain the dyes 
when treated with acid and alcohol solutions. This is a well-developed method of testing for 
TB in patients with pulmonary TB, and can be performed within 48 hours. However, this 
method is less sensitive in detecting TB in patients who have low bacillary load in sputum, 
such as those with HIV-1 co-infection (Department of Health SA, 2014). A more sensitive 
test would be the culture method of detecting TB, which is also able to detect TB in children 
and those infected with HIV-1 with smear negative pulmonary TB. However, this test is more 
expensive, prone to contamination, as the bacteria are grown on a plate or tube, and time 
consuming, as results take  up to 6 weeks to complete (Department of Health SA, 2014). 
Two of the most commonly used molecular techniques in the detection of TB, and the 
resistance to TB drugs in South Africa, is the Xpert MTB/RIF (Cepheid, CA, USA) and the 
line probe assay called Genotype MTBDRplus (Hain Lifesciences, Nehen, Germany). Both 
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these tests are polymerase chain reaction (PCR) techniques with the Xpert MTB/RIF testing 
for M.tb, as well as resistance to RIF, generating a result within two hours. The Xpert 
MTB/RIF is a preferred technique as each sample is tested in a closed cartridge system 
which minimises the risk of contamination and human error. Similarly, the line probe assay 
detects the presence of MDR-TB and TB drug resistance to RIF and INH which are two of 
the most powerful first-line TB drugs currently available in the world. While the line probe 
assay is effective in detecting TB and MDR-TB in seven days, it is labour intensive and is 
prone to human error, as this test requires three different rooms to carry out the entire 
experiment (Department of Health SA, 2014). The Quantiferon TB Goldtube test is a blood 
test, which is used to distinguish between latent and active disease. This test is an immune 
diagnostic test, which involves T cell stimulation and measures the amount of interferon 
(IFN)-ү production (Quest Diagnostics, NJ USA). Besides laboratory diagnostics; a clinical 
diagnosis of TB can be given via X-ray abnormalities and physical symptoms such as 
coughing for an extended period of time (longer than three weeks), past history of TB, 
sudden weight loss and night sweats (WHO, 2015). 
2.4.2 TB treatment 
Most healthy individuals who come in contact with M.tb effectively recover and control the 
bacteria for a lifetime. This is classified as latent TB (Stanley et al., 2014). In the event that a 
person has latent TB, the bacteria remain dormant and contained within granulomas. The 
granuloma consists of a collection of T cells, macrophages (MØ) and fibroblasts, which 
slowly replace themselves over time to maintain the entire structure (Walker et al., 2013; 
Nunes-Alves et al., 2014). These cells act as a wall-like structure in which the bacterium is 
unable to multiply. However, in 10% of cases, latent TB will go through a process of 
reactivation (Morris et al., 2013; Yang et al., 2013; Jiang et al., 2014; Yang et al., 2014). This 
occurs when the immune cells have become compromised due to autoimmune disease, 
organ transplant medications, or immuno-suppression due to HIV/AIDS. The T cells are 
unable to maintain the wall-like structure or to keep bacterial replication in check and the 
bacteria are able to break through the granuloma to actively replicate. Active TB disease is 
classified when the immune cells are unable to control M.tb. At this point, first-line 
chemotherapy will be administered. First-line defence against TB is conducted by the use of 
a combination of chemotherapy agents, typically RIF, INH, EMB and PZA, which are 
international standard treatments recommended by the WHO. These approved TB drugs 
have either bactericidal or bacteriostatic properties. Combination therapy reduces risk of 
drug resistance developing (UNAIDS, 2015). INH, RIF and PZA are bactericidal agents 
which destroy the bacteria in a matter of hours of administering the drugs. For example, 
between INH and RIF, 90% of the active bacilli are destroyed and become incapable of 
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actively causing disease after 24 hours of administration. Furthermore, EMB has 
bacteriostatic properties and minimises the risk of drug resistance (Department of Health SA, 
2014). This treatment lasts six months or longer in order to clear the active disease to a 
controlled latent form. In the first two months of treatment, INH, RIF, PZA and EMB are 
prescribed in order to rapidly destroy the tubercle bacilli. This is- then followed by a final four 
month treatment of INH with a target of rapid to intermediate growing bacilli, and RIF with a 
target of all degrees of growing bacilli, including dormant bacilli to ensure that active M.tb 
infection is cleared to minimize risk of future active M.tb infection (Department of Health SA, 
2014).  
 
Figure 2.5: Steps in the pathogenesis of tuberculosis. The bacterium travels from one infected 
person to another through the air and into the lungs. Half of the newly infected individuals are able to 
clear the infection. The other half of the newly infected individuals will form bacterial containing 
structures called granulomas. Granulomas consist of a collection of immune cells which are able to 
stop the spread of the infection.  However, for a few individuals with a compromised immune system, 
granuloma formation is hindered and the bacteria are able to spread (Tuberculosis, 2013).   
2.4.3 Directly Observed Treatment, short course in South Africa 
According to Loveday et al., (2012), KZN is the province in South Africa with the highest 
recorded incidence of TB, at 1163 cases per 100 000 population. Fortunately, the WHO 
developed the Directly Observed Treatment short course (DOTS) programme, which was 
designed to one day be able to eradicate TB entirely. In 1972, the WHO implemented this 
programme to help control the spread of TB infection in the world through a course of 
chemotherapy. The DOTS programme is based on directly observed treatment surveillance 
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where people in the community volunteer to ensure that patients infected with TB adhere to 
taking all their TB medication for the recommended time period (Pasipanodya and Gumbo, 
2013). While there are many individual tablets that are administered during the course of 
treatment, The World Bank states that the DOTS programme is one of the most cost-
effective of all health interventions (Frieden and Sbarbaro, 2007). Although this treatment is 
between six and nine months in length, financial support from various international 
organizations has made it possible for these people to have access to medication. However, 
some of the patients, now estimated at 500 thousand per year, will be reported to have 
MDR-TB, requiring second-line drugs that are more expensive, toxic, and may require up to 
two years of supervised adherence (Henao-Tamayo et al., 2011).  
As chronic HIV-1 infection is the core component of the current study, a more detailed 
introduction to the causative agent, its replication, pathology and the immune responses are 
covered in the sections below.  
 HIV causal agent 2.5
There are two strains of HIV that have been found to cause disease in humans. Both HIV-1 
and HIV-2 are RNA viruses of the Retroviridae family and lentivirus group. The virus is 
classified as a retrovirus because of the ability to utilise a reverse transcriptase enzyme to 
produce DNA from RNA. Furthermore, this virus is then able to insert the cDNA copy of the 
full viral genome directly into the human genome using the viral enzyme intergrase (Sierra et 
al., 2005). Once the viral genome is integrated into the human genome, the virus is free to 
use host proteins and machinery (particularly polymerase enzymes for transcription and 
translation) to manufacture new virus particles. HIV-2 is less virulent than HIV-1 and found 
mostly in West African regions. HIV-1 is the predominant strain infecting humans and is 
responsible for the AIDS epidemic worldwide (Abram et al., 2014; Holmes et al., 2015). The 
virus is grouped into M, N, O, P and further subdivided into subtypes A-K (Girard et al., 
2011). In the South African population, Group M (major), subtype C is the predominant 
circulating strain of HIV-1 found among infected individuals (Jacobs et al., 2014).  
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Figure 2.6: HIV viral structure. The virus is composed of a lipid membrane, gp120 and gp41 
envelope proteins, followed by an outer P17 matrix protein matrix with a p24 capsule core, which 
contains two single stranded RNA molecules, reverse transcriptase enzyme, integrase, P7/P9 Gag, 
regulatory proteins (Tat and Rev) and accessory proteins (Vif, Vpr and Vpu) (Rubbert et al., 2011).   
The mature HIV-1 virion is approximately 120 nm in diameter and is composed of an 
external bi-lipid layer membrane called the envelope, followed by an internal p24 capsid 
protein layer (Figure 2.6). Inside the capsid, the intergrase, reverse transcriptase, two 
identical single strain positive sense RNA molecules and viral proteins can be found (Girard 
et al., 2011). The genome is 9.7kbp in length and codes for nine genes within many open 
reading frames (ORF). These ORFs encode three structural (Gag, Pol and Env), three 
accessory (Vif, Vpr and Vpu) and three regulatory proteins (Tat, Rev and Nef). The HIV-1 
genes, their products, functions and localization are indicated in Table 2.2.  
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Table 2. 2 List of HIV RNA gene and functions 
Name Size Function Localization  
Gag  
P17, p24, 
p7, p9 
Membrane anchoring Virion 
Protease P11 Gag/pol cleavage Virion 
Reverse Transcriptase P66 Reverse transcriptase activity Virion 
Env Gp120/gp41 External viral proteins 
Plasma membrane, 
virion envelope 
Tat P16/p14 Viral transcriptional transactivator Primary in nucleus 
Rev P19 RNA transport Primary in nucleus 
Vif P23 Promotes viral maturation Cytoplasm, Virion 
Vpr P15 Inhibits cell division Virion, nucleus 
Vpu P16 
Promotes extracellular release of 
viral proteins 
Integral membrane 
protein 
Nef P27 Down regulation of CD4 proteins 
Plasma membrane, 
cytoplasm 
P=protein, GP=glycoprotein, number e.g. 19 = kd size, 19kD (Knipe and Howley, 2013). 
 
Flanking the structural and functional genes are the long terminal repeat (LTR) sequences, 
functioning as transcription promoters. Expression of the full genome requires multiple frame 
shifts to synthesize mRNA from overlapping genes (Holmes et al., 2015). Figure 2.7 displays 
the genomic organisation of the afore-mentioned viral genes of HIV-1. 
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Figure 2.7: Genome of HIV. HIV-1 genome is organized into 9 genes which include gag, pol, env, 
tat, rev, nef, vif, vpr and vpu coding for various proteins and enzymes. The intergration of proviral 
DNA from RNA into the host cell’s chromosome is carried out by reverse transcriptase. Diagram 
illustrates gene overlaps and LTR flanking regions (Rubbert et al., 2011). 
2.5.1 HIV replication cycle 
HIV-1 replication is initiated once a replication competent virus successfully crosses the 
epithelial layer/mucosal lining and attaches to a susceptible host cell containing surface host 
proteins CD4 as the primary receptor, together with CCR5 or CXCR4 as the co-receptors 
(Girard et al., 2011; Arrildt et al., 2012). CD4 is expressed on T cells, dendritic cells (DCs) 
and MO/MØ, thymocytes (immature thymus T cells) and microglial cells (Shankar et al., 
2015). CCR5 is expressed on activated and memory CD4+ T cells and MØ, with CXCR4 
most often expressed on naïve CD4+ T cells (Arrildt et al., 2012). The HIV-1 replication cycle 
can be divided into an early phase which consists of the virus attaching to the surface of the 
cell until when the virus has integrated into the human genome; and a late phase which 
consists of viral gene expression until budding and maturation of the new virion (Freed, 
2015). Upon entering the host, the virus will attached to the host receptors, a conformational 
change occurs which allows the virus to empty the viral capsid into the host cytoplasm. The 
viral envelope fuses with the host cell membrane; the capsid enters the cell cytoplasm, and 
is then uncoated, releasing viral RNA and enzymes into the cytoplasm (Figure 2.8). The 
reverse transcriptase enzyme reverse transcribes the RNA into double-stranded molecule 
viral DNA. This is termed complimentary or cDNA. Integration occurs next, and is when viral 
cDNA enters the nucleus and is integrated into the host’s DNA via the viral integrase 
enzyme. At this point the viral DNA is called a provirus (Sierra et al., 2005). Once integrated, 
the cDNA can lay latent (integrated provirus constitutes the so-called “latent reservoir” in 
treated patients) until the host cell is activated and host cell gene transcription occurs. 
Integrated viral DNA is used as a template to make viral RNA in a process called 
transcription. Transcription produces multiple RNA copies of the cDNA which translocate 
from the nucleus to the cytoplasm. During the late phase, translation of the viral RNA leads 
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to formation of new viral proteins, both structural proteins and enzymes. Assembly involves 
viral proteins, viral RNA and enzymes moving towards the host cell’s membrane to form a 
bud in preparation to exit the host cell (Dinkins et al., 2014). Release and maturation are the 
final stage in the cycle, where the virus buds from the host cell membrane and the viral 
enzyme protease cuts the long polypeptide protein chain to form a functional core structure. 
The entire replication cycle can be completed in approximately 20 hours, at which time the 
newly formed virus leaves the first host cell and will continues to infect adjacent cells 
(Holmes et al., 2015).  
 
Figure 2.8: HIV replication cycle. HIV-1 replication cycle divided into seven main points of viral 
formation in the host cell. The cycle begins with the virus attaching to the host cell and ends with the 
release of a mature virus particle able to infect the next CD4
+
 T cell (AIDS research centre, 2012).  
2.5.2 Mode of HIV transmission 
HIV-1 enters the human body in a number of different ways and at different sites, namely: 1) 
through unprotected sexual intercourse (female genital tract or rectal mucosa); 2) by vertical 
infection, between an infected mother to her child in utero, during childbirth, post-partum or 
via breast feeding; 3) parenteral transmission by means of a) sharing or reusing 
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contaminated IV needles; b) work related needle stick injuries and c) blood transfusions in a 
hospital setting (Girard et al., 2011; Sharp and Hahn, 2011; Walker et al., 2013). 
According to Delva and Karim (2014), transmission of the virus is most often seen in 
heterosexual populations with multiple sex partners or in monogamous relationships where 
HIV-1 status of a partner is not known at the start of the relationship. The number of new 
infections is also high for sex workers and their clients.  
WHO summarised (in the 2015 guidelines) that the five groups bearing the highest risk for 
new HIV-1 infection globally to include: men who have sex with men (MSM), sex workers, 
people who inject drugs, transgendered people and people in prison with the strong 
recommendation to administer pre-exposure prophylaxis (PrEP) in order to minimise future 
infection. Importantly, in South Africa, heterosexual people who engage in multiple sexual 
partners are at an equal, if not higher risk of HIV-1 infection as the above mentioned groups 
(WHO, 2015).    
 TB and HIV pathogenesis 2.6
TB and HIV-1 both have pathogenesis pathways involving multiple cell types and immune 
mediators. The co-occurrence of both pathogens in a single host naturally further 
complicates the process. It is well known that having either disease predisposes the 
individual to worse outcome if acquiring the other disease. In the following section, the 
pathogenic processes of both diseases are presented, highlighting pathways that may be 
most important when co-infections occur.  
2.6.1 TB pathogenesis  
TB is transferred between people via aerosol droplets from coughing (Nunes-Alves et al., 
2014). Once the bacteria have been inhaled into the lungs, they settle in the distal lung 
alveoli, which initiate the recruitment of inflammatory cells to the site of infection (Russell, et 
al., 2010). The first point of contact is the alveolar resident MØ which engulf the M.tb. MØ 
have the ability to secrete proteolytic enzymes and cytokines that exhibit anti-microbial 
effects, including interleukin (IL)-1 which is associated with inflammation, IL-6 which 
enhances proliferation of B cells, IL-10 and tumour necrosis factor (TNF)-α which signals the 
production of nitric oxide metabolites and granuloma formation (Van Crevel et al., 2002). 
This is subsequently followed by recruitment of DCs, which also engulf the M.tb. Initial innate 
recognition of the bacteria by MØ and DC is possible by pathogen-associated molecular 
patterns (PAMPs) on the surface of the bacteria via receptors on host cell surface, namely 
toll-like receptors (TLR), nucleotide-binding oligomerization domain receptor (NOD) and nod 
like receptors (NLRS) (Mesman and Geijtenbeek, 2012; Rustagi and Gale, 2013; Nunes-
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Alves et al., 2014). Recognition of M.tb occurs primarily through lipoarabinomannan (LAM), 
which is the major cell wall component of M.tb. The main receptor responsible for 
recognising LAM is TLR-2 on the phagocytic cells (Quesniaux et al., 2004). The receptor on 
the phagocytic cell  that is responsible for inducing the uptake of the bacteria could be either 
complement receptor (CR) 1, CR3, mannose receptor or a type A scavenger receptor (Van 
Crevel et al., 2002). M.tb, which escapes or survives this initial innate immune response, will 
multiply.  Increased antigen will be detected by resident phagocytes, which in turn, signals 
recruitment of blood MO to the site of infection. The MO differentiates into MØ, which engulf 
the M.tb but do not destroy the bacterium, as the MØ requires further activation from the T 
cells (Pawlowski et al., 2012). 
DCs engulf the antigen and migrate to the closest lymph node (Morris et al., 2013; Lai et al., 
2014; Nunes-Alves et al., 2014). It is here, in the lymph node, where the DCs display a 
peptide fragment of the antigen to the naïve T cells via MHC (Larsson et al., 2013; Morris et 
al., 2013). Once the T cell has recognised the peptide fragment, it is able to mount a 
powerful immune response to control the infection (Pawlowski et al., 2012; Lai et al., 2014). 
In order for a T cell to become activated it requires two signals (Figure 2.9). The first signal is 
between the major histocompatibility complex (MHC) receptor of the DC and the T cell 
receptor (TCR) of the T cell (Larsson et al., 2013; Martinez et al., 2015). The second signal 
is between the co-stimulating molecules CD80/CD86 with CD28, which results in clonal 
expansion and differentiation into effector T cells (Larsson et al., 2013; Littman, 2015).  
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Figure 2.9: Nature and laboratory co-stimulation of T cells. T cell activation requires at least 
two signals to become fully activated. The first occurs after engagement of the TCR by MHC, and 
the second by subsequent engagement of co-stimulatory molecules. The most potent T cell co-
stimulator is CD28. These signals are transmitted to the nucleus and result in 1) Clonal expansion 
of T cells; 2) Up-regulation of activation markers on the cell surface; 3) Differentiation into effector 
cells; 4) Induction of cytotoxicity or cytokine secretion; 5) Induction of apoptosis (T cell activation, 
2015). 
The effector T cell then migrates to the lung in the form of T helper (Th) 1 cells, which are 
able to activate the MØ to destroy the engulfed M.tb via the production of IFN-γ (Van Crevel 
et al., 2002). Interestingly, IL-12 which is expressed by activated MØ and DCs plays a role in 
the activation of Th1 cells which in turn stimulate the activation of the MØ to destroy the 
bacterium and control infection (Lai et al., 2015). While TB can spread to other organs in the 
human body, pulmonary TB infection will be the main focus of this study as it is the most 
commonly reported co-infection found in the South African HIV-1 population.  
2.6.2 CD4+ T cells as a link between TB and HIV 
The role of CD4+ T cells in the human immune system is numerous; in particular, Th1 cells 
are responsible for the activation of other immune cells to effectively ward off infections. 
Firstly, Th1 cells are responsible for the activation of MØ, which aid in enhancing elimination 
of M.tb (Yang et al., 2013; Bandaru et al., 2014; Boer et al., 2014; Lai et al., 2014; Stylianou 
et al., 2014;). Th1 cells are recruited to the site of M.tb infection, where they secrete the 
cytokines IFN-ү and TNF-α, which activates MØ to control bacterial growth (Hertoghe et al., 
2000; Tousif et al., 2011; Qiu et al., 2012; Day et al., 2014; Lai et al., 2014; Stanley et al., 
2014). CD4 knockout mice were more prone to TB infection when compared to wild type 
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mice (this holds true for HIV-1 patients with a very low CD4 count as they too are at a 
greater risk of TB infection) (Tousif et al., 2011; Yang et al., 2013). In a similar study by 
Bandaru et al., (2014), IL-7, a pro-inflammatory cytokine, also had an important role in 
immunity against M.tb. IL-7 has been recorded as having a positive effect in vaccine-induced 
protective immune responses against M.tb infection. After vaccination with M. bovis Bacille 
Calmette Guerin (BCG), Th17 cells are shown to activate chemokine production, which 
recruits IFN-ү producing T cells. Secondly, Th1 cells are responsible for the activation of the 
killing action of CD8+ cytotoxic T lymphocytes (CTL). Thirdly, Th1 cells generally have a 
central role in the activation and maturation of B cells, which aid in antibody production 
against HIV-1 and TB. Fourthly, Th1 cells secrete IL-2, IFN-ү and lymphotoxin, which are 
important for autoimmunity and for the development and maintenance of secondary 
lymphoid organ structure, as well as in the formation of memory T cells (Munier et al., 2013; 
Kahan et al., 2014; Levy et al., 2014). And finally, Th1 cells delay hypersensitivity reactions.  
Due to the vast number of activities performed by Th1 cells, when a person is infected with 
HIV-1, all these functions are impaired due to CD4+ T cells being the target cell of HIV-1 and 
the cell type selectively deleted (Shankar et al., 2015). 
2.6.3 HIV pathogenesis 
The pathogenesis of HIV-1 can be broadly divided into three distinct phases based on CD4 
count, viral load (VL) and AIDS defining opportunistic infections resulting in death. These 
three stages are acute phase (primary infection), chronic phase (clinical latency) and 
finally AIDS (progression to death) (Figure 2.10). The acute phase is characterised by 
primary infection, followed by plasma VL increasing drastically to around 106 -107 viral 
copies per ml and accompanied by flu-like symptoms (Veazey et al., 1998; Veazey et al., 
2000). The rate of viral replication will gradually decrease to a set point, which will continue 
throughout the chronic phase or clinical latency. It is possible for the chronic phase to last up 
to 10 years without ART or even longer with ART. During the chronic phase, untreated HIV-
1, CD4+ T cells are continually depleted and the susceptibility to opportunistic infections 
increases. The final AIDS stage is marked by extremely low CD4 count (<250 cells/mm3), 
high VL and stage III or stage IV WHO disease classification. This phase results in death 
(UNAIDS, 2015).      
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Figure 2.10: HIV disease stages according to CD4 count and VL. The acute stage is characterized 
by a drastic peak in viral load and depletion of CD4
+
 T cells; the clinical latency stage is characterized 
by a gradual decrease of CD4
+
 T cells and gradual increase in VL; and the final AIDS stage results in 
high VL and low CD4 count, opportunistic infections, wasting and death (HIV and Disability, 2010). 
2.6.4 Depletion of CD4+ T cells 
In the acute phase of HIV-1 infection, a rapid depletion of CD4+T cells in peripheral and 
mucosal lymphoid tissue accompanied by high levels of virus are common hallmarks 
(Ghiglione et al., 2014). Arnoczy et al., (2012), explained that during the acute phase of HIV-
1 infection, the high level of virus is due to the limitation of the T cell repertoire against this 
newly encountered virus. It is during the acute phase, when HIV-1 is able to directly and 
indirectly destroy the normal functioning of CD4+ T cells, which in turn, leads to lifelong 
immunodeficiency (Sauce et al., 2011; Kulpa et al., 2013; Munier et al., 2013; Shankar et al., 
2015). The virus directly affects the production of T cells by infecting the thymus, inhibiting 
thymopoiesis and affecting thymic output, decreasing the total number of new naïve T cells 
entering into circulation (Sauce et al., 2011).  
There are various mechanisms by which HIV-1 decreases the total number of CD4+ T cells.  
Firstly, viral replication inside the CD4+ T cell causes cell damage resulting in apoptosis. It is 
believed that the budding off of the new viral particle causes an influx of calcium into the cell, 
which activates apoptosis. This process also increases the amount of water moving into the 
cell, which also leads to osmotic lysis. Secondly, CD4+ T cells are depleted by the virus 
hijacking the host cell machinery to assemble viral protein, instead of the essential proteins 
needed for host cell survival. A less common action of HIV-1 on the host cell is giant cell 
formation (syncytium) between an HIV-1 infected CD4+ T cell and an uninfected CD4+ T cell. 
Both CD4+ T cells are joined by the gp120-CD4 interaction on the HIV-1 infected CD4+ T 
cell. CD4+ T cells are unable to function as a multinucleated giant CD4+ T cell and as a 
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result, the host cell dies. DCs and MØs also display the CD4 marker and are also 
susceptible to HIV-1 infection. However they are more resistant to the disease, but can 
transfer the viral infection to CD4+ T cells and therefore assist in the depletion of the overall 
CD4+ T cell number. And finally, the DCs attach and transport the virus and directly display it 
to the naïve T cell, increasing HIV-1 infection of the CD4+ T cells (Larsson et al., 2013; 
Dinkins et al., 2015). A final pathway of T cell death is inflammation/immune activation-
associated up-regulation of death receptors and AICD, which will be discussed in 
subsequent paragraphs.   
2.6.5 CD8+ T cell response to HIV 
CD8+ T cells play a crucial role in the killing of virus-infected cells, as well as defending 
against cancer (Zajac et al., 1998; Wherry, 2011; Legat et al., 2013; Rahim et al., 2013; 
Buzon et al., 2014; Ghiglione et al., 2014). In a study by Yamamoto et al., (2011), it was 
found that as soon as the CD8+ T cells were unable to effectively launch a cytotoxic 
response in HIV-1 infected individuals, the progression to AIDS and death was significantly 
increased due to the inability to control the virus. Furthermore, in the absence of CD4+ T 
cells, the CD8+ T cells lack the overall ability to effectively produce cytokines and 
proliferation was decreased after in vitro stimulation. Moreover, CD8+ T cells were more 
sensitive to cell death in populations infected with HIV-1 when compared to CD8+ T cells in 
healthy controls. As a result, targeting the effector function and survival of CD8+ T cells could 
enhance immune control of HIV-1 infection and therefore increase survival of the individual 
(Zajac et al., 1998; Munier et al., 2013). As mentioned earlier, CTLs recognise antigen on 
the surface of cells that display the MHC I molecule. The activation of CTLs is reliant on the 
help of CD4+ T cells via cytokine release. However, the full activation of CTLs is initiated 
upon activation of CD4+ T cells by the antigen presenting cells. Once the CD4+ T cell is 
activated, it secretes cytokines, such as IL-2, IL-6, IL-12 and IL-15, which trigger the 
differentiation of the CD8+ T cell into an activated MHC class I restricted CTL. These CTLs 
are able to combat a virus-infected cell through several mechanisms, such as lytic granules, 
which would include perforins, granzymes and the cytokine TNF-α. The granules are able to 
induce pore formation in the membrane of the virus-infected cell within minutes (Sakhardi et 
al., 2012; Day et al., 2014). Furthermore, CTLs are also able to induce apoptosis by means 
of the Fas pathway (Ju et al., 1994). Importantly, CD8+ T cells also play a functional role in 
the management of M.tb by means of killing the bacteria by granzyme independent 
mechanisms (Qiu et al., 2012; Day et al., 2014; Lindenstrom et al., 2014). 
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2.7 Chronic viral infection 
Chronic HIV-1 infection leads to compromises in cell-mediated immunity, which hinders the 
ability to ward off opportunistic infections (Camargo et al., 2014). Furthermore, diseases that 
were once kept under control by the immune system are no longer controlled (Masia et al., 
2014). Diseases such as Epstein-Barr virus (EBV), which infect 90% of the general 
population, are associated with a higher risk of lymphomas in HIV-1 positive individuals 
(Sachithanandham et al., 2014). Similarly, the reactivation of varicella-zoster virus (VZV) in 
HIV-1 positive individuals is associated with ophthalmic and neurological complications. 
Another reactivated virus that is associated with many lifelong conditions is cytomegalovirus 
(CMV) (Masia et al., 2014). In HIV-1 positive individuals, CMV is directly linked to CD4 count 
and the most common disease is retinitis, which affects 15 to 40% of patients with a low CD4 
count (Griffiths et al., 2012). Bacterial infections are also problematic, Abimbola and Marston 
(2012), showed that TB, cryptococcal meningitis, pneumonia and diarrheal illness are the 
most common diseases responsible for early mortality of HIV-1 positive patients living on the 
African continent. 
There are also a number of STIs that are associated with increased risk of acquisition and 
with accelerating HIV-1 disease progression and death. One of the best researched is 
human papilloma virus (HPV), which has a direct role in the development of cervical cancer. 
In healthy young women, the immune system is able to control and even eliminate the virus. 
However, in HIV-1 positive women there is a rise in mild dysplasia by 80% when compared 
to 27% found in healthy, HIV-1 negative women. Furthermore, in HIV-1 positive women 
there is a drastic increase in the development of aggressive lesions and a lower response to 
treatment when compared to healthy HIV-1 negative women (Camargo et al., 2014). 
 Immune activation and immune exhaustion in chronic HIV-1 infection 2.8
When a cell exhibits immune activation or exhaustion due to chronic viral infection, nuclear 
transcription factors induce production of host proteins, which are presented on the cell 
surface as receptors or ligands (cell biomarkers). These receptor proteins can either induce 
non-responsiveness or down-regulate cell defences (immune exhaustion) or activate the cell 
(immune activation) on binding with its respective ligand. The up-regulation of immune 
exhaustion markers on the surface of the cell is protective as the immune system attempts to 
minimise cellular and tissue damage due to long term inflammation and cytokine production. 
Conversely, this up-regulation of inhibitory surface markers is also detrimental to the immune 
system as the down-regulation of the immune cell function enables the virus to gain an 
advantage (Zajac et al., 1998). 
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In HIV-1 negative persons, acute viral infections stimulate inflammation and immune 
activation, which are quickly resolved in the clearance of the antigen (Haas et al., 2013). The 
regular course of action entails the naïve T cells becoming activated and differentiating into 
effector T cells. These effector cells proliferate to form a collection of specialised cells, which 
are able to clear the infection. Once the infection has been cleared, inflammation and 
immune activation is decreased and the activated T cells are cleared due to apoptosis or 
transition to long-lived memory cells. Only a small number of effector T cells are retained as 
memory T cells, which have the ability to transform into effector T cells on secondary 
infection of the same pathogen.  
Conversely, in several chronic diseases such as HIV-1, lifelong inflammation and immune 
activation is seen, resulting in immune and tissue damage. This is due to the constant 
filtration of the immune cells and the immune response via pro-inflammatory cytokines (Haas 
et al., 2013). Furthermore, chronic immune activation is associated with immune aging and 
weakening of the immune cells referred to as immuno-senescence (Chalan et al., 2015; 
Shankar et al., 2015). Over time, functional impairment of the immune cells increases 
vulnerability to opportunistic infections and cancers, which are not normally found in healthy 
populations (Camargo et al., 2014; Mutlu et al., 2014).  
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Figure 2.11: Chronic viral infection leading to immune exhaustion. Acute viral infections result in 
T cell effector function, and clearance of the antigen results in memory T cells. Chronic viral infection 
results in T cell effector function, increase in T cell activation and inflammation due to prolonged 
exposure to the antigen, leading to the activation of exhaustion surface markers, decrease in T cell 
function and lack of memory T cell formation (Velu et al., 2015).  
Studies of lymphocytic choriomeningitis virus (LCMV) in mice have contributed greatly to the 
current knowledge about immune exhaustion (Moskophidis et al., 1993; Zajac et al., 1998). 
In chronic viral infection, T cells are constantly exposed to the virus and this is the primary 
cause of immune exhaustion (Zajac et al., 1998; Sakhdari et al., 2012; Ezinne et al., 2014; 
Wherry and Kurachi, 2015). Immune exhaustion results from a process of unresolved and 
prolonged inflammation of the T cells due to immune activation and the inability of these 
cells to eliminate the pathogen burden over an extended time period (Wittkop et al., 2013; Lu 
et al., 2015; Martinez et al., 2015). PD-1 and Tim-3, among others in this study, are two 
examples of markers of T cell exhaustion up-regulated on T cells in patients with a viral or 
bacterial infection that is associated with prolonged unresolved immune activation (Martinez 
et al., 2015). Both exhaustion markers are involved in the down-regulation of T cell function, 
and both are categorised as T cell inhibitory markers. T cell exhaustion is damaging to the 
overall functioning of the immune system by means of multiple factors including the loss of a 
robust T cell effector function, up-regulation of inhibitory receptors on the cell surface, errors 
in the expression of transcription factors and limited cytokine production (Sakhdari et al., 
2012; Smith et al., 2013; Wherry and Kurachi, 2015). With a combination of all these 
disabling factors, T cells are unable to transition into a resting state and form memory T cells 
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(Wherry and Kurachi, 2015). Similarly, Wang et al., (2011), found that inhibitory marker Tim-
3 was up-regulated on virus-specific CD8+ T cells in patients with chronic progressive HIV-1 
infection, and also on antigen-specific CD8+ T cells in patients with active TB. 
In a recent KZN-based study, Sullivan et al., (2015), found immune activation and 
inflammation in active TB patients with or without HIV-1 infection. It has been well 
documented in the relevant literature that HIV-TB co-infected individuals display increased 
levels of inflammation, as well as an increased up-regulation of surface markers due to the 
added disease burden (Shankar et al., 2015). Furthermore, co-infection results in a 
significant increase in the amount of immune activation as evidenced by increased human 
leukocyte antigen (HLA)-DR and CD38 expression on T cells (Wittkop et al., 2013; Tenorio 
et al., 2014; Shankar et al., 2015). HIV-1 positive patients with latent TB also expressed high 
levels of immune activation when compared to those HIV-1 positive, but TB negative 
patients. It has been found that immune activation in HIV-1 positive patients is linked to 
immune exhaustion and progression to AIDS and is a better marker of survival than CD4+ T 
cell count and VL (Sauce et al., 2011; Dunham et al., 2014). 
HIV-related inflammation is well described in the literature resulting from mechanisms such 
as: microbial translocation, co-infections such as CMV reactivation, persistent HIV 
antigenemia and the direct effect of the virus on CD4+ T cell depletion (Kolter et al., 1984; 
Hunt et al., 2011; Burgener et al., 2015). Doitsh et al., (2014), found that when CD4+ T cells 
were depleted, IL-1β cytokine was released which is known to have potent pro-inflammatory 
properties. Chronic immune activation and inflammation can remain high throughout the 
lifetime of patients, despite ART. Non AIDS related illnesses, such as cardiovascular 
disease, renal disease and type II diabetes are believed to be related to this chronic 
activation/inflammation and, as a result, add strain to the already compromised immune 
system (Deeks and Phillips, 2009).      
Microbial translocation is associated with physical damage of the mucosal associated 
lymphoid tissue (MALT) of the gastrointestinal tract (GIT) primarily due to destruction of tight 
junctions in the epithelium. The damage and associated translocation is a driver of on-going 
inflammation and immune activation, which adds to immune burden and equates to the 
accelerated HIV-1 disease progression to death (Guadalupe et al., 2003). In the majority of 
healthy HIV-1 negative individuals, the integrity of the gut lining is preserved due to the 
immunological and anatomical barriers which stop microbes and microbial products from 
entering across into the internal environment. The point of contact is the single layer of cells 
lining the gut which is covered by a protective mucus layer containing immunoglobulin (Ig) A 
and glycocalyx. Directly below this single layer of cells, in the lamina propria, DC, MØ, 
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granulocytes, mast cells, B and T cells can be found. The majority of the CD4+ T cells found 
in the  gut associated lymphoid tissue (GALT) are activated, displaying the CCR5 co-
receptor, which is one of the core receptors needed for HIV-1 to bind and enter the host cell. 
During acute phase HIV-1 infection, memory CD4+ T cells (which are CCR5+) found in the 
lamina propria is most severely depleted. The GALT is the storage location of the majority of 
memory T cells, and is thus the favoured site for viral replication (Novati et al., 2015). This 
sudden depletion of CD4+ T cells is accompanied by an increase in immune activation and 
inflammation, which continues for many years throughout the chronic phase of the disease 
(Guadalupe et al., 2003). While ART has shown to significantly decrease VL in peripheral 
blood, the GALT serves as a viral reservoir for the virus as it continuously replicates and 
infects CD4+ T cells in this region (Anton et al., 2003; Chun et al., 2008).  
As early as 1984, Kotler et al., (1984), reported a distinct link between damage of the gut, 
microbial movement into the blood and progression to AIDS. A few years later it was found 
that high levels of microbial lipoplysaccarides (LPS) in the blood correlated with high levels 
of immune activation and inflammation of the gut lining. The movement of LPS across the 
gut lining elicits both innate and adaptive responses in efforts to preserve the integrity of the 
internal environment (Brenchley et al., 2006). Reactivation of latent diseases, such as CMV 
and VZV, further burden the immune system through eliciting high proliferation responses in 
mucosal lining (Guadalupe et al., 2003). Microbial translocation also worsens with the 
addition of antibiotic therapy (Berg, 1981), burns (Deitch and Berg, 1987) and haemorrhagic 
shock (Rush et al., 1988).   
 Characterization of T cell-associated negative regulatory and exhaustion markers 2.9
Yamamoto et al., (2011), reported that the CD8+ T cell response during chronic viral infection 
in mice is controlled by a pattern of inhibitory, exhaustion and activation receptors. These 
receptors include Tim-3, PD-1, 2B4, LAG-3 and many others (Wherry, 2011; Legat et al., 
2013). Furthermore, many studies have found that the greater the degree of exhaustion 
exhibited by the virus-specific CD8+ T cells in mice and humans, the greater the co-
expression of inhibitory receptors (Yamamoto et al., 2011; Legat et al., 2013; Lanteri et al., 
2014).  
In the current study, we have examined a number of markers associated with immune 
activation, exhaustion and death. These together with others (such as CTLA-4) are 
discussed below.  
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2.9.1 CTLA-4 
One of the first T cell markers to be characterised in the early 1980’s was Cytotoxic T-
lymphocyte-associated antigen-4 (CTLA-4) which is believed to have a role in T cell 
activation (Littman, 2015). This marker is part of the immunoglobulin family similar to that of 
CD28. CTLA-4 (also known as CD152) is responsible for regulating the magnitude of the T 
cell response and as such was first described as a down-regulator of T cell stimulation. 
CTLA-4 surface marker expression depends on the strength of the TCR signal.  CTLA-4 is 
able to reduce this TCR signalling process and in turn down-regulate cell function. 
Furthermore, CTLA-4 is also able to down-regulate expression of the co-stimulatory ligand 
CD80 and CD86 on the antigen presenting cells, thereby reducing T cell CD28 engagement 
by means of the second signal of T cell activation (Wang et al., 2015). CTLA-4 acts as an 
antagonist to CD28 by means of blocking the PI3K pathway, which in turn has a negative 
effect on protein synthesis and cell survival (Wang et al., 2015). Mice deficient in CTLA-4 
produce a lethal condition of hyper proliferation of T cells, which reinforces the regulatory 
importance of CTLA-4 is a negative regulator of T cell activation (Callaham and Wolchok, 
2015).   
Most of the current advances in medical research concerning immune check point therapies 
such as; cancer, autoimmune disease and chronic viral infections have focused on CTLA-4 
and PD-1 (Littman, 2015; Ye et al., 2015). CTLA-4 is expressed on antigen presenting cells, 
B cells and most importantly, T cells. In advanced HIV-1 diseased T cells, it was found that 
CTLA-4 was highly expressed on exhausted CD4+ T cells but not expressed on CTL’s. 
Additionally, blocking of CTLA-4 on exhausted CD4+ T cells was found to improve 
proliferation and effector function (Kaufmann and Walker, 2009).  
2.9.2 PD-1 inhibitory marker 
PD-1 is a member of the CD28/cytotoxic T lymphocyte-associated protein-4 (CTLA-4)/B7 Ig 
family and is classified as a marker of immune exhaustion by inhibiting or down-regulating 
gene expression when interacting with its ligand PD-1L (Tousif et al., 2011; Dietze et al., 
2013; Kulpa et al., 2013; Larsson et al., 2013; Ezinne et al., 2014). In 1992, PD-1, also 
referred to as CD279, and has subsequently been shown to have beneficial properties in 
controlling inflammation in many disease models by decreasing T cell activity (Littman, 
2015).  PD-1 is found on the surface of many immune cells, including T cells, B cells, natural 
killer (NK) cells and MØ cells (Tousif et al., 2011; Larsson et al., 2013; Seung et al., 2013; 
McBerry et al., 2014). In bacterial infections such as TB, Jiang et al., (2014), found that by 
blocking the PD-1 pathway, there was significant improvement in the production of IFN-ү, 
which is central to M.tb control in MØ.  
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PD-1 expression is controlled at the transcriptional level and the exact mechanism is 
currently still unknown. However, the PD-1 pathway is believed to be regulated by 
mechanisms involving T-bet, a cell-associated transcription factor, and B lymphocyte-
induced maturation protein 1 (BLIMP-1) on CD8+ and CD4+ T cells (Shin et al., 2009; Kao et 
al., 2011; Lu et al., 2014). In the presence of antigen, TCRs signal PD-1 gene expression via 
the transcriptional factor NFATc1 pathway. It was once thought that T-bet had a role in the 
suppression of the transcription pathway, but this was discredited as T-bet could not express 
a strong enough response to decrease PD-1 expression in large quantities. Lu et al., (2014), 
found that during acute viral infections, transcription repressor BLIMP-1 was able to 
suppress the expression of PD-1 on effector T cells. BLIMP-1 knockout mice were used to 
further support this observation and it was confirmed that these mice displayed higher levels 
of PD-1 and reduced effectiveness in clearing acute infections (Lu et al., 2014). In chronic 
viral infection, PD-1 was also found to have a role in the TCR signalling pathway of T cells 
decreasing IL-2, IFN-ү and TNF-α production which are crucial for T cell survival (Wherry, 
2011; Kahan et al., 2014; Martinez et al., 2015). Similarly, in a review by Balkhi et al., (2015), 
it was discussed that exhausted T cell which displayed PD-1 had a distinct gene 
transcription profile that is very different from that of healthy T cells; notably these unique 
transcription factors including BLIMP-1, Eomes, T-bet, IKZF and FoxO1 were up-regulated. 
Balkhi et al., (2015), noted that the action of IL-2 was believed to be two fold, one for cell 
survival and the other in a feedback loop to PI3K in NFATc1 pathway (Figure 2.12). While 
this signalling pathway of IL-2 during exhaustion is not fully understood, it is proposed that 
the binding of PD-1/PDL-1 could negatively influence the production of IL-2 resulting in the 
progression of T cell exhaustion (Balkhi et al., 2015). 
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Figure 2.12: PD-1 pathway. A schematic of the proposed PD-1/PD-L1 pathway. PD-1/PD-L1 binding 
activates SHP-2 in binding with the ITSM tail of PD-1. This decreases the TCR signalling by means of 
blocking CD3 and inhibits PI3K/Akt pathway. PD-1/PD-L1 binding leads to a down-regulation of 
survival transcription factor mTOR, Bcl-xl and Ras while promoting dysregulation and increased 
expression of PD-1 via BATF and Fox01 (Chinai et al., 2015).  
One of the first studies that noted the importance of PD-1 with respect to CD8+ T cell 
exhaustion was characterised using the LCMV model (Moskophidis et al., 1993; Larsson et 
al., 2013; Legat et al., 2013; Seung et al., 2013). This model showed that by blocking certain 
pathways, there could be a reverse effect in the dysfunction of the cell and this, in turn, could 
promote an improved ability to control viral replication (Larsson et al., 2013; Munier et al., 
2013; Ezinne et al., 2014; Kloverpris et al., 2014). Furthermore, Smith et al., (2013), found 
that PD-1 was upregulated on CD8+ T cells with respect to infection with the Hepatitis C 
virus (HCV), West Nile virus (WNV), Hepatitis B virus (HBV) and HIV-1 (Seung et al., 2013; 
Lanteri et al., 2014). It was also found that the level of PD-1 expression positively correlated 
with the extent of disease progression (Tousif et al., 2011; Rahim et al., 2013; Lanteri et al., 
2014). In a similar study with a group of SIV positive macaques, PD-1 blocking antibodies 
was administered, resulting in effective CD8+ T cell immunity and survival conserved 
(Kloverpris et al., 2014). 
Smith et al., (2013), found that PD-1 expression on CD4+ T cells was elevated on those cells 
that also express CD38 and HLA-DR in both HIV-1 positive and negative groups. In the 
same study, Smith et al., (2013), showed higher levels of activation on CD4+ T cells in 
samples from patients infected with HIV-1, followed by EBV, CMV, HSV and VZV infections. 
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This hierarchy of immune activation may be related to the level of persistence or the 
likelihood of reactivation of the virus. 
Many studies have highlighted the link between PD-1 expression on the surface of HIV-1 
specific CD8+ T cells, VL and disease progression to AIDS (Yamamoto et al., 2011; Rahim 
et al., 2013; Smith et al., 2013). PD-1 expressing CD8+ T cells are more susceptible to both 
activation induced cell death (AICD) and Fas-mediated apoptosis. This was illustrated in a 
study by Yamamoto et al., (2011), who observed a reduction in viral load in patients initiating 
ART. In addition greater T cell survival, which was believed to be due to a decrease in PD-1 
levels on CD8+ T cells were also observed.  
2.9.3 Tim-3 inhibitory marker 
The T cell marker, Tim-3, is a membrane protein that was first documented in mouse models 
and functions as a negative regulator on T cells (Qiu et al., 2012; Dietze et al., 2013; Yang et 
al., 2013). Galectin-9 is the ligand for Tim-3 in T cells, however, this is debated by some, as 
phosphatidyl serine (PS) has also been able to bind to Tim-3 on the surface of phagocytes 
(Dietze et al., 2013; Leitner et al., 2013; Zhang and Shan, 2014). Nevertheless, when Tim-3 
binds to its ligand, the interaction is either T cell death or T cell tolerance (Khaitan and 
Unutmaz, 2011; Sakhdari et al., 2012; Larsson et al., 2013; Leitner et al., 2013; Zhang and 
Shan, 2013). The proposed pathways is similar to that of PD-1, with Galactin-9 binding to 
Tim-3 activating the phosphorylation of SHP-2 to block the PI3K pathways which intern 
blocks NF-AT and limits IL-2 and other pro survival cytokines. Moreover, the binding of Tim-
3 with Galactin-9 also inhibits the T cell receptor and down regulates TCR signalling 
(Tomkowicz et al., 2015).   
Additionally, Tim-3 is expressed on MO, MØ and DCs, but especially severely exhausted T 
cells, which secrete low levels of cytokines and have poor proliferative abilities (Gautron et 
al., 2014; Kuchroo et al., 2014). In a study by Wang et al., (2011), Tim-3 was found to have 
immunological suppressive effects on active TB-infected individuals. Furthermore, the 
regulation of Th17+ cells, which are known for their role in arthritis with respect to 
inflammatory properties, is also under a form of control by Tim-3 (Khaitan and Unutmaz, 
2011; Gautron et al., 2014). Increased levels of Tim-3 on activated Th1 cells are linked to the 
autoimmune mediated bleeding disease called immune thrombocytopenia. This disorder is 
characterised by a decreased production of platelets (Zhang and Shan, 2013). Several other 
reports also confirmed that CTLs in individuals infected with HIV-1, have higher levels of 
Tim-3 and displayed poor proliferation ability, as well as a dysfunctional cytokine response 
(Larsson et al., 2013; Leitner et al., 2013; Gautron et al., 2014). Likewise, studies have found 
that patients with active TB infection demonstrated increased expression of Tim-3 on CD8+ T 
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cells when compared to healthy controls, but no significant difference could be found on 
CD4+ T cells. Higher levels of Tim-3 expression were found on CD8+ T cells which also 
expressed lower levels of IFN-ү. This is an important finding, as IFN-ү is one of the main 
cytokines in MØ defence against M.tb and also a key cytokine in the immune response 
against HIV-1 (Wang et al., 2011 Leitner et al., 2013; Yang et al., 2013). 
2.9.4 HLA-DR and CD38 as markers of immune activation 
HLA-DR, a MHC class II molecule, was characterised as an activation marker of T cells as 
early as 1995, and studies have shown that levels of HLA-DR and CD38 on CD8+ T cells are 
significantly increased in HIV-1 positive patients. CD38 is a transmembrane glycoprotein, 
which is expressed on numerous activated cells, especially activated T cells in the presence 
of chronic viral infection (Deeks et al, 2004). Expression of CD38 is linked to processes such 
as cell-to-cell adhesion, production of cytokines, and increased proliferation of CD4+ T cells. 
CD38 upregulation is also linked to exposure of oxidative stress and reactive oxygen species 
(Reyes et al., 2015). High levels of CD38 expression on CD8+ T cells are used as an 
instrument to determine immune activation in HIV-1 positive individuals (Lederman et al., 
2000).     
Xiao et al., (2011), found an increase in HLA-DR and CD38 expression on CD8+ T cells from 
8% in healthy individuals, and 49% in asymptomatic HIV-1 positive individuals. HLA-DR and 
CD38 expression on CD8+ T cells is believed to be a strong predictor of HIV-1 progression to 
AIDS (Xiao et al., 2011; Tenorio et al., 2014; Sullivan et al., 2015). 
Musyoki et al., (2014), measured the expression of HLA-DR and CD38 in pregnant women 
with HIV-1, versus non-pregnant women with HIV-1. The results of the study showed that 
pregnant women expressed lower levels of HLA-DR and CD38 on CD8+ T cells when 
compared to the non-pregnant women. The lower levels of activation on CD8+ T cells 
inversely correlated with an increased survival of CD4+ T cells. Multiple other studies have 
found that the expression of CD38 and HLA-DR on CD8+ T cells is correlated with its 
cytotoxic effector function and therefore increased clearance of viral infected cells (Hertoghe 
et al., 2000; Cockerham et al., 2014; Musyoki et al., 2014; Tenorio et al., 2014).  
Hua et al., (2014), analysed the phenotype of HIV-1 controllers (HIC) in relation to CD38 and 
HLA-DR expression. It was established that the HIC group expressed low levels of CD38 
with high levels of HLA-DR on their T cells. These findings are not in line with previous 
studies, as low levels of CD38 are associated with an inactive state and high levels of HLA-
DR are associated with an activated state. While these findings are contradicting, B cell 
lymphoma (Bcl)-2 expression was also found at significantly higher levels, which is well 
known for its apoptotic protective properties. With the phenotype CD38lowHLA-DRhigh, 
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together with an increased expression of Bcl-2, T cells were shown to limit the degree of 
activation and overall effector function (Hua et al., 2014). 
Finally, in a drug study conducted by Tenorio et al., (2014), Rifaximin (which is a common 
ART drug used in first-line therapy in South Africa) was tested in relation to HLA-DR and 
CD38 expression. It was found that, even after starting ART, 25% of individuals did not 
increase their CD4+ count to more than 350 cells/mm3 after 3 years, and that both activation 
markers continued to be highly expressed. Those individuals expressing high levels of HLA-
DR and CD38 seemed to be less responsive to drug therapy. Therefore, high levels of HLA-
DR and CD38 expression are strong predictors of disease progression.  
2.9.5 2B4 and LAG-3 as putative markers of activation and inhibition 
CD244 (2B4) is classified as a signalling lymphocyte activation molecule (SLAM) (or CD150) 
and controls immune reactions (Aldy et al., 2011; Yang et al., 2013; Ezinne et al., 2014). 
This receptor is expressed on NK cells, CD4 T cells, CD8 T cells, MOs, eosinophils and 
basophils and is upregulated in viral infections (Ezinne et al., 2014; Liu et al., 2014). 2B4 
interacts with ligand CD48 (Kahan et al., 2014), which upon binding, leads to cell 
proliferation, IL-2 production and cell survival by means of activating the SHP-2 pathways 
which in turn activates the PI3K/AKT signalling pathway (Aldy et al., 2011; Ezinne et al., 
2014). Furthermore, Elishmereni and Levi-Schaffer (2011), found that decreasing the binding 
of ligand to the receptor led to a decrease in CTL activity. Similarly, Aldy et al., (2011), found 
that the levels of 2B4+ CD8+ T cells were increased in HIV-1 positive individuals when 
compared to the control group, and that the 2B4 pathway may be implicated in the cytotoxic 
action of CD8+ T cells. Furthermore, it was found that, by blocking the 2B4 pathway, the 
killing action of the CTLs was impaired. Other groups have also reported 2B4’s dual  
activating and inhibitory functions, with activation manifesting at low level expression and 
inhibition at high 2B4 expression (Yang et al., 2011; Larsson et al., 2013; Kuchroo et al., 
2014; Liu et al., 2014). Furthermore, in relation to chronic viral infections such as HBV, HCV, 
LCMV and HIV-1, the expression of 2B4 on CD8+ T cells was increased which resulted in 
decreased virus-specific proliferation and cytotoxic function and is then classified as a 
marker of T cell dysfunction (Yang et al., 2013). 
LAG-3 is a transmembrane protein found on T cells, B cells, NK cells and DCs (Sega et al., 
2014). The ligand to LAG-3 is MHC class II which, according to Juno et al., (2015), binds 
with greater affinity to MHC class II than CD4. The signalling pathway for LAG-3 has not 
been confirmed, however it is known that the intracellular domain KIEELE is involved (Nirsch 
and Drake, 2013). 
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Mouse models demonstrated that LAG-3 was inducible on T cells, and this was linked to the 
functional exhaustion of CD8+ T cells in persistent infections (Larsson et al. 2013; Sega et 
al., 2014). Furthermore, according to Khaitan (2011), during HIV infection LAG-3 has shown 
to correlate with HIV viral load in patients unresponsive to antiretroviral therapy. Similar to 
PD-1, LAG-3 has been linked to the down regulation of T cell proliferation, activation and 
suppression of Treg function. Furthermore, Kahan et al., (2014), found that LAG-3 was able 
to decrease calcium levels which influence the TCR signalling pathway. LAG-3 is also 
associated with a decrease of cytokine production and T cell proliferation when co 
expressed with PD-1 (Kahan et al., 2014; Sega et al., 2014). Blocking PD-1 and LAG-3 on 
exhausted HIV infected T cells resulted in an increase in viral control and T cell functioning 
was significantly improved (Pena et al., 2014).  
2.9.6 Fas activation-associated and death pathway 
Fas (CD95) is a death receptor on the surface of cells that leads to programmed cell death 
or apoptosis (extrinsic pathway) (Hertoghe et al., 2000). Another pathway leading to 
apoptotic cell death is the intrinsic pathway. The intrinsic pathway refers to the apoptosis 
pathway process inside the cell, in the mitochondrial membrane. When the mitochondrial 
membrane is disrupted, bcl-2 proteins activate the release of cytochrome c resulting in 
activation of caspase 3, which in turn initiates apoptosis of the cell (Figure 2.13). Conversely, 
the extrinsic pathway is associated with the binding of ligand to receptor via the Fas/FasL 
apoptosis pathway on the outside of the cell (Nardacci et al., 2015). The extrinsic pathway is 
also associated with TNRF1 and TRAILR, which together activate apoptosis. For the 
purpose of this study, Fas/FasL (CD95/CD95L) will be the main focus. Together these 
apoptotic surface receptors bind to their respective ligands and activate the release of 
caspases 8 and 10, which further activates caspases 3 and 7, leading to death of the cell 
(Alimonti et al., 2003). Fas/FasL is part of the TNF family (Baier-Bitterlich et al., 1997) and 
the nerve growth factor (NGF) family of receptors and is highly expressed on activated T 
cells (Waring and Mullbacher, 1999).  
Fas have a central role in the regulation of the immune response after the elimination of 
antigen. The process is important in limiting damage and inflammation to the surrounding 
tissue by restricting clonal expansion of T cells (Waring and Mullbacher, 1999; Cencioni et 
al., 2015). Mice deficient in the gene, which codes for Fas/FasL, displayed 
lymphoproliferative autoimmune disorders, such as systematic lupus erythematosus as a 
result of CD4+ and CD8+ T cell build-up (Takahashi et al., 1994; Watanabe-Fukunaga et al., 
1999).  
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Figure 2.13: Fas death pathway. A schematic depicting viral proteins activating the intrinsic pathway 
by means of disrupting the mitochondrial membrane resulting in cell death. The Fas and FasL 
pathways are also depicted which activate caspase 8 leading to the activation of caspase 3 and/or 
disruption of the mitochondrial membrane resulting in cell death (Cummins and Badley, 2010).   
In HIV-1 positive individuals, the largest depletion of CD4+ T cells is as a result of AICD 
induced by the Fas/FasL pathway. This pathway is significantly up-regulated in individuals 
with persistent viral infections (Barathan et al., 2015). Fas/FasL pathway is activated by the 
interaction of gp120 viral proteins, CXCR4, CCR5 with the CD4+ T cell membrane resulting 
in cell death (Oyaizu et al., 1994). Uninfected, bystander CD4+ T cells are most affected by 
this process, which results in drastic CD4+ T cell depletion increasing progression of 
morbidity and mortality. Furthermore, Nardacci et al., (2015), concluded that with a decrease 
of bystander CD4+ T cells in HIV positive individuals, a marked decrease in immune 
protection can be found against intracellular microbes, including helminthes and fungal 
infections which further weaken the immune system.          
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Problem statement 
South Africa has one of the highest rates of HIV-1/TB co-infection and mortality in the world. 
While it is known how these two diseases increase the burden on the immune cells, little is 
known on how this impacts specific markers of the immune system in South African 
individuals. This problem was addressed by using 3 distinct patient groups namely a healthy 
control group, HIV positive group and a dually HIV/TB positive group. HIV-1 is associated 
with exhaustion (PD-1 and Tim-3), activation (HLA-DR and CD38), apoptosis (Fas) and 
inhibitory or negative regulatory markers (LAG-3 and 2B4). TB has similarly been associated 
with differential marker upregulation. This study addressed co-infection and how these 
markers link immune activation and exhaustion in such a setting.  
Hypothesis  
Chronic HIV-1 infection together with active TB disease amplifies the expression of all 
activation and exhaustion/inhibitory markers (CD38, HLA-DR, Fas PD-1, TIM-3, LAG-3 and 
2B4) on CD4+ and CD8+ T cells. 
Aims 
The primary aim of this current study was to investigate the impact of TB (active disease) on 
exhaustion marker expression in chronic untreated HIV.  
Objectives 
1) To examine expression of the inhibitory markers PD-1 and Tim-3 on CD8+ T cell 
subsets in 3 patient groups – uninfected, HIV-1 infected and HIV-1/TB co-infected 
individuals. 
2) To compare PD-1, Tim-3, CD38+ and HLA-DR expression to other less well-
characterized inhibitory markers (LAG-3 and 2B4) and their association with clinical 
markers of disease progression (CD4 count and viral load). 
3) To assess functional responsiveness of αCD3 stimulation T cells in the 3 study 
groups, and the impact of inhibitory pathway blockade. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Study design 
Ethics approval 
The Health Ethics Committee of Stellenbosch University approved the study.  Registration 
numbers N07/06/133 (2007 to 2011) and N12/02/008 (2012 to 2015)(Addendum A). 
 
Three participant study groups were included in the current study: HIV-1 infected, HIV-1/TB 
co-infected and an uninfected control group. The study comprised two components: a pilot 
study, which examined two exhaustion/negative regulatory markers, PD-1 and Tim-3, in 
fresh whole blood. A follow-up main study assessed these two markers in addition to 2B4 
and LAG-3 in frozen PBMC. The main study also included a functional component in which 
αCD3 and αCD28 stimulated CD4+ and CD8+ T cells were monitored for proliferation by 
CFSE dilution, in the presence or absence of blocking of the PD-1 and Tim-3 pathways. 
  
Figure 3.1: Overview of work flow.  (A) Main study using frozen Peripheral blood mononuclear cells 
(PBMC) on a ten colour flow cytometer, markers included DAPI viability,CD45, CD3, CD4, CD8, PD-1, 
Tim-3, Fas, CD38, 2B4, LAG-3, HLA-DR (B) Pilot study using fresh whole blood on a four colour flow 
cytometer, markers included CD3, CD4, CD8, CD38, Fas, PD-1 and Tim-3.   
 
Both studies were cross-sectional in design with a functional experimental component in the 
main study. The main objective of these studies was to determine the phenotype of CD4+ 
and CD8+ T lymphocytes which have been exposed to chronic viral infection with/without 
active TB disease by means of evaluation of a range of T cell surface markers. Markers of T 
cell inhibition included the well-defined PD-1 and Tim-3 markers together with the less well-
defined LAG-3 (CD223) and 2B4 (CD244) markers. Fas (CD95) is associated with T cell 
Collection of patient 
blood  
Frozen PBMC 
Main Study 
n= 107 
functional component 
surface staining 
10 colour flow 
Fresh whole blood 
 Pilot Study 
n= 75 
surface staining 
4 colour flow  
A 
B 
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death, but its expression is also related to immune activation. Other markers of T cell 
activation include CD38 and HLA-DR. To try to obtain a clearer understanding of the 
relationship between these processes, a range of exhaustion/negative regulatory markers 
with markers of immune activation and death was combined. PBMC and fresh whole blood 
was used in phenotypic assessment by flow cytometry techniques. Flow cytometry panels 
(Tables 3.1 and 3.3) were constructed to evaluate expression of inhibitory markers together 
in relation to the other markers. The functional capacity of the T cells (following αCD28 and 
αCD3 stimulation) in chronic HIV-1 infection was measured by means of one flow panel 
(Table 3.7).       
3.2 Study participants 
Study participants were recruited from various HIV-1 and Wellness Clinics in the Western 
Cape area which include, Kayamandi Clinic, Durbanville Clinic, Idas Valley Clinic, Klapmuts 
Clinic, Kraaifontein Community Health Centre, Eerste River Hospital, Stellenbosch Provincial 
Hospital, Tygerberg Hospital, and Karl Bremer Hospital. Study participants were recruited by 
a research nurse and written consent was given by participants before inclusion into this 
study. Routine VL and CD4 counts were done on arrival of the blood at the Division of 
Medical Virology, NHLS laboratory, Faculty of Medicine and Health Sciences, Tygerberg 
Campus.  
3.3 Inclusion criteria 
The pilot study utilized fresh whole blood and the main study utilized cryopreserved PBMCs.  
The control group for both studies consisted of 52 patients who had never been infected with 
HIV-1 and showed no clinical signs of active TB infection. Clinical records were referenced 
to confirm either infection. The HIV-1 positive group consisted of 100 HIV-1 positive patients. 
HIV-1 status of all 100 patients was confirmed with the use of two rapid HIV-1 testing strips 
which was performed at the clinics. Patients were regarded as TB negative if there were no 
clinical symptoms of active infection and lack of record of any such disease in the medical 
records. Finally, for the 25 patients dually infected with HIV-1 and active TB, confirmation of 
HIV-1 was confirmed by rapid HIV testing strips and active TB infection was diagnosed when 
medical records confirmed culture positivity or affirmative chest x-ray (CXR). ART was an 
exclusion criterion for this group (i.e. all participants were treatment naïve). All patients in the 
TB group were on early phase TB treatment (less than or equal to 3 months maximum).   
3.4 Blood collection by venipuncture 
Whole blood was collected from the clinics mentioned in section 3.2 by the research nurse 
and transported to the NHLS Medical Virology laboratory, Faculty of Medicine and Health 
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Sciences, Tygerberg Campus within 2 hours of collection.  A total of 15ml was collected from 
each patient: 10ml in sodium Heparin tubes and 5ml in ethylenediamine tetraacetic acid 
(EDTA) tubes. HIV-1 VL testing and CD4 counts were done on the EDTA blood (from 
plasma and whole blood, respectively), while p24 enzyme-linked immunosorbent assay 
(ELISA) was done on plasma from sodium heparin tubes.    
3.5 Data collection methods and instruments 
The HIV-1 positive group underwent two rapid HIV-1 tests for confirmatory purposes at the 
clinic. The TB positive group underwent sputum culture tests, pulmonary chest x-ray and 
clinical comprehensive examination to confirm their status at the clinic before enrolling in this 
study. The HIV-1 negative group first underwent a rapid HIV-1 test (First response HIV test) 
at the clinic. A confirmationatory p24 ELISA test (Vironostika, BioMerieux, The Netherlands) 
was done using their plasma from their blood at the in the NHLS Medical Virology laboratory, 
Faculty of Medicine and Health Sciences, Tygerberg Campus.  
3.5.1 Rapid HIV test  
For both the pilot and the main study, rapid HIV-1 tests were administrated by a registered 
nurse at the clinics before the blood was collected and brought to NHLS Medical Virology 
laboratory, Faculty of Medicine and Health Sciences, Tygerberg Campus for processing. 
Once the patient had agreed to take part in this study, an informed consent form was signed. 
The First Response HIV test (Premier Medical Corporation Limited, Daman, India) was the 
rapid test used to check for antibodies against HIV-1 and HIV-2. In the event that the rapid 
test was positive for HIV-1 or HIV-2, a secondary confirmatory test (Abon Biopharm, 
Hangzhou, China) was preformed to verify the result. In the event that one test was positive 
and one test was negative, a repeat of the first test was performed using the First Response 
HIV test.   
The sensitivity and specificity of the First Response HIV test is 94% and 91% respectively 
and it can detect both HIV-1 and HIV-2. The device contains membrane coated recombinant 
HIV-1 antigens on a specific test area of the strip, which binds to HIV-1 and HIV-2 antibodies 
in the patient full blood sample.  
3.5.2 p24 ELISA  
This assay was conducted in order to ensure that all samples collected from HIV-1 negative 
patients were true negatives. The Vironostika HIV-1 Antigen Microelisa system (BioMerieux, 
The Netherlands) is a quantitative enzyme-linked immunosorbent assay (ELISA) specific for 
the HIV-1 p24 core antigen and was done on HIV negative patient samples only.  
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Briefly, the Vironostika p24 ELISA was performed as follows.  Murine monoclonal antibodies 
to the HIV-1 p24 antigen are attached to the microwells of the plate, which was provided with 
the assay kit. Disruption buffer was added to all the microwells, whereafter standards, 
controls and plasma were added to all respective microwells, the plate was incubated at 
37°C for 1 hour. In the event that there was HIV-1 present in the sample being tested, viral 
antibodies in the sample would bind to the antigen attached to the wells. Unbound protein 
was then removed by washing the plate on a Multiwash II Tri-continental plate washer 
(Healthcare Technologies, Cape Town, South Africa). Monoclonal mouse anti-human HIV-1 
conjugate labelled with horse radish peroxide (HRP) was then added to all microwells and 
the plate incubated again at 37°C for 1 hour. During this incubation step, the labelled 
antibody could bind to the solid phase antibody/antigen complex. Another wash step 
followed to remove all unbound complexes before adding the tetramethylbenzidine (TMB) 
substrate.  During a 30 minute incubation period at 30°C, a colour change developed, which 
was stopped with 1 M sulphuric acid. This changed the blue colour to yellow and the plate is 
then read on a spectrophotometer at 450 nm. The intensity of the colour was directly 
proportional to the concentration in mg/ml, which was calculated from the standard curve 
generated by an Elx800 ELISA reader according to SOP.BSL3.00026.2, NHLS Medical 
Virology laboratory, Faculty of Medicine and Health Sciences, Tygerberg Campus.  
3.5.3 CD4 count  
CD4 counts were conducted for all patients in the three study groups. CD4 tests are 
regarded as a clinical marker of HIV-1 disease progression. Flow cytometry was used with 
the BD Multi Test True Count kit (BD Biosciences, San Jose, CA, USA), which includes the 
associated antibodies and tubes needed for this study. The flow cytometer utilised a four-
colour technique for CD4 quantification (BD FACS Calibur, San Jose, CA, USA). All CD4 
counts were determined in the in the Medical Virology Laboratory, Faculty of Medicine and 
Health Sciences, Tygerberg Campus. 
Fresh blood collected in EDTA tubes was stained with an antibody cocktail (CD3/8/45/4) that 
enables quantification of total CD8+ and CD3+ cells. The results from this test show total T 
cells (CD3+), Th cells (CD3+CD4+) and CTL cells (CD3+CD8+). Both absolute counts and 
percentages are determined when using the BD MultiSET® staining kit with Tru-count tubes 
(BD Biosciences, San Jose, CA, USA) in accordance with SOP.MOL.00016.5, NHLS 
Medical Virology laboratory, Faculty of Medicine and Health Sciences, Tygerberg Campus. 
3.5.4 Viral load tests 
HIV-1 VL was measured on all HIV-1 positive and HIV-1/TB co-infected patient samples. 
This test was done according to the SANAS accredited Abbott RealTime HIV-1 (Abbott 
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Laboratories, Germany) method in the routine NHLS Medical Virology laboratory, Faculty of 
Medicine and Health Sciences, Tygerberg Campus (SOP: HAE1455 NHLS version 5). It 
quantifies and reports the number of viral copies of HIV-1 that are present in 1 ml of whole 
blood in EDTA tubes (Abbott Laboratories, Germany). All VL tests were determined in the in 
the NHLS Medical Virology laboratory, Faculty of Medicine and Health Sciences, Tygerberg 
Campus.  
3.5.5 PBMC isolation   
Processing of whole blood for PBMC isolation was performed as outlined in the standard 
protocol used in the NHLS Medical Virology laboratory, Faculty of Medicine and Health 
Sciences, Tygerberg Campus (SOP: VIRO.BSL3.SOP.00042.0). Briefly, on arrival, the 
sample was centrifuged at 2000 rpm (~ 500 x g) for 10 minutes to separate the cells into 
their respective layers as shown (Figure 3.2). The plasma layer of the sample was removed 
and replaced with an equal volume of phosphate buffered saline (PBS) (LONZA, 
BioWhittaker, Belgium). Plasma was stored at -80°C in 1 ml cryogenic vials for subsequent 
p24 ELISA testing of HIV-1negative samples.  
 
Figure 3.2: Blood components. A visual representation of the 3 main layers of blood including 
plasma (containing cytokines), buffy coat (containing leukocytes and platelets) and erythrocytes (the 
red blood cell) (Blood and Immunity Test, 2015).    
Ficoll Histopaque (FH) (Sigma Life Sciences, St. Louis, MO, USA) was used in the process 
of separating PBMC based on density gradient. The concept behind FH is that once fresh 
whole blood has been layered on top of FH and centrifuged, the cells with the highest 
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density (red blood cells) move below while less dense cells (PBMC) remain above the FH. 
FH was used in a 1:2 ratio with the blood-PBS mixture. In a separate tube, the whole blood 
was carefully layered on top of the FH with special care not to mix the two layers together. 
Once layered, the sample was centrifuged again at 2000 rpm (~500 x g) for 30 minutes at 
room temperature (22ºC – 26ºC).  
On removing the sample tube from the centrifuge, PBMC layer was clearly visible (Figure 
3.3). The PBMC layer and was removed in a circular motion using a Pasteur pipette 3 ml 
(Lasec, SA) and transferred to a 15 ml BD falcon tube (BD Biosciences, San Jose, CA, 
USA). PBS was then added to the 15ml mark to perform the first wash step. The tube was 
centrifuged again at 1200 rpm (~300 x g) for 17 minutes at room temperature. The 
supernatant fluid was poured off and the pellet was re-suspended. PBS was again added to 
the sample and a second wash step was done by another centrifugation step at 1200 rpm 
(~300 x g) for 17 minutes at room temperature. The supernatant fluid was discarded again 
and the pellet re-suspended in 1ml of PBS. 
 
Figure 3.3: Separating blood into individual components using Ficoll Histopaque. A visual 
representation of the layering of blood on top of Ficoll Histopaque as a method of separating cells 
according to size (Lin et al., 2014).   
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3.5.6 Cell viability  
Viable cell counting was performed by adding 10 µl Trypan blue which stains dead cells 
based on the principle that viable/live cells do not take up this dye (LONZA, BioWhittaker, 
USA) to 10 µl of PBMC sample and mixed thoroughly. The mixture was then placed on a 
BIO-RAD dual chamber cell counter slide (BIORAD, USA) and inserted into the automated 
cell counter (BIORAD, USA). Cell counts are performed to determine both number of cells 
and their viability prior to preparation a total of one million cells for freezing in 2 ml cryogenic 
vials (Corning Incorporated, New York) before cryopreservation. 
3.5.7 PBMC freezing procedure/ Cryopreservation  
Freezing medium was prepared, consisting of 10% dimethyl sulfoxide (DMSO) in foetal 
bovine serum (FBS) (Capricorn Scientific, South America) and DMSO (Sigma Life Sciences, 
Mo, USA).  It was added to the cells in a drop-wise manner in order to minimize cell damage. 
One million cells were frozen per ml. PBMCs in cryogenic vials were placed in a Mr Frosty™ 
freezing container (Nalgene, USA) and storedovernight in a -80°C ultra-low temperature 
freezer.  The cryogenic vials were then individually stored in appropriate cryogenic boxes for 
long term storage in the liquid nitrogen tank at -127°C until further processing and analysis.    
3.5.8 Thawing of frozen PBMC  
A water bath was heated to 37°C prior to thawing the cells for 1-2 minutes. Once thawed 
fully, the content was quickly poured into a 15 ml BD falcon tube. Growth medium was 
prepared prior to defrosting the sample consisting of 10% FBS and 90% RPMI 1640 (Life 
Technologies, UK). The growth medium was added to the defrosted sample to the 15 ml 
mark and centrifuged for 10 minutes at 1000 rpm (~250 x g). The pellet was gently re-
suspended and centrifuged at 1000 rpm (~250 x g) for 10 minutes. The supernatant was 
discarded and the pellet was gently re-suspended in 1 ml of growth medium prior to cell 
count. Cells were counted and adjusted to the correct concentration based on the Trypan 
blue staining results. Once the cell count was performed, the tube was centrifuged again at 
1000 rpm (~250 x g) for 10 minutes to separate cells from the medium in preparation for 
staining for flow cytometry or for functional experiments (Refer to sections 3.6.1, 3.6.3 and 
3.7.1). For staining purposes, the supernatant was discarded and 1 ml of staining solution 
(BioWhittaker, Walkersville, MD, USA) was added to the cells.   
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3.6 Surface marker antibody staining 
3.6.1  Fresh blood processing for pilot study 
The fresh whole blood sample was divided into 100 µl aliquots, which were each added to 
the individual panels using four 5 ml FACS tubes (BD Falcon, BD Biosciences, MA, USA) 
respectively. Blood was added to the antibody cocktail and the sample was incubated for 30 
minutes in the dark at room temperature in order for the antibodies to bind to the blood. The 
sample was kept in the dark in order to preserve the fluorochromes of the antibodies (Table 
3.1). After the first incubation period, 2 ml of lysing solution (BD San Jose, CA, USA) was 
added to lyse the red blood cells.  
The sample was incubated for a further 15 minutes in the dark at room temperature. The 
sample centrifuged for five minutes at 1500 rpm (~375 x g). Supernatant and 2 ml of staining 
buffer were added. Staining buffer (BioWhittaker Walkersville, MD, USA) was used to 
stabilise the cells, and as a medium to wash the cells of leftover cell debris.  
The FACS tube was lightly tapped in order to gently mix the remaining pellet into solution. 
The sample was again centrifuged at 1500 rpm (~375 x g). The resulting supernatant was 
discarded and 350 µl of staining buffer was added to ensure the integrity of the cells until the 
sample could be processed later on the same day using a BD FACS CALIBUR flow 
cytometer. BD Stabilising Fixative (BD San Jose, CA, USA) was used to preserve the cells 
for up to a week to stop degradation of the markers and antibodies until ready to process on 
the BD FACS CALIBUR flow cytometer (San Jose, CA, USA). These samples were 
processed within a 2-day time frame using the BD FACS CALIBUR flow cytometer. All 
sample data were collected using BD CellQuest Pro Software (BD Biosciences, San Jose, 
CA, USA).  
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Table 3.1: Pilot study antibody cocktails for assigned panels. Four antibodies were added per 
tube to make up the cocktail mix in panel. Then whole blood was added to each tube. Both panels 1 
and 2 are focused on CD38 and PD-1 expression on CD8
+
 and CD4
+ 
T cell activity. Panels 3 and 4 
are focused on Tim -3 and CD95 expression on CD4
+
 and CD8
+
 T cell activity.  
3.6.2 Sources of monoclonal antibodies for pilot study  
Below is a comprehensive tabulated list of all antibodies used in this study. Volumes were 
based on manufacturer’s recommendations and subsequently confirmed by titration (Table 
3.2).   
Table 3.2: Pilot study: List of antibodies, manufacturers, isotypes and clones 
Antibodies Panel Manufacturer Cat # Volume (µl) Clone Isotype 
CD3 - FITC BB BD Biosciences, CA, USA 555339 10 HIT3a IgG2,k  
Tim-3 - PE P2,P3 Biolegend, CA, USA,  345006 2.5 F38-2E2 IgG1,k 
CD95 -  APC P3,P4 Biolegend, CA, USA 305612 2.5 DX2 IgG1,k 
PD-1 - PE P1,P4 Ebioscience, CA, USA 737659 2.5 J105 IgG1, k 
CD4 - PerCP  P3,P4 BD Biosciences, CA, USA 345770 10 sk3 IgG1,k 
CD8 - PerCP P1,P2 BD Biosciences, CA, USA 34774 10 HB-7 IgG1,k 
CD38 - APC  P1,P2 Biolegend, CA, USA 345807 2.5 HIT2 IgG1,k 
PerCp = Peridinin chlorophyll protein; APC = Allophycocyanin; PE = Phycoerythrin; FITC = Fluorescein 
isothocyanate; P1 = Panel 1; P2 =Panel 2; P3= Panel 3; P4= Panel 4; BB = Back bone. 
 
3.6.3 Preparation of panels for main study  
Antibodies were combined to form two antibody cocktails as shown in Table 3.3. The sample 
was divided into 0.5 million cells which were used for the individual panels in two 5 ml FACS 
tubes (BD Biosciences, MA, USA). Sample was added to the antibody cocktail based on 
manufacturer recommendations and titration experiments and the sample was incubated for 
30 minutes in the dark at room temperature in order for the antibodies to bind to the cells. 
Panel FITC PE PerCP APC Total volume (µl) 
1 CD3 (10 µl) PD-1  (2.5 µl) CD8 (10 µl) CD38 (2.5 µl) 25 µl 
2 CD3 (10 µl) TIM-3 (2.5 µl) CD8 (10 µl) CD38 (2.5 µl) 25 µl 
3 CD3 (10 µl) TIM-3 (2.5 µl) CD4 (10 µl) CD95 (2.5 µl) 25 µl 
4 CD3( 10 µl) PD-1  (2.5 µl) CD4 (10 µl) CD95 (2.5 µl) 25 µl 
PerCp = Peridinin chlorophyll protein; APC = Allophycocyanin; PE = Phycoerythrin; FITC = Fluorescein isothocyanate 
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After the incubation period, the sample was centrifuged for ten minutes at 1000 rpm (~250 x 
g). The FACS tube was lightly tapped in order to gently mix the remaining pellet into solution. 
Sample was again centrifuged at 1000 rpm (~250 x g) for 10 minutes. The resulting 
supernatant was discarded and 500 μl of staining buffer was added to ensure the integrity of 
the cells until the sample could be processed later on the same day using the Navios, 
Beckman Coulter flow cytometer (Beckman Coulter, CA, USA). Five hundred microliters of 
BD Stabilising Fixative (BD Biosciences, San Jose, CA, USA) was used to preserve the cells 
for up to a week to stop degradation of the markers and antibodies until ready to process on 
the Beckman Coulter flow cytometer. However, samples were usually processed within a 
day. 
Table 3.3: Main study: Antibody cocktails for assigned panels. Nine antibodies were added per 
tube to make up the cocktail mix in panel. Panel 1 includes novel inhibitory/exhaustion markers. Panel 
2 includes markers associated with inhibitory/exhaustion and apoptosis. 
Panel FITC PE ECD PE5 PE7 A647 A700 APC PB KO TV 
1 
CD244 
(2.5µl) 
TIM-3 
(2.5µl) 
CD8 
(10µl) 
X 
CD223 
(2.5µl) 
PD-1 
(2.5µl) 
CD3 
(2.5µl) 
CD4 
(5µl) 
DV 
(2.5µl) 
CD45 
(10µl) 
 
40µl 
2 
CD95 
(10µl) 
CD38 
(10µl) 
CD8 
(10µl) 
DR 
(10µl) 
X 
PD-1 
(2.5µl) 
CD3 
(2.5µl) 
CD4 
(5µl) 
DV 
(2.5µl) 
CD45 
(10µl) 
 
62.5µl 
PE5=PE-CY5; PE7=PE-CY7; A647=ALEXA647; A700=ALEXA700; PB=PACIFIC BLUE; KO=KROME ORANGE; 
DV=DAPI VIABILITY; DR= HLA-DR; TV=Total volume in µl. 
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3.6.4 Sources of monoclonal antibodies for main study  
Below is a comprehensive tabulated list of all antibodies used in this study. Volumes were 
based on manufacturer’s recommendations and subsequently confirmed by titration (Table 
3.4).    
Table 3.4: Main study: List of antibodies, manufacturers, isotypes and clones 
Antibodies Panel Manufacturer Cat # 
Volume 
(µl) 
Clone Isotype 
CD95 – FITC P2 Beckman Coulter, France IM1506 10 UB2 IgG1 
CD38 – RPE P2 Beckman Coulter, France A07779 10 LS198-4-3 IgG1 
CD4 – APC BB Beckman Coulter, France A94682 5 13B8.2 IgG1 
CD8 – ECD BB 
Beckman Coulter, CA, 
USA 
737659 10 
SFCI12Thy2
D3
5,6,22,23
 
IgG1
23
 
DAPI Viability BB 
Beckman Coulter, CA, 
USA 
B30437 2.5 
REF: 
B30437 
PN: 
B37432-
AB 
CD45 – KO BB Beckman Coulter, France A96416 10 J.33 IgG1,k 
CD223 – PE-Cy7 P1 eBioscience, CA, USA 252239 2.5 3DS223H IgG1, k 
CD244 – FITC P1 BioLegend, CA, USA 329506 2.5 C1.7 IgG1.k 
TIM-3 – PE P1 BioLegend, CA, USA 345006 2.5 F38-2E2 IgG1, k 
PD-1 – AF647 BB BioLegend, CA, USA 329910 2.5 EH12.2H7 IgG1, k 
CD3 – AF700 BB BioLegend, CA, USA 317340 2.5 OKT3 IgG2a, k 
HLA-DR–PE-CY5 P2 BD Biosciences, CA, USA 551375 10 TU36 IgG2b, k 
αCD3 F eBiosciecnes, CA, USA 160037 50 OKT3 IgG2a, k 
αPD-1 F BioLegend, CA, USA 329912 50 EH12.2H7 IgG1, K 
αCD28 F eBiosciences, CA, USA 160289 50 CD28.2 IgG1, k 
αTim-3 F BioLegend, CA, USA 345004 50 F38-2E2 IgG1, k 
PerCp = Peridinin chlorophyll protein; APC = Allophycocyanin; PE = Phycoerythrin; FITC = Fluorescein 
isothocyanate; F= Functional; P1 = Panel 1; P2 =Panel 2; BB = Back bone 
Last four antibodies were used in the proliferation assay as blocking agents.  
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3.7 Functional Component for main study 
3.7.1 In vitro stimulation  
A total of ten patient samples were used for this component. Selection was based on 
sufficient stored material being available (>4 vials per patient remaining after completion of 
the previous staining procedures). This work included stimulation of PBMC with 
αCD3/αCD28 in the presence/absence of αPD-1 and/or αTim-3. The control included an 
unstimulated sample. In the pathway component five conditions were analysed in order to 
understand if blocking certain inhibitory pathways results in improved cell effector function.  
3.7.2 Coating plates for stimulation assay 
Round bottom 96 well plates (Greiner Bio-One, Germany) were used with corresponding 
plate lids (Greiner Bio-One, Germany). A final concentration of 0.25 µg/µl of functional αCD3 
(eBioscience, USA) was used with 10% RPMI working stock as recommended by the 
manufacturer for T cell stimulation. Fifty microliters was then added to four wells in 
preparation for cell stimulation. Fifty microliters of PBS was added to one well which was 
used as the unstimulated control well (Table 3.5). The plate was covered with the plate lid 
and left overnight at room temperature as recommended by the manufacturer to obtain 
plate-bound αCD3 (eBioscience, USA).    
Table 3.5: Experimental plate setup. Each well was coated with functional αCD3 (except for 
unstimulated) 
 Well  1 Well  2 Well  3 Well  4 Well  5 
 US SO STim-3 SPD-1 S
+
T
+
P 
PBS 50µl X X X X 
Functional grade αCD3 X 50µl 50µl 50µl 50µl 
US= unstimulated; SO= stimulated only; STim-3= stimulated Tim-3; SPD-1; S
+
T
+
P= stimulated and Tim-3 and 
PD-1 
 
3.7.3 Cell staining with CFSE for proliferation determination 
A 5 mM 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) stock solution was 
prepared by adding 1 vial of CFSE 100 µg (BioLegend, CA, USA) into a 5 ml BD falcon tube 
together with 36 µl of DMSO. This was then further diluted by adding 1 ml of PBS. The final 
CFSE concentration which was added to the cells was 5 µM. The amount of CFSE 
(BioLegend, CA, USA) added to the cells for in vitro proliferation was dependent on the cell 
count per ml as indicated on the product package insert.  
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Cells were incubated for 10 minutes at 37°C. The reaction was stopped by adding 44 ml of 
ice cold 10% RPMI stock solution. Cells were centrifuged for 10 minutes at 1000 rpm (~250 
x g). Supernatant was discarded and pellet re-suspended in 500 µl of growth medium.   
3.7.4 Cell stimulation and pathway blocking  
Fifty microliters of CFSE-labelled cells were transferred to each of the five wells as shown in 
Table 3.6. In the unstimulated well: 150 µl of growth medium (RPMI+ 10% FBS) was added 
to the cells as shown in Table 3.6. 
In the stimulated only well (i.e. no blocking): 100 µl of growth medium was added to the 
cells, diluted with growth medium for a final concentration of 10 µl of functional αCD28.  
In the stimulated and αTim-3 well, 50 µl of growth medium was added to the cells diluted 
with growth medium for a final concentration of 10 µl of functional αCD28. Fifty microlitres of 
functional αTim-3 at a final concentration of 2.0 µg/µl was added to the cells with growth 
medium. An additional 50 µl of growth medium was added. 
In the stimulated and αPD-1, 50 µl of growth medium was added to the cells diluted with 
growth medium for a final concentration of 10 µl of functional αCD28. Fifty µl of functional 
αPD-1 at a final concentration of 0.5 µg/µl was added to the cells with growth medium. An 
additional 50µl of growth medium was added. 
Finally, in the stimulated well with αPD-1 and αTim-3, 50µl of growth medium was added to 
the cells diluted with growth medium for a final concentration of 10 µl of functional αCD28. 
50 µl of functional αPD-1 at a final concentration of 0.5 µg/µl was added to the cells with 
growth medium. And 50 µl of functional αTim-3 at a final concentration of 2.0 µg/µl was 
added to the cells with growth medium. 
The plates were covered and placed in the incubator at 37°C for 24-48 hours as 
recommended by the manufacturer (eBiosciences, USA).  
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Table 3.6: Antibody blocking setup. Reagents add to each round bottom well per patient sample 
 Well  1 Well  2 Well  3 Well  4 Well  5 
 US SO STim-3 SPD-1 S
+
T
+
P 
Functional grade αCD28 
(µl) 
X 50µl 50µl 50µl 50µl 
Functional grade αTim-3 
(µl) 
X X 50µl X 50µl 
Functional grade αPD-1 (µl) X X X 50µl 50µl 
Cells (µl) 50µl 50µl 50µl 50µl 50µl 
10% RPMI working stock 
(µl) 
150µl 100µl 50µl 50µl X 
Total in each well (µl) 200µl 200µl 200µl 200µl 200µl 
US= unstimulated; SO= stimulated only; STim-3= stimulated Tim-3; SPD-1; S
+
T
+
P= stimulated and Tim-3 and PD-1 
 
3.7.5 Functional staining panel  
The 96 well plates were centrifuged for ten minutes at 1000 rpm (~250 x g). The supernatant 
was discarded and the content of each well was pipetted into five 5 ml BD Falcon tubes in 
preparation for cell surface staining (Table 3.7). Sample was added to the antibody cocktail 
as recommended by manufacturer or as per titration and incubated for 30 minutes in the 
dark at room temperature. After the incubation period, the sample was centrifuged for ten 
minutes at 1000 rpm (~250 x g). The supernatant was discarded, the pellet re-suspended in 
1 ml of BD fixative and processed on Beckman Coulter flow cytometer on the same day.   
Table 3.7: Functional panel 3. Using CFSE staining to track the change in proliferation events 
Panel FITC PE ECD PE5 PE7 A647 A700 APC PB KO 
3 CFSE CD38 CD8 X X PD-1 CD3 CD4 DV CD45 
PE5=PE-CY5; PE7=PE-CY7; A647=ALEXA647; A700=ALEXA700; PB=PACIFIC BLUE; KO=KROME ORANGE; 
DV=DAPI VIABILITY 
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3.8 Flow cytometry data acquisition for pilot study  
Flow cytometry was performed using BD CellQuest Pro software (BD Biosciences, CA, USA) 
for the BD FACS CALIBUR flow cytometer. Cells were gated based on FSC verse SSC (G1 
–R1) and SSC versus CD3 (G2 – R2). CD8+ on CD4+ associated expression of Fas, PD-1, 
Tim-3 and CD38+ was then possible on a two colour dot plots.  
With respect to data acquisition, events acquired were 20 000 CD3+ lymphocyte gated 
events.  
3.9 Flow cytometry data acquisition for main study 
Samples were acquired and analysed on a Beckman Coulter, Navios flow cytometer with 
Navios software (Beckman Coulter, CA, USA). Additional post-acquisition analysis was 
performed using Kaluza version 1.3 software (Beckman Coulter, FL, USA). 
A total of 100 000 events was acquired although in some patients with low overall CD4 count 
of <250 µl less than 100 000 events were acquired.  Cells were gated according to singlet 
discrimination (Population 1, P1) followed by DAPI viability dye which stains dead cells 
(Population 2, P1) followed by CD45 vs. SS for lymphocytes (Population 3, P1), CD3 for T 
lymphocytes (population 4, P1) CD4 and CD8 (Population 5, P1). Gating on these first five 
populations was common to all three panels conducted in this study. Additionally, panel 1 
included markers of exhaustion while panel 2 included markers of activation and apoptosis. 
All surface markers of interest were plotted against each other on both CD4+ T cells and 
CD8+ T cells. Forward scatter and side scatter were used to define the lymphocyte 
population (Figure 3.4).   
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Figure 3.4 Gating strategy common to all panels in the main study. (A) single cells, (B) cell 
viability, (C) CD45
+
 for leukocytes, (D) CD3
+
 lymphocytes, (E) CD4
+
 T cells and CD8
+
 T cells   
  
A B 
D C 
E 
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Figure 3.5 Panel 1. Highlighting marker expression on CD8
+
 T cells of LAG-3, 2B4, Tim-3 and PD-1 
which was the common expression marker between the two panels. The same gating strategy was 
used all markers for CD4
+
 T cells (not shown).  
  
C 
B 
D 
A 
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Figure 3.6 Panel 2. Highlighting marker expression of Fas, CD38, HLA-DR and PD-1 which is the 
common expression marker between the two panels. The same grating strategy was conducted for 
CD4
+
 T cells (not shown).  
  
  
B A 
D C 
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Figure 3.7 Panel 3. Highlighting the five blocking conditions and how well the cells were able to 
proliferate thereafter. Diagram A and B are resting, unstimulated CD4
+
 and CD8
+
 T cells. Diagram C 
and D illustrate proliferation of the cells with marked populations on the left side of each diagram for 
both CD4
+ 
and CD8
+
 T cells.   
  
Stimulated 
Unstimulated 
B A 
D 
C 
95.9% 4.8% 95.4% 4.4 % 
79.1 % 20.9 % 27.8 % 72.5 % 
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3.10 Calculations of percentage of proliferating cells 
The percentage proliferating cells was calculated by setting a population region discriminator 
in the unstimulated cells. All events to the left of the CFSE peak were considered 
proliferating. In the above figure the unstimulated CD4+ T cells displayed 4.80% proliferation, 
and the stimulated 9.30%. Similarly, in the CD8+ T cells, the unstimulated cells displayed 
4.55% proliferating cells, whereas the stimulated 7.57%. 
3.11 Optimizing flow cytometry  
Standardization/optimization was divided into three sections namely, antibody titrations, 
Fluorescence Minus One (FMO) and compensation (Maeker and Trotter, 2006). 
3.11.1 Titrations  
Original manufacturer’s recommended volumes were used, which were later re-adapted 
based on titrations. Titrations are preformed to ensure that the correct amount of antibody is 
added to the cells in order not to over or under saturate the cells of interest as well as save 
money by not wasting antibodies. Titrations were conducted for the main study for antibodies 
of interest. The titrations were conducted on healthy PBMC controls which had been 
exposed to cryopreservation conditions for three weeks before conducting these 
experiments. A total of one million PBMCs were added to the antibody cocktails as 
suggested by the manufacturer except for the antibody of interest. For example, the 
manufacturer suggests that 10 µl of CD4 antibody be added to each test. The current 
titration experiment was divided into five tubes with five diverse amounts of CD4 antibody. In 
the first tube, double the recommended amount of CD4 antibody was added (20 µl). In the 
second tube, recommended amount of antibody was added (10 µl). In the third tube, the 
recommended amount minus 2.5 µl was added (7.5 µl). In the fourth tube, the recommended 
amount minus 5 µl was added (5 µl). In the fifth tube, the recommended minus 7.5 µl was 
added (2.5 µl). Regular staining protocol was followed as shown in section 3.6.3. All five 
tubes were analysed on the Beckman Coulter Navios flow cytometer and the results and 
graphs were produced using Kaluza Analysis Software v1.3 (Beckman Coulter, Miami, FL, 
USA).  Final selected values are indicated in Table 3.3.      
3.11.2 Fluorescence Minus One 
FMO is a control which is used to identify positive events and eliminate background noise 
from the sample. When conducting FMO experiments, all the regular antibodies are added to 
the normal amount of cells except for the one antibody of interest. The full panel is analysed 
and discriminator set for the missing antibody (minus one). All events in channel of interest 
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for the antibody were negative. Once FMO has been set a full panel is run including the 
previously absent one to check that positive vs. negative discrimination is accurate. 
3.11.3 Compensation  
The principle of compensation is to adjust for spectral overlap between fluorochromes 
emitting light that can be detected in more than one detector channel. When there are two or 
more fluorochromes used in a staining panel, whose emission spectra overlap, 
compensation has to be conducted to subtract the signal which is detected in the adjacent 
detector channel. For example FITC and PE are often used in routine flow cytometry. Their 
emission spectra overlap and portions of the PE signal is detected in the FITC channel, and 
vice versa. By using single and dual/multiple stained samples (often done with beads), the 
signal spilling into the incorrect channel can be compensated for (Hardung 2014). 
3.12 Statistical analysis  
Once all the samples were analysed using the flow cytometer, the data was compared and 
statistical analysis was conducted to confirm whether there was a significant difference 
between the median levels of inhibitory markers between the groups of interest. Flow 
cytometric data in the form of percentage positive gated events were collected on a 
Microsoft Excel spread sheet. All statistics were analysed using GraphPad Prism 6 software 
2015 (GraphPad Software, San Diego, CA, USA). One-way analysis of variance (ANOVA) 
was used for analysing all three groups together (HIV- group, HIV-1+ group and the HIV-
1+TB+ group) based on group wise comparison. A non-parametric t-test was used when 
comparing two variables such as VL for the HIV-1+ group compared to the VL of the HIV-
1+TB+ group. Hypothesis testing was done at 95% confidence intervals and results were 
regarded as significant if p<0.05 and highly significant if p<0.01. 
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CHAPTER 4: RESULTS  
In this section there will be a focus on the comparison between the results of the pilot study 
and the results of the main study. The pilot study examined four markers expressed on both 
CD4+ and CD8+ T cells namely Tim-3, PD-1, Fas and CD38 together with CD4 count and 
HIV-1 VL as clinical markers of disease progression. Furthermore, the main study included 
all the markers of the pilot study as well as LAG-3, 2B4, and HLA-DR in efforts to better 
understand if there was a connection between the respective markers and immune 
activation and/or immune exhaustion.  
4.1 Pilot study demographics 
The total number of participants who enrolled for the pilot study was 75 (Table 4.1). They 
were between the ages of 17 and 63 (mean age of 33.5 ± 11.6 years). There were 18 (24%) 
participants from Durbanville Clinic, 38 (51%) participants from Khayamandi Clinic and 19 
(25%) participants from Idas Valley Clinic. 
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Table 4.1 Patient demographics in pilot study 
 Total recruited Controls HIV+ HIV+/TB+ 
Recruited 75 30 30 15 
Analysed 73 30 28 15 
Male : Female 19 : 54 2 : 28 10 : 18 7 : 8 
Age (years) Mean ± SD 43.0 ± 12.4 30.0 ± 10.3 42.0 ± 10.2 
CD count  
(cells/µl) 
Mean ± SD 1020.0 ± 337.7 336.5 ± 251.6 277.7 ± 258.4 
Median 1014.0 309.5 234.0 
 IQR 824.3-1150 220.3-380.8 48.0-443.0 
Viral Load 
(copies/ml) 
Mean ± SD Not done 124 056.0 ± 
186 652.0 
385 603.0 ± 
455 869.0 
Median  43 688.0 213 650.0 
 IQR  14 604.0- 
158 361.0 
119 345.0-
550 990.0 
IQR = Interquartile range; SD=standard deviation 
4.1.1 Viral load  
The co-infected group had a significantly higher VL than the HIV-1 positive group (p<0.01). 
Median VL of HIV-1 positive group was 43 688.0 copies/ml, whereas in the co-infected group 
it was 213 650.0 copies/ml (Figure 4.1A). The co-infected group had a VL that is almost 5 
times more than the HIV-1 positive group. Viral load data is illustrated in Figure 4.1.A. All 
graphic representation of data across groups is by box-and whisker plot. In each plot the 
horizontal line represents the median, the box encompasses 50% of the data spread 
(interquartile range or 25-75% confidence limits), the upper and lower whisker-like 
projections represent the upper 90% and the lower 10% (i.e. data within range from tip to tip 
of whisker encompasses 80% of data, or 10-90% confidence limits). Outliers are shown as 
dots, these are values outside of the 80% spread (McKillup, 2008). 
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4.1.2 CD4 count  
The CD4 count for the control group was 1 014.0 cells/µl (IQR 824.3- 1150.0); in the HIV-1 
positive group 309.5 cells/µl (IQR 220.3- 380.8) and in the co-infected group 234.0 cells/µl 
(IQR 48.0- 443.0). The interquartile range denotes the middle 50% of values shown from 
25% to 75%. There was a significant difference (p< 0.01) between the 3 groups. The HIV-1 
VL of the two infected groups show an inverted spread when compared to CD4 count 
(Figure 4.1B).  
 
Figure 4.1 (A) Standard clinical markers of HIV and immune activation. (A) Viral load. The VL with respect 
to the number of copies found per ml of blood was significantly different between the two infected groups. 
There also appears to be a larger data spread in the HIV-1 positive group compared to the HIV-1/TB co-
infected group. (B) CD4 count. The CD4 count was highest among the control group and lowest amount the 
HIV-1 positive and HIV-1/TB co-infected groups.     
4.2 Single marker expression  
Recognition of clear patterns of spread of markers of activation, exhaustion and apoptosis 
expressed on CD4+ T was problematic throughout the pilot and the main study. As noted in 
the literature review, CD4+ T cells are the target cell for HIV-1 and a large proportion of these 
cells are lost in the acute infection stage (refer to section 2.6.3 and Figure 2.10) (Shankar et 
al., 2015). For this reason, the expression patterns displayed on CD4+ T cells may be more 
variable than on CD8+ counterparts. Consequently, a greater focus will be on CD8+ T cells 
expression pattern and how this relates to disease progression.    
4.2.1 CD38 expression on CD4+ and CD8+ T cells  
CD38 is a marker of immune activation on T cells. CD38 is known to be a useful marker of 
disease progression to AIDS when expressed on CD8+ T cells which is normally positively 
correlated to VL (Hua et al., 2014). CD38 expression was determined for both CD4+ and 
P<0.01 
B A P<0.01 
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CD8+ T cells. The CD38 expression on CD4+ T cells for the control group was 21.0% of cells 
(IQR 14.6-26.5), in the HIV-1 positive group 13.4% of cells (IQR 8.2-21.1) and in the co-
infected group 8.0% of cells (IQR 3.6-13.9). The three groups were significantly different 
(p<0.01) from each other with respect to CD38 expression (Figure 4.2A).  
The CD38 expression on CD8+ T was the inverse of CD4+ cells. The control group had a 
median value of 10.5% of cells (IQR 7.1-14.5), in the HIV-1 positive group 39.3% of cells 
(IQR 32.3-52.4) and in the co-infected group 51.7% of cells (IQR 33.9-70.8). There was a 
significant difference (p<0.01) between the three groups (Figure 4.2B). CD38 appears to 
have a similar expression pattern on CD8+ T cells as VL. CD38 was highly expressed on the 
co-infected group which also has the highest VL. CD38 expression on CD8+ T cells also 
appears to display an opposite expression pattern to CD4 count as the control group had the 
lowest CD38 expression and also the highest CD4 count compared to the other two groups 
with increased CD38 expression. TB co-infection was associated with the highest level of 
CD38 expression.       
 
Figure 4.2 (A) Activation marker CD38 on CD4+ T cells. There is a high level of CD38 
expression on CD4
+
 cells in the control group and there is a significant decrease between the HIV-1 
positive group and the HIV-1/TB co-infected group; this was not expected as CD38 is a marker of 
activation and it would not be expected that the control group would have higher expression than the 
HIV-1/TB co-infected group. A similar pattern of expression to the CD8
+
 T cells would be expected (B) 
Activation marker CD38 on CD8
+
 T cells. CD38 expression was highest in the co-infected group. 
CD38 expression on CD8
+
 T cells follows the expected pattern as the data displays greater immune 
burden and a higher expected activation. The overall CD38 expression was similar between the two 
infected groups when compared to the control.   
 
4.2.2 Fas expression on CD4+ and CD8+ T cells 
Fas is a death marker receptor and its interaction with FasL induces apoptosis. Fas 
expression has also been associated with T cell activation (Cencioni et al., 2015). The Fas 
expression on CD4+ T cells in the control group had a median value of 31.1% of cells (IQR 
26.4- 52.0), in the HIV-1 positive group 11.9% of cells (IQR 8.7- 16.0) and in the co-infected 
group 17.3% of cells (IQR 4.2- 17.9). There was a significant difference (p<0.01) between 
p<0.01 p<0.01 
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the three groups (Figure 4.3A). As with CD38 data, the Fas expression on CD8+ T cells was 
significantly higher in the disease groups. The control group had a median value of 14.6% of 
cells (IQR 10.9- 19.7), in the HIV-1 positive group 48.6% of cells (IQR 37.3- 60.5) and in the 
co-infected group 55.4% of cells (IQR 49.5- 75.1). There was a significant difference 
(p<0.01) between the three groups (Figure 4.3B). HIV-1/TB co-infection was associated with 
the highest level of Fas expression. 
 
Figure 4.3 Death marker Fas on CD4+ T cells. (A) Similar to the CD38 expression, Fas expression 
on CD4
+
 T cells was highest for control group and lowest for the HIV-1/TB co-infected group. By the 
looks of the figure, CD4
+
 T cells appear to display higher marker expression, but this may not be a 
true representation of CD4
+
 T cell processes. (B) Death marker Fas on CD8
+
 T cells. Alternatively, 
Fas expression on CD8
+
 T cells was highest on the HIV-1/TB co-infected group and lowest on the 
control group which appears to be more constant with the literature.   
 
4.2.3 PD-1 expression on CD4+ and CD8+ T cells 
PD-1 is the best described T cell exhaustion marker and highly expressed on exhausted T 
cells exposed to chronic viral infections. PD-1 is a member of the CD28/CTLA-4 family and 
once bound to its ligand, PD-L1 and PD-L2, down-regulates T cell function (Kloverpris et al., 
2014). The PD-1 expression on CD4+ T cells in the control group had a median of 8.9% of 
cells (IQR 5.1- 13.8), in the HIV-1 positive group 5.6% of cells (IQR 3.9- 9.5), and in the HIV-
1/TB co-infected group 4.2% of cells (IQR 2.9- 6.9). There was a significant difference 
(p<0.05) between the three groups (Figure 4.4A). The PD-1 expression on CD8+ T cells in 
the control group had a median value of 2.8% of cells (IQR 1.3- 6.3), in the HIV-1 positive 
group 15.2% of cells (IQR 9.6- 27.1), and in the HIV-1/TB co-infected group 11.5% of cells 
(IQR 5.7- 35.2). There was a significant difference (p<0.01) between the three groups 
(Figure 4.4B). Unlike for CD38 and Fas, the HIV-1/TB co-infected did not display the highest 
level of PD-1. 
p<0.01 p<0.01 A B 
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Figure 4.4 Inhibitory marker PD-1 on CD4+ and CD8+ T cells. (A) Inhibitory marker PD-1 on 
CD4
+
 T cells. PD-1 expression is higher in the control group and lowest in the HIV-1/TB co-infected 
group. Similar to the previous mentioned markers, it would not be expected that the healthy cells 
could display high levels of exhaustion when compared to co-infection with HIV and TB. As mentioned 
previously, the inconsistencies of the CD4
+
 T cells could be attributed to the high loss of CD4
+
 T cells 
due to viral infection. (B) Inhibitory marker PD-1 on CD8
+
 T cells. PD-1 expression on CD8
+
 T cells is 
highest in the HIV-1/TB co-infected group and lowest on the control group. These findings would be 
more in line with what was expected as chronic viral infection leads to an increase in PD-1 expression  
4.2.4 Tim-3 expression on CD4+ and CD8+ T cells 
Tim-3, like PD-1 has been associated with the exhaustion phenotype (Gautron et al., 2014). 
The Tim-3 expression on CD4+ T cells in the control group had a median value of 0.4% of 
cells (IQR 0.1- 0.6), in the HIV-1 positive group 2.3% of cells (IQR 0.4- 4.7) and in the HIV-
1/TB co-infected group 1.3% of cells (IQR 0.9- 5.7). There was a significant difference 
(p<0.01) between the three groups (Figure 4.5A).  
The Tim-3 expression on CD8+ T cells in the control group had a median value of 0.7% of 
cells (IQR 0.2- 3.3), in the HIV-1 positive group 5.9% of cells (IQR 1.4- 11.9), and in the HIV-
1/TB co-infected group 11.7% of cells (IQR 7.0- 23.9). There was a significant difference 
(p<0.01) between the three groups (Figure 4.5B). As with PD-1 expression, the HIV-1/TB co-
infected group did not display the highest median Tim-3 expression. 
  
p<0.05 p<0.01 
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Figure 4.5 Inhibitory marker Tim-3 on CD4+ and CD8+ T cells. (A) Inhibitory marker Tim-3 on 
CD4
+
 T cells. The control group appear to be displaying extremely low levels of Tim-3 while the HIV 
positive group and the HIV-1/TB co-infected group appear to have significantly higher levels. Tim-3 
expression on CD4
+
 T cells appears to follow a similar pattern to the CD8
+
 T cells (B) Inhibitory 
marker Tim-3 on CD8
+
 T cells. Tim-3 is lowest in the control group and highest in the HIV-1/TB co- 
infected group which would be expected as the infected groups are undergoing a process of immune 
exhaustion which is displayed by an upregulation of the inhibitory marker.  
4.2.5 Summary of the main findings of the pilot study 
The main finding of the pilot study was that CD38, Fas and PD-1, all followed similar 
expression patterns, with high expression of the marker in the control group for CD4+ T cells, 
while higher expression of the marker was found of the HIV-1/TB co-infected groups for 
CD8+ T cells. Tim-3 however did not follow this trend as the other markers in the pilot study 
were less than 5% expression on CD4+ T cells and below 20% expression on CD8+ T cells 
(however despite low expression on CD8+ cells, expression pattern was similar to PD-1). 
Based on the findings from the pilot study, a larger study examining activation, exhaustion 
and negative-regulation in T cell subsets was implemented. For the main study, correlations 
were calculated for all the markers of interest for both CD4+ and CD8+ T cells, which will be 
referred to as the expression data.  
4.3 Main study demographics  
The total number of participants who enrolled for this study was 107 (Table 4.2). They were 
between the ages of 17 and 62 (mean age of 37.5). There were six (5%) participants from 
Stellenbosch Day Hospital, 39 (36%) participants from Durbanville Clinic, 41 (38%) 
participants from Kayamandi Hospital, and 21 (20%) participants from Idas Valley Day 
Hospital.   
p<0.01 p<0.01 
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Table 4.2 Patient demographics in main study 
 Total recruited Controls HIV
+
 HIV
+
/TB
+
 
Recruited 107 22 73 12 
Analysed 105 22 73 10 
Male: Female 42:63 7:15 32:41 3:7 
Age (years) Mean±SD 37.4±13.7 35.6±10.6 39.6±8.6 
CD4 count 
(cells/µl) 
Mean±SD 
Median 
IQR 
1021.6±254.1 
1042.0 
788.3-1188.0 
340.6±225.4 
305.0 
190.0-456.0 
371.8±356.1 
282.5 
92.0-487.8 
Viral Load 
(copies/ml) 
Mean±SD 
 
Median 
IQR 
 
 
Not done 
237 515.5 ±     
421 055.9 
46 000.0 
15 145.0-
354 910.0 
184 888.6 ±        
219 069.1 
129 347.5 
5 635.0- 
293 561.0 
IQR= interquartile range; SD= standard deviation 
4.3.1 Viral load 
The VL in the HIV-1 infected group had a median value of 46 000.0 copies/ml, (IQR 
15 145.0- 354 910.0) whereas in the HIV-TB co-infected group it was 129 347.5 copies/ml 
(IQR 5 635.0- 293 561.0). The median VL was higher in the co-infected group compared to 
the HIV-1/TB co-infected group although this difference was not significant (p=0.9) (Figure 
4.6A). When comparing the differences between the VL of the two studies, it appears that 
the pilot study has a 1.7 times higher VL in the HIV-1/TB co-infected group compared to the 
main study’s HIV-1/TB co-infected group. Conversely, the pilot study and the main study 
appear to have similar VLs among the HIV-1 positive groups.  
4.3.2 CD4 count  
The CD4 count in the control group was 1 042.0 cells/µl (IQR 788.3- 1 188.0); in the HIV-1 
positive group 306.0 cells/µl (IQR 190.0- 456.0) and in the co-infected group 282.3 cells/µl 
(IQR 92.0- 487.8). There was a significant difference (p< 0.01) between the three groups. 
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The VL of the two infected groups did have an impact on the CD4 count, with a negative 
correlation (r=-0.4630, p<0.01 refer to Addendum D) (Figure 4.7A). The control groups 
between the two studies appear to be almost equal with a CD4 count of 1 014.0 and 1 042.0 
cells/µl. Comparing the CD4 count between the HIV-1 only positive groups, it was interesting 
to find that even though there was a two-fold difference in HIV-1 VL between the two groups, 
the data spread rendered this difference statistically insignificant (p=0.90).  
 
 
Figure 4.6 Standard clinical markers of HIV and immune activation (A) Viral load. The VL 
with respect to the number of copies found per ml of blood was not significantly different between the 
two infected groups. There also appears to be a larger data spread in the HIV-1 positive group 
compared to the HIV-1/TB co-infected group. (B) CD4 count. The CD4 count was highest among the 
control group and lowest amount the HIV-1 positive and HIV-1/TB co-infected groups.     
4.4 Single marker expression  
4.4.1 CD38 expression on CD4+ and CD8+ T cells 
When compared to the pilot study, expression of CD38 was much higher in the main study 
on both CD4+ and CD8+ T cells, and unlike the pilot study the CD4+ T cells expression 
followed patterns of CD8+ T cells, i.e. increased in diseased groups. For the main study, 
median CD38 expression on CD4+ T cells for the control group was 16.7% of cells (IQR 9.3-
23.1), in the HIV-1 positive group 42.8% of cells (IQR 26.0- 53.9), and the co-infected group 
41.7% of cells (IQR 12.3- 49.3). There was a significant difference (p<0.01) between the 
three groups (Figure 4.3 A). The CD38 expression on CD8+ T cells for the control group was 
49.6% of cells (IQR 35.9- 57.1), in the HIV-1 positive group 88.6% of cells (IQR 71.9- 96.1), 
and the co-infected group 80.3% of cells (IQR 71.0- 96.7). There was a significant difference 
(p<0.01) between the three groups (Figure 4.3B). According to the pilot study, with respect 
to CD4+ T cells, the HIV-1/TB co-infected group has the lowest expression of CD38 which 
was 1.7 times lower than the HIV-1 positive group and 2.2 times lower than the control 
A B 
p<0.01 p=0.90 
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group. Conversely, in the main study, CD38 expression was highly expressed on the HIV-
1/TB co-infected group which was 2.2 times higher than the control but 1.1 times lower than 
the HIV-1 positive group. HIV-1 VL and CD38 expression were positively correlated 
(r=0.4104, p<0.01, refer to Addendum E). The median CD38 expression value on CD4+ T 
cells was 13% for the pilot study and 43% for the main study in the HIV-1 infected group. 
The discrepancy may be due to a number of factors (see Discussion). Figure 4.8 and 4.9 
displays the expression pattern between the three groups.     
 
Figure 4.7 Activation marker CD38 on CD4+ and CD8+ T cells (A) Activation marker CD38 
on CD4
+
 T cells. The control group appears to be displaying low levels of CD38 while the HIV-1 
positive and HIV-1/TB co-infected group appear to have significantly higher levels. (B) Activation 
marker CD38 on CD8
+
 T cells. CD38 expression in the HIV-1 positive group and the HIV-1/TB co-
infected group is higher than in the control group. For both studies this marker was significant across 
the board which was expected as it is a marker of immune activation  
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Figure 4.8 Surface marker CD38 expressed on CD4+ T cells as displayed using flow 
cytometry. Surface marker CD38 expressed on CD4+ T cells as displayed using flow cytometry 
using Software plots. Each plot is representative of one individual patient sample. (A) Control group; 
(B) HIV-1 positive group; (C) HIV-1/TB co-infected group. It can be seen from these diagrams that the 
expression of CD38 on CD4
+
 T cells of the control is almost double that of the infected groups. These 
illustrates that when comparing the amount of activation expressed between the HIV-1/TB positive 
group and the co-infected group, TB co-infection appear to not influence the amount of activation 
expressed on CD4
+
 T cells.  
 
                               
Figure 4.9 Surface marker CD38 expressed on CD8+ T cells as displayed using flow 
cytometry. Surface marker CD38 expressed on CD8+ T cells as displayed using flow cytometry. (A) 
Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. Similar to the CD4
+
 group, it 
appears that co-infection with TB does not have such a big difference between the HIV-1 and HIV-
1/TB co-infected groups as shown in the pilot study. The expression of CD38 of the main study was 
two times the expression of the pilot study in the HIV-1 positive groups. Similar to the CD4
+
 cells, 
there was a higher level of granularity in the HIV-1 positive group 
4.4.2 Fas expression on CD4+ and CD8+ T cells 
Having found changes in Fas expression in the pilot study, further investigation was needed 
as there was an interest in the negative regulation (apoptosis) of exhausted T cells. In the 
main study, Fas expression on CD4+ T cells for the control group was 53.5% (IQR 43.0-
59.4), in the HIV-1 positive group 52.9% of cells (IQR 35.2- 75.2), and the co-infected group 
58.4% of cells (IQR 39.1- 93.1). There was no significant difference between the three 
groups (p=0.4 refer to Addendum C) (Figure 4.10). The Fas expression on CD8+ T cells 
displayed similar expression pattern to the pilot study, with the control group expressing 
15.9% of cells (IQR 6.7- 26.4), in the HIV-1 positive group expression was 34.0% of cells 
(IQR 16.1- 52.8), and the HIV-1/TB co-infected group expression was 43.9% of cells (IQR 
A C B 
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23.1- 63.8). There was a significant difference (p<0.05) between the three groups but there 
was no significant correlation found between Fas and VL or CD4 count (r=0.0615, p=0.6); 
(r=0.0196, p=0.9 refer to Addendum F) respectively (Figure 4.11). 
 
 
Figure 4.10 Death marker Fas on CD4+ and CD8+ T cells (A) Death marker Fas on CD4+ T 
cells. The HIV-1/TB co-infected group appears to be displaying higher levels of Fas while the HIV-1 
positive and control group appear to have no significantly difference. By observing the above figure, it 
is unlikely that Fas would be equally expressed between the three groups at such a high expression 
of 50% (B) Death marker Fas on CD8
+
 T cells. Fas expression in the HIV-1 positive group and the 
HIV-1/TB co-infected group is higher than in the control group. This expression pattern of Fas on 
CD8
+
 T cells was also found in the pilot study and is also the common trend of the other surface 
markers in this study.   
 
                          
Figure 4.11 Surface marker CD38 expressed on CD8+ T cells as displayed using flow 
cytometry Surface marker CD95 expressed on CD8+ T cells as displayed using flow cytometry. (A) 
Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. The expression of Fas was 
over three times higher in the HIV-1/TB co-infected groups when compared to the control group. 
There was a two fold increase between the control and the HIV-1 positive group.  
  
p<0.05 p=0.40 
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4.4.3 PD-1 expression on CD4+ and CD8+ T cells 
PD-1 expression on CD4+ T cells for the pilot study was lower than the main study. The PD-
1 expression on CD4+ T cells for the control group was 53.5% (IQR 43.0- 59.1), for the HIV-1 
positive group 53.9% of cells (IQR 35.3- 75.2), and for the HIV-1/TB co-infected group 
58.4% of cells (IQR 39.1- 93.1). Similar to Fas, there was high level of expression but no 
difference across the groups (Figure 4.13A). The PD-1 expression on CD8+ T cells for the 
control group was 9.5% (IQR 3.9- 15.3), in the HIV-1 positive group 31.6% (IQR 2.9- 43.3), 
and the HIV-1/TB co-infected group 34.9% (IQR 22.7- 45.5). There was a significant 
difference (p<0.01) between the three groups (Figure 4.12, Figure 4.13 and Figure 4.14). 
The PD-1 data on CD8+ T cells was comparable across the two studies.  
  
 
                           
Figure 4.12 Surface marker PD-1 expressed on CD4+ T cells as displayed using flow 
cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. Only a 
small difference was observed between the three groups which are also found on CD4
+
 T cells 
expressing Fas. 
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Figure 4.13 Exhaustion marker PD-1 on CD4+ and CD8+ T cells. (A) Exhaustion marker PD-
1 on CD4
+
 T cells. The control group appears to be displaying almost equal levels of PD-1 as the HIV-
1 positive group while the HIV-1/TB co-infected group appear to have significantly higher levels. It 
would not be expected that all three group would express similar amounts of PD-1 suggesting that all 
three groups express the same levels of exhaustion regardless of HIV infection. Reflecting on the pilot 
study, lower levels of PD-1 expression on CD4
+
 T cells was found although  higher levels of PD-1 was 
expressed in the control groups which was unexpected (B) Exhaustion marker PD-1 on CD8
+
 T cells. 
PD-1 expression in the HIV-1 positive group and the HIV-1/TB co-infected group is higher than in the 
control group. Comparing the PD-1 expression between the infected groups, it appears that there was 
almost no difference, the same was found to be true in the pilot study. 
 
                    
Figure 4.14 Surface marker PD-1 expressed on CD8+ T cells as displayed using flow 
cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. It can be 
seen that PD-1 expression was very low on the control group and significantly higher in the infected 
groups.   
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4.4.4 Tim-3 expression on CD4+ and CD8+ T cells 
In  the pilot study, the freshly isolated cells expressed very low levels of Tim-3 with a median 
expression of 3% in the HIV-1 group when compared to a median value of  almost 20% for 
frozen PBMC. High level marker expression was also found for Fas, CD38 and PD-1. The 
Tim-3 expression on CD4+ T cells for the control group was 26.6% (IQR 4.8- 12.7), for the 
HIV-1 positive group 19.6% of cells (IQR 3.2- 13.2) and for the HIV-1/TB co-infected group 
18.8% (IQR 2.7- 17.9). There was no significant difference between the three groups (p=0.6 
refer to Addendum C) (Figure 4.15A). The Tim-3 expression on CD8+ T cells for the control 
group was 6.3% (IQR 4.8- 12.7), for the HIV-1 positive group 5.5% of cells (IQR 3.5- 13.2) 
and for the HIV-1/TB co-infected group 3.5% (IQR 2.7- 17.9). There was also no significant 
difference between the three groups (p=0.6, Refer to Addendum D) (Figure 4.15B). When 
fresh blood was tested, Tim-3 expression on CD8+ T cells was almost two times higher in the 
HIV-1/TB co-infected group than in the HIV-1 only group. The control group expressed a 
very low amount of Tim-3 as expressed with a mean value of 1.8 compared to the HIV-1/TB 
co-infected group with a mean value of 16.0 which is over eight times higher in the HIV-1/TB 
co-infected group than the control group, and a difference of over 4.5 times more Tim-3 
expression in the HIV-1 group than the control group.  
 
 
Figure 4.15 Exhaustion marker Tim-3 on CD4+ and CD8+ T cells. (A) Exhaustion marker 
Tim-3 on CD4
+
 T cells. The control group appears to be displaying slightly higher levels of Tim-3 while 
the HIV-1 positive and HIV-1/TB co-infected group appear to display no difference. When compared 
to the pilot study, Tim-3 expression was 3% in the pilot study compared to 20% expression in the 
main study (B) Exhaustion marker Tim-3 on CD8
+
 T cells. Tim-3 expression in the HIV-1 positive 
group and the HIV-1/TB co-infected group is slightly lower than the control group.  
4.4.5 2B4 expression on CD4+ and CD8+ T cells 
2B4 is an inhibitory marker which has been documented to increase in expression on 
exhausted CD8+ T cells with disease progression to AIDS (Aldy et al., 2011) The 2B4 
A B 
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expression on CD4+ T cells in the control group was 21.6% (IQR 9.2- 41.3), in the HIV-1 
positive group 10.7% of cells (IQR 3.1- 21.1) and in the HIV-1/TB co-infected group 16.1% 
(IQR 2.5- 22.3). There was a significant difference (p<0.05 refer to Addendum C) between 
the three groups (Figure 4.17A and Figure 4.16). The 2B4 expression on CD8+ T cells for the 
control group was 59.2% of cells (IQR 49.7- 69.5), in the HIV-1 positive group 69.6% of cells 
(IQR 58.91- 80.98) and in the HIV-1/TB co-infected group 75.1% of cells (IQR 44.3- 79.6). 
There was a significant difference (p<0.05) between the three groups (Figure 4.17B and 
Figure 4.18). Interestingly the 2B4 data showed a trend observed in the pilot study for CD38, 
Fas and PD-1 – namely decreased expression in CD4+ T cells across groups, but increased 
expression in CD8+ T cells across the groups. 
 
 
                            
 
 
 
 
  
 
 
Figure 4.17 Inhibitory marker 2B4 on CD4+ and CD8+ T cells. (A) Inhibitory marker 2B4 on 
CD4
+
 T cells. The control group appears to be displaying higher levels of 2B4 while the HIV-1 positive 
and HIV-1/TB co-infected group appear to have significantly lower levels. (B) Inhibitory marker 2B4 on 
CD8
+
 T cells. 2B4 expression in the HIV-1 positive group and the HIV-1/TB co-infected group is higher 
than in the control group. Novel marker 2B4, displayed an opposite expression pattern between CD4
+
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Figure 4.16 Surface marker CD244 expressed on CD4+ T cells as 
displayed using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) 
HIV-1/TB co-infected group. It appears that this marker is highly expressed on the 
control and to a lesser extend expressed on the infected groups. 
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and CD8
+
 T cells which is similar to the expression pattern of Fas in the main study and Fas, CD38 
and PD-1 in the pilot study. The expression of 2B4 between the control groups three times higher in 
CD8
+
 T cells. The expression of this marker was also seven times higher on the CD8
+
 T cells 
compared to the CD4
+
 T cells.     
 
 
     
                                           
Figure 4.18 Surface marker CD244 expressed on CD8+ T cells as displayed using flow 
cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. This 
gradual increase in 2B4 expression could suggest that this marker is an indicator of immune 
exhaustion in CD8
+
 T cells  
4.4.6 HLA-DR expression on CD4+ and CD8+ T cells  
HLA-DR is a marker of immune activation and normally follows a similar expression pattern 
to CD38 when expressed on CD8+ T cells (Sullivan et al., 2015). HLA-DR expression on 
CD4+ T cells did indeed appear to follow a similar expression pattern to CD38 which would 
be expected as both are markers of immune activation. The HLA-DR expression on CD4+ T 
cells for the control group was 1.9% of cells (IQR 0.9- 2.5), in the HIV-1 positive group 5.7% 
of cells (IQR 3.2- 9.8) and the HIV-1/TB co-infected group 5.9% of cells (IQR 3.7- 19.5). 
There was a significant difference (p<0.01 refer to Addendum C) between the three groups 
(Figure 4.19A and Figure 4.20). The HLA-DR expression on CD8+ T cells for the control 
group was 100% (IQR 99.9- 100), in the HIV-1 positive group 99.9% of cells (IQR 99.9- 100) 
and the HIV-1/TB co-infected group 100% (IQR 99.9- 100). There was no significant 
difference between the three groups (p=0.5 refer to Addendum D) (Figure 4.19B). These 
were unexpected data – and may be indicative of antibody saturation or other factors (see 
Discussion) 
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Figure 4.19 Activation marker HLA-DR on CD4+ and CD8+ T cells. (A) Activation marker 
HLA-DR on CD4
+
 T cells. The control group appears to be displaying lower levels of HLA-DR while 
the HIV-1 positive and HIV-1/TB co-infected group appear to have significantly higher levels. 
Comparable to CD38 as a marker of T cell activation, HLA-DR is following a similar expression 
pattern. (B) Activation marker HLA-DR on CD8
+
 T cells. HLA-DR expression in the HIV-1 positive 
group, HIV-1/TB co-infected group and the control group are out of range and will be discussed in the 
results section.   
 
 
                            
Figure 4.20 Surface marker HLA-DR expressed on CD4+ T cells as displayed using 
flow cytometry. Surface marker HLA-DRC expressed on CD4+ T cells as displayed using flow 
cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. Even though 
the expression of HLA-DR is quite low, it can be seen that the expression pattern increases as 
disease burden increases. 
4.4.7 LAG-3 expression on CD4+ and CD8+T cells 
High expression of LAG-3 on the surface of T cells is associated with advanced HIV-1 
disease (Pena et al., 2014). The LAG-3 expression on CD4+ T cells for the control group was 
2.9% (IQR 1.2- 5.4), in the HIV-1 positive group 1.3% of cells (IQR 0.2- 4.4) and the HIV-
1/TB co-infected group 1.4% of cells (IQR 0.5- 7.0). There was no significant difference 
between the three groups (p=0.1 refer to Addendum C) (Figure 4.21A). The LAG-3 
expression on CD8+ T cells for the control group was 3.3% of cells (IQR 2.0- 4.6), in the HIV-
1 positive group 3.2% of cells of cells (IQR 1.1- 5.9) and the HIV-1/TB co-infected group 
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2.2% of cells (IQR 1.0- 6.9). There was no significant difference between the three groups 
(p=0.9 refer to Addendum D) (Figure 4.21B). This was thus overall poor expression of this 
marker in both cell types examined and in both healthy and diseased groups.  
 
 
Figure 4.21 Inhibitory marker LAG-3 on CD4+ and CD8+ T cells. (A) Inhibitory marker LAG-3 
on CD4
+
 T cells. The control group appears to be displaying slightly higher levels of LAG-3 while the 
HIV-1 positive group and HIV-1/TB co-infected group appear to have equal levels of expression. (B) 
Inhibitory marker LAG-3 on CD8
+
 T cells. LAG-3 expression in the HIV-1 positive group and the 
control group is almost equal while the HIV-1/TB co-infected group is slightly lower. It was 
disappointing to find that LAG-3 did not give significantly difference expression patterns between the 
groups, however, LAG-3 appears to be expressed mostly in the control groups which is not in 
accordance with the literature which describes this marker as being elevated on exhausted CD8
+
 T 
cells.  
4.4.8 Summary of the main findings of the main study in relation to single 
marker expression 
To summarize the above data, it appears that markers 2B4, PD-1, Fas and CD38 were up-
regulated on CD8+ T cells in disease groups and share a similar expression pattern. There 
was not a significant difference in the marker expression between the groups for LAG-3, 
HLA-DR and Tim-3. Co-expression of PD-1, LAG-3, Tim-3, 2B4, Fas and CD38 were further 
analysed to understand if co-expression of these marker is higher than single expression 
and how this relates to disease progression.     
4.5 Dual marker expression (co-expression) 
Extensive analysis of dual expression was performed. From this several markers gave 
statistical significant differences across the patient groups, these are indicated below.    
p=0.90 p=0.10 
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4.5.1 PD-1 and LAG-3 expression on CD8+ T cells may be linked 
Although only PD-1 showed a significant increase in the infected groups in single 
expression, co-expression with LAG-3 on CD8+ T cells was significantly different between 
the groups, despite being very low expression levels. The dual expression of these markers 
on CD8+ T cells for the control group was 0.4% of cells (IQR 0.2- 0.8), in the HIV-1 positive 
group 1.2% of cells (IQR 0.3- 2.7) and the HIV-1/TB co-infected group 1.1% of cells (IQR 
0.3- 3.5). There was a significant difference (p<0.05) between the three groups (Figure 4.22 
A). PD-1 and LAG-3 positively correlated (r=0.3825, p=0.01 refer to Addendum F) on CD8+ T 
cells which could imply that as PD-1 is co-expressed with LAG-3 on exhausted T cells in low 
amounts when compared to single expression of 3.2% and 31.6% for LAG-3 and PD-1 
respectively. The dual expression of these markers on CD4+ T cells for the control group 
was 0.7% of cells (IQR 0.2- 1.1), in the HIV-1 positive group 0.5% of cells (IQR 0.1- 2.0) and 
the HIV-1/TB co-infected group 0.2% of cells (IQR 0.0- 1.1). There was no significant 
difference between the three groups (p=0.9 Refer to Addendum C) (Figure 4.22 and Figure 
4.23A). 
 
                               
Figure 4.22 Surface markers LAG-3 and PD-1 expressed on CD8+ T cells as displayed 
using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. 
It can be seen from the diagrams above that the overall dual expression of these markers is low 
compared to the more dominant expression of PD-1 alone.   
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Figure 4.23 Exhaustion marker PD-1 and inhibitory marker LAG-3 on CD8+ T cells (A) 
Exhaustion marker PD-1 and inhibitory marker LAG-3 on CD8
+
 T cells. The control group appears to 
be displaying lower levels of both markers while the HIV-1 positive and HIV-1/TB co-infected group 
appear to have significantly higher levels. (B) Exhaustion marker PD-1 and inhibitory marker 2B4 on 
CD8
+
 T cells. Both markers are expressed at significantly higher levels in the HIV-1 positive group and 
the HIV-1/TB co-infected group when compared to the control group.  
4.5.2 PD-1 and 2B4 expression on CD4+ and CD8+ T cells 
Both PD-1 and 2B4 displayed significant differences as single markers across the study 
groups. The dual expression of these markers on CD4+ T cells for the control group was 
3.9% of cells (IQR 1.7- 11.2), in the HIV-1 positive group 5.4% of cells (IQR 1.8- 48.6) and 
the HIV-1/TB co-infected group 3.8% of cells (IQR 0.8- 15.8). There was no significant 
difference between the three groups (p=0.7 refer to Addendum C). The dual expression of 
these markers on CD8+ T cells for the control group was 8.3% of cells (IQR 5.4- 14.4), in the 
HIV-1 positive group 27.2% of cells (IQR 18.3- 35.5) and the HIV-1/TB co-infected group 
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25.6% of cells (IQR 20.4- 32.2). While there was a significant difference (p<0.01) between 
the three groups (Figure 4.23B and Figure 24), there was no correlation between the two 
markers (r=0.2065, p=0.1 refer to Addendum F). 
 
 
                 
Figure 4.24 Exhaustion marker PD-1 and inhibitory marker 2B4 expressed on CD8+ T 
cells as displayed using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-
1/TB co-infected group. On first glance, it appears that PD-1 and 2B4 expression is highest when 
expressed together on CD8
+
 T cells; however, single expression of these markers has shown to be 
even higher in expression.   
4.5.3 Tim-3 and 2B4 expression on CD4+ and CD8+ T cells 
The dual expression of these markers on CD4+ T cells for the control group was 7.3% (IQR 
3.2- 15.2) in the HIV-1 positive group 3.5% of cells (IQR 1.1- 7.4) and the HIV-1/TB co-
infected group 2.4% of cells (IQR 1.1- 6.8). There was a significant difference (p<0.05) 
between the three groups (Figure 4.25 and Figure 4.26) as well as displaying a positive 
correlation (r=0.4918, p<0.05 refer to Addendum E). The dual expression of these two 
markers is lower than the single expression of these markers, which could suggest that 
these markers, while positively correlated, are better markers of exhaustion when examined 
individually on CD4+ T cell. The dual expression of these markers on CD8+ T cells for the 
control group was 5.6% of cells (IQR 2.8- 8.4), in the HIV-1 positive group 3.8% of cells (IQR 
2.1- 8.8) and the HIV-1/TB co-infected group 3.1% (IQR 1.2- 11.3). There was no significant 
difference between the three groups (p=0.6 refer to Addendum D).  
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Figure 4.25 Surface markers 2B4 and Tim-3 expressed on CD4+ T cells as displayed 
using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-infected group. 
The overall single expression of Tim-3 is almost twice that of 2B4. While compared to the single 
expression of these markers, Tim-3 expression was over 5.5 times higher than dual expression of 
these markers.  
 
 
 
Figure 4.26 Exhaustion marker Tim-3 and inhibitory marker 2B4 on CD4+ T cells. The 
control group appears to be displaying higher levels of both markers while the HIV-1 positive and co-
infected group appear to have significantly lower levels.   
4.5.4 LAG-3 and 2B4 expression on CD4+ and CD8+ T cells 
The dual expression of these markers on CD4+ T cells for the control group was 1.0% of 
cells (IQR 0.4- 2.4), in the HIV-1 positive group 0.2% of cells (IQR 0.1- 1.2) and the HIV-
1/TB co-infected group 0.2% of cells (IQR 0.0- 0.8). Even though the expression was low on 
CD4+ T cells, there was a significant difference (p<0.05) between the three groups (Figure 
4.27 and Figure 4.28) and a positive correlation (r=0.0113, p=0.01 refer to Addendum E) 
between the two markers. Similar to the dual expresion of Tim-3 and 2B4, these two 
inhibitory markers are expressed higher individually than mutrually. The dual expression of 
these markers on CD8+ T cells for the control group was 1.9% of cells (IQR 1.2- 3.2), in the 
A 
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HIV-1 positive group 2.6% of cells (IQR 0.9- 4.6) and the HIV-1/TB co-infected group 1.8% 
of cells (IQR 0.8- 3.6). There was no significant difference between the three groups (p=0.6 
refer to Addendum D).  
 
 
Figure 4.27 Inhibitory markers LAG-3 and 2B4 on CD4+ T cells. Both markers are 
expressed at significantly lower levels in the HIV group and the HIV-1/TB co-infected group when 
compared to the control group. Both these sets of surface markers expressed on CD4
+
 T cells 
correlated positively however, that dual expression was lower than single expression of these 
markers.  
 
                          
Figure 4.28 Surface markers CD244 (2B4) and CD223 (LAG-3) expressed on CD4+ T 
cells as displayed using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-
1/TB co-infected group. Overall the expression of 1.3% for single expression of LAG-3 was over six 
times higher than the co-expression of both markers of interest.  
4.5.5 Fas and CD38 expression on CD4+ and CD8+ T cells 
The dual expression of these markers on CD4+ T cells for the control group was 0.4% of 
cells (IQR 0.2- 0.7), in the HIV-1 positive group 2.2% of cells (IQR 0.8- 3.4) and the HIV-
1/TB co-infected group 2.4% of cells (IQR 0.6- 16.7). There was a significant difference 
(p<0.01) between the three groups (Figure 4.29 and Figure 4.30) but there was no 
correlation of these markers on either CD4+ or CD8+ T cells. The dual expression of these 
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markers on CD8+ T cells for the control group was 1.8% of cells (IQR 0.3- 4.1), in the HIV-1 
positive group 14.6% of cells (IQR 0.0- 22.4) and the HIV-1/TB co-infected group 18.4% of 
cells (IQR 3.2- 36.4). There was a significant difference (p<0.01) between the three groups 
(Figure 4.30 and Figure 4.31). While there was no correlation between these two markers on 
CD4+ T cells there was six times higher expression on the co-infected group when compared 
to the control group. Between the infected groups, the HIV-1/TB co-infected group 
expressed over two times more Fas and CD38 when compared to the HIV-1 only group. 
Dual expression of these two markers on CD8+ T cells was highest on the HIV-1/TB co-
infected group and lowest on the control group which is in line with the current literature. 
Dual expression of these markers was 1.3 times higher in the HIV-1/TB co-infected group 
than the HIV group and over nine times higher in the HIV-1/TB co-infected group compared 
to the control group.  
 
                             
Figure 4.29 Surface markers CD38 and CD95 (Fas) expressed on CD4+ T cells as 
displayed using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-
infected group. These two markers were not correlated even though the co-expression was 
significantly difference between the groups. The low levels of co-expression compared to the high 
single expression of CD38 could mean that these markers are better analysed separately.   
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Figure 4.30 Death marker Fas and activation marker CD38 on CD4+ and CD8+ T cells. 
(A) Death marker Fas and activation marker CD38 on CD4
+
 T cells. The control group appears to be 
displaying low levels of both markers while the HIV-1 positive and HIV-1/TB co-infected group appear 
to have significantly higher levels. (B) Death marker Fas and activation marker CD38 on CD8
+
 T cells. 
Dual expression in the HIV-1 positive group and the HIV-1/TB co-infected group is higher than in the 
control group. These are two important markers of T cell activation and apoptosis. However, dually 
expressed, these markers did not correlate as it would be expected. It would be expected that a large 
number of CD4
+
 cells would express Fas as well as CD38 as these cells are the target cell for this 
virus.   
 
 
B 
A 
p<0.01 
p<0.01 
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Figure 4.31 Surface markers CD38 and CD95 (Fas) expressed on CD8+ T cells as 
displayed using flow cytometry. (A) Control group; (B) HIV-1 positive group; (C) HIV-1/TB co-
infected group. Dual expression of CD38 and Fas appears to be following a pattern of increased 
express as disease burden increases among the groups. However, it was also found that single 
expression of both these markers was higher than dual expression.    
 
4.6 T cell stimulation (Proliferation) 
Having established in both the pilot study and the main study that diseased groups display 
elevated levels of activation, exhaustion and death markers (especially the CD8+ T cell 
subset), the next step was to investigate whether these cells in vitro were functionally 
impaired and whether blocking exhaustion markers could restore function. Functional 
responses were monitored in the HIV-1 positive group alone, following αCD3 and αCD28 
stimulation of CFSE labelled cells. To assess the role of PD-1 and Tim-3 exhaustion 
pathways, these markers were blocked independently and together. 
 
The stimulation procedure resulted in increased median proliferation in both CD4 and CD8 T 
cells. The median unstimulated proliferation in CD4+ T cells was 4.8%, and following 
stimulation 9.3% of cells. In CD8+ T cells unstimulated proliferation was 4.6%, and following 
stimulation 7.8% of cells. In both CD4+ and CD8+ T cells, the change in proliferating cells 
was statistically significant (Refer to Table 4.3). The blocking of the Tim-3 and PD-1 
pathways was not effective in enhancing responsiveness overall. Only Tim-3 blocking in the 
CD8+ group showed an increased in median proliferating cell percentage (10.1%), however 
this was not statistically significant. 
 
When comparing the CD8+ T cells it appeared that blocking Tim-3 and PD-1 was not as 
beneficial as blocking Tim-3 alone with a mean value of 12.28 (Figure 4.32B). One of the 
main findings of the current study was the negative correlation between CD4 count together, 
Tim-3 (inhibition marker), CD38 (activation marker) and VL on CD8+ T cells. It appears that 
CD8+ T cells were more susceptible to Tim-3 blocking than PD-1 blocking which is 
unexpected as the expression of Tim-3 on CD8+ T cells was on 6% compared to PD-1 of 
31.6%.  
B C A 
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Figure 4.32 Proliferation assay. (A) Proliferations assay on CD4+ T cells displaying the five 
cell conditions. (B) Proliferation assay on CD8+ T cells displaying the five cell conditions. 
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Table 4.3 Functional responses to αCD3 and αCD28 proliferation assay. This blocking 
and proliferation assay was conducted using five conditions. 
 Unstimulated Stimulated Block Tim-3 Block PD-1 Block both 
CD4
+
 T cells 
Median 
 
IQR 
 
4.8  
 
2.0-5.5 
 
9.3  
(4.5% change) 
4.8-22.1 
 
9.85  
(0.5% change) 
4.75-17.0 
 
7.88  
(-1.97% change) 
5.0-28.7 
 
6.52  
(-1.36% change) 
2.4-28.4 
CD8
+
 T cells 
Median 
 
IQR 
 
4.55 
 
2.9-5.4 
 
7.57 
(3.02% 
change) 
6.6-20.2 
 
10.11 
(2.54% change) 
6.3-18.4 
 
7.58  
(-2.53% change) 
5.0-16.1 
 
7.63  
(0.05% change) 
2.6-14.4 
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CHAPTER 5: DISCUSSION  
In this study the expression of a range of co-inhibitory/exhaustion markers (PD-1, Tim-3, 
LAG-3 and 2B4) together with activation markers (HLA-DR and CD38) and death marker 
CD95/Fas was investigated in uninfected, HIV-1 infected and HIV/TB co-infected patients. 
The primary aim was to relate these markers to clinical indicators (CD4 count and VL) of 
disease progression to AIDS.  
Inhibitory/exhaustion markers are a topic of intense research as they offer potential targets 
for therapeutic intervention in chronic disease. Human check-point therapy in cancer has 
proven potentially highly efficacious and the application of this approach in chronic infectious 
diseases is envisaged in the future. Another primary aim of this study was to ascertain if TB 
co-infection (active disease) exacerbates the expression of these markers and also whether 
any of the novel markers (LAG-3 and 2B4) are better biomarkers/targets based on good 
relevance (correlation) to standard clinical markers. While the two studies (pilot study on 
fresh whole blood and the main study on frozen PBMC) were comparable with respect to 
sampling criteria, we did however find differences in the marker expression which was 
unexpected.  
5.1 Clinical markers of disease progression to AIDS 
As described in many studies, we observed that the VL for the HIV-1 positive groups (mono- 
and co-infected) was highest among these individuals with the lowest CD4 count (Wanchu et 
al., 2010; Hunt et al., 2011; Sauce et al, 2011). As reported by Pillay et al., (2009) and Hunt 
et al., (2011), TB co-infection with HIV-1 leads to dysfunctional CTL responses, which could 
then lead to an inability of the CTL to control viral replication. With high viral replication in the 
blood and tissues, this leaves the individual exposed to opportunistic infections, which could 
result in death.   
CD4+ T cells (as reviewed by Siawaya et al., 2007), play a major role in the protection 
against TB infection and reactivation. When a patient is infected with HIV-1, the CD4+ T cells 
are depleted and cannot control the TB either. The CD4 count was significantly different 
between all three study groups as expected with the infected groups displaying the lowest 
CD4 count. This appears to be in line with the current literature which states that there is an 
inverse relationship between VL and CD4 count (Hertoghe et al., 2000; Smith et al., 2013). 
This has been attributed to dysfunctional CTL responses that lead to the inability to control 
viral replication, resulting in an increase in the number of circulating viral particles. With an 
increase in the number of circulating virus particles, there is depletion in the total number of 
infected CD4+ T cells and uninfected bystander CD4+ T cells. Nardacci et al., (2015), state 
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that with a decrease in uninfected bystander CD4+ T cells there is a greater likelihood of 
opportunistic diseases due to weakening of the immune system.  
 
The control of TB in HIV uninfected individuals is well documented to be linked to functional 
CD4+ T cells producing cytokines, such as IFN-ү and TNF-α. These cytokines lead to an 
increased recruitment of cells, such as monocytes and granulocytes to the granuloma. 
Increased cytokine production in turn, would lead to enhanced and more effective 
phagocytosis of TB bacteria and containment of disease (Li et al., 2007; Siawaya et al., 
2007). CTLs only become activated during active TB infection and not during latent TB 
infection. Furthermore, in line with previous studies, Rozot et al., (2013), highlighted the 
essential role of CD4+ T cells in protection against TB, since CD4+ T cell depletion is also 
associated with TB reactivation in HIV-1 infected patients and those with uncontrolled 
mycobacterial growth.  
 
5.2 Clinical marker of immune activation and disease progression 
CD38 is a well characterised marker of immune activation and is regularly used as an 
indicator of accelerated disease progression to death (Cockerham et al., 2014). In the main 
study it was found that there was a significant negative correlation between CD38 
expression on CD8+ T cells and CD4 count in the HIV-1/TB co-infected group. The theory 
behind pairing immune activation and disease progression is due to highly activated CD8+ T 
cells leading to T cell exhaustion and the inability of the CD8+ T cell to perform its cytotoxic 
function in controlling viral replication (Musyoki et al., 2014). While the expression pattern 
was found to be true for both the pilot and the main study, no significant correlation was 
found to support the findings by Musyoki and colleagues. 
 
Furthermore, in the main study it was found that CD4 count negatively correlated with Tim-3 
expression, CD38 expression on CD8+ T cells and viral load. As stated earlier, This could 
then suggest that with high activation (CD38) over an extended period of time, the CD8+ T 
cells tire, effective cytotoxic function decreases leading to an increase in VL and a decrease 
in CD4 count (Dietze et al., 2013; Ezinne et al., 2014). To support our current findings, 
Gornalusse et al., (2015), found that there was a link between immune activation and the 
number of CCR5 receptors available for HIV binding to CD4+ T cells resulting in a decrease 
in CD4 count. Furthermore, this is in line with the literature that explains the high levels of 
CD38 expression on CD8+ T cells is a good clinical marker of disease progression (Holm et 
al., 2008; Sullivan et al., 2015). It was found in this study that both infected groups showed 
higher expression of CD38 on CD8+ T cells when compared to the control group. Siawaya et 
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al., (2007), found that a 10% increased expression of CD38+ on CD8+T cells is associated 
with an 88% added risk that AIDS could develop. Similarly, as reviewed by Hua et al., 
(2014), CD38 expression on CD8+ T cells is one of the strongest predictors of disease 
progression towards AIDS. A low CD38+ expression was observed in the control group (as 
expected) in both studies.  
 
Similarly in the current study, CD4 count negatively correlated with CD38 and VL as well as 
HLA-DR on CD4+ T cells for the HIV-1 positive group. As mentioned earlier, VL increases 
the expression of CD38 and HLA-DR on activated CD4+ T cells which also express more 
CCR5 receptors leading to an increase in infection of these cells (Oyaizu et al., 1994). Smith 
et al., (2013) also found that CD38 and HLA-DR were up-regulated on CD4+ T cells in HIV-1 
positive groups with a high VL. Our findings are in line with previous studies that have found 
an inverse relationship between VL and CD4 count together with an increase in immune 
activation on both CD4+ and CD8+ T cells as the disease progresses to AIDS (Cockerham et 
al., 2014). Bastidas et al., (2013), states that continuous loss of CD4+ T cells and an 
increase in CD8+ T cell activation is expected in individuals with HIV infection with as high as 
60% dual expression of CD38 and HLA-DR. In line with the current study, , CD38 and HLA-
DR dual expression (of almost 40%) on CD8+ T cells was the two highest dual expressing 
markers in this study (p<0.01).   
 
In comparison, studies which examined the dual expression on CD38 and HLA-DR in elite 
HIV controllers, have found that these individuals have a genetic mutation which allows them 
to maintain viral replication at a very low level and in turn decrease the adverse effects of 
immune activation (Hua et al., 2014). These individuals are able to maintain a healthy CD4 
count (> 500 cells/µl) for more than 10 years without ART (Munier et al., 2013). Therefore, 
by limiting the amount of circulating virus in the blood for many years, they are able to slow 
down the progression to AIDS (Sauce et al., 2011; Smith et al., 2013). This also limits the 
amount of immune activation of the T cells  
 
The expression of HLA-DR on CD8+ T cells in the main study was problematic as all three 
groups appear to express almost 100% of this marker. This would incorrectly imply that the 
control group was expressing the same degree of immune activation as the HIV-1 positive 
and co-infected groups, which is not in line with the current literature. We surmised that the 
result may have been due to antibody saturation, non-specific binding, incorrect 
compensation or voltage setting. The absence of a similar finding in the CD4+ group seems 
to exclude saturation as a potential cause.  
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5.3 The effects of cryopreservation on T cell marker expression    
It was interesting to note that an overall expression of CD38 on CD8+ T cells for the HIV-1 
positive group of 40% for fresh whole blood and 88% for frozen PBMCs, which could be 
attributed to the process of long term cryopreservation. While the topic of long term cell 
preservation and whether it causes irreversible damage to the cells is still in debate, Holm et 
al., (2008), found that the expression of CD38 tended to decrease on frozen T cell when 
compared to the fresh sample which is the opposite of what was found in the current study. 
They also found that cryopreserved CD4+ T cells from HIV positive individuals experienced a 
high level of apoptosis at a rate loss of approximately -45.7 cells per year. The rate loss 
denotes that for every year which a HIV-1 positive CD4+ T cells are kept under 
cryopreservation conditions, on average 45.7 CD4+ T cells are lost due to apoptosis. 
Germann et al., (2013), also found that cells exposed to the harsh conditions of 
cryopreservation were more prone to apoptosis than those cells which had not undergone 
the process. Their study concluded that cells expressing high levels of PD-1 and CD38 on 
CD8+ T cells experienced the greatest CD4+ T cell loss. In relation to the poor overall 
performance of the CD4+ T cells in this study, Holm et al., (2008), supports the notion that 
frozen cells performed less than optimally as a result of extremely high levels of CD38+ on 
CD8+ T cells together with PD-1. It has been well documented that the CD8+ T cells which 
express CD38 and PD-1 are less able to control viral replication leading to a decrease in 
CD4+ T cells (Cockerham et al., 2014). It should be noted that in the current study, 
cryopreservation was not the only variable between the pilot and the main study; whole 
blood versus PBMC, 4 colour verse 9 colour flow cytometry and different gating strategies 
(with or without CD45 and viability) were additional variables.   
 
On the other hand, Weinberg et al, (2009), found no significant difference between fresh and 
frozen T cells with regard to the markers expressed, viability and proliferation of the cells due 
to long term storage. Similarly, Riccio et al., (2002), also found that PBMCs which were 
exposed to cryopreservation did not increase the likelihood of apoptosis. It must be noted 
that Weinberg et al., (2009), examined cells which were cryopreserved for a period not 
longer than 15 months, which does not address the issue of longer term damage caused by 
cryopreservation for samples stored for a number of years. In the current study, cells were 
kept under cryopreservation conditions for almost 36 months.     
5.4 PD-1 down regulates T cell effector function 
PD-1 is a well characterised exhaustion marker of T cells expressed in chronic HIV infection. 
PD-1 has been found to down-regulate T cell function during inflammation (Wherry, 2011). 
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While down-regulation can be viewed as a protective mechanism, decreasing CD8+ T cell 
function has a negative effect on the overall immune survival by decreased effector function 
in the control of viral replication. Rozot et al. (2013), showed that CTLs responded to high TB 
antigen burden, as the protective role of CTLs in TB is based on the ability to lyse infected 
cells.  
In the pilot study, PD-1 expression on CD8+ T cells was 3 times as high in the HIV-1/TB 
group as the control group (p<0.01). According to Kulpa et al., (2013), chronic viral infection 
leads to increase levels of PD-1 and a reduced ability to clear viral infection. The PD-1 
expression on CD8+ T cells in the pilot study was almost double the amount on the co-
infected cells when compared to the HIV-1 only group (p<0.01). This holds true to the 
literature that states that an increased immune burden in a co-infected setting is associated 
with an increase in exhaustion markers.  
5.5 Novel marker Tim-3 expression was inconsistent  
The purpose of the pilot study was to investigate if there was a significant difference 
expressed of the marker Tim-3. On completion of the pilot study it was found that Tim-3 
displayed a significant difference in levels of expression across the three groups on CD4+ 
and CD8+ T cells. Tim-3 was expressed in lower levels on CD4+ T cells (less than 5%) when 
compared to CD8+ T cells. Further research was needed to understand if Tim-3 acts 
independently of PD-1 expression or if Tim-3 was up-regulated simultaneously with PD-1. It 
was concluded in the pilot study that Tim-3 was most likely unrelated to PD-1 because Tim-3 
was expressed at much lower levels than PD-1 and with a very different expression pattern 
on CD4+ and CD8+ T cells.  
 
Tim-3 was added to the main study to investigate if other related surface markers of 
activation and exhaustion would have an effect on the Tim-3 expression pattern. The pilot 
study showed that Tim-3 expression on CD8+ T cells was almost twice as high in the HIV-
1/TB group as in the HIV-1 only group. The expression of Tim-3 in the HIV-1/TB group was 
almost 9 times higher than in the control group (p<0.01). This would be expected as Tim-3 
has been documented as a marker of immune exhaustion, which is not expected to be 
present in healthy participants. Similarly, a study by Sakhdari et al., (2012), found that there 
was an increase in expression of Tim-3 on CD8+ T cells, which were infected with HIV-1. In 
the main study it was found that Tim-3 expression on CD4+ T cells while low was slightly 
higher in the control group when compared to the HIV and co-infected groups. As Tim-3 is a 
marker of T cell exhaustion, it would be expected that both infected groups would elicit 
greater expression. The Tim-3 expression pattern on CD8+ T cells did not follow that of the 
pilot study and is not in line with the literature. Perhaps the low level of Tim-3 expression on 
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CD8+ T cells could be attributed to the fact that this group had a lower VL when compared to 
the pilot study suggesting that these cells were not as exhausted as those cells found in the 
pilot study. Alternatively, as noted above in section 5.3, cryopreservation may have led to the 
loss of exhausted Tim-3 cells. Also, a similar trend was observed for Fas/CD95 expression.  
 
Wang et al., (2011), found that Tim-3 was up-regulated on virus-specific CD8+ T cells in 
patients with chronic progressive HIV-1 infection and that Tim-3 was up-regulated on 
antigen-specific CD8+ T cells in patients with active TB. This illustrates that the inhibitory 
receptor and the ligand interaction have a role in host immunity to HIV-1 and TB. In a normal 
immune response, there would be a confirmatory interaction of the antigen T cell receptor in 
addition to secondary co-stimulation. At the end of an immune response there is a switch to 
co-inhibition to restore the immune system to a homeostatic set point. However, in chronic 
infection, co-stimulatory interactions (B7 and CD28) are up-regulated even if the antigen is 
cleared, which over extended periods of time may lead to immune exhaustion. 
5.6 Fas was well expressed on CD8+ T cells 
CD95/Fas expression on CD8+ T cells was highest in the HIV-1/TB co-infected group for 
both studies. This was in accordance with a review article by Alimonti et al., (2003), who also 
found that HIV-1 infection resulted in both CD4+ and CD8+ T cells expressing higher levels of 
Fas and undergoing apoptosis more readily than non-infected individuals. Our CD8+ T cell 
data confirms up-regulated expression in the HIV positive and co-infected groups, which is 
related to T cell activation. CD4 data was problematic for both the pilot and the main study 
as it was assumed that CD4+ T cell expression of Fas would follow the same expression 
pattern as CD8+ T cells. In the pilot study, Fas expression on CD4+ T cells was highest in the 
control group; this may be due to the CD4+ T cells undergoing apoptosis during the ex vivo 
manipulation, therefore, apparent high Fas expression may be lost and the decrease may 
not be a true reflection for the pilot study. While in the main study, Fas on CD4+ T cells was 
equally expressed across all three groups suggesting that HIV-uninfected individuals are 
experiencing equal levels of cell apoptosis as individuals who are co-infected with HIV and 
TB. This does not follow the findings of the literature as Hertoghe et al., (2000), states that 
the expression of Fas is increased on both CD4+ and CD8+ T cells in both HIV-1 and co-
infection groups with the highest level of Fas expression found on CD8+ T cells with up to 
75% expression when compared to the current main study of approximately 62% expression 
on the co-infected group (p<0.05). Similarly, in the pilot study, CD8+ T cells display 
approximate 75% expression (p<0.01) of Fas in the co-infected groups which appears to be 
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in line with the literature. The high level of Fas expression combined with exhaustion implies 
that cells are both functionally susceptible to death in chronic infection.     
5.7 Expression of PD-1 was higher on frozen PBMCs on both CD4+ and CD8+ T 
cells 
PD-1 on CD8+ T cells was highly expressed on both fresh and frozen samples in our study. 
On fresh whole blood PD-1 expression was over 4 times higher in the HIV-1 positive group 
than the control group. On frozen PBMCs, PD-1 was expressed on 3 times as many cells in 
the HIV-1 positive and co-infected groups than the control group. The expression in the HIV-
1 positive and co-infected groups appeared to be similar.  
 
On fresh whole blood, PD-1 expression on CD4+ T cells was significantly different between 
the different groups with a 1.2 times higher expression in the HIV-1 positive group than the 
co-infected group. PD-1 expression appeared to be highest in the control group which was 
1.4 times higher than in the HIV-1 positive group. In comparison, PD-1 expression on frozen 
PBMCs did not differ significantly across the groups as expected. The overall expression of 
PD-1 in the HIV positive group was 5% for fresh whole blood and 53% for frozen PBMCs. 
Campbell et al., (2009), investigated the expression of PD-1 using fresh whole blood 
compared to frozen PBMCs and their findings suggested that cryopreservation does have a 
negative effect on this surface marker expression. Furthermore, Campbell et al., (2009), 
found that cryopreservation has little effect on the expression of PD-1 on CD4+ T cells when 
compared to fresh whole blood, however, on CD8+ T cells there was a 2.8 times decrease in 
PD-1 which underwent cryopreservation when compared to fresh samples.   
 
5.8 Expression of PD-1 and LAG-3 correlate on CD8+ T cells; whereas PD-1 
expression does not correlate with 2B4  
LAG-3 is described in the literature as a marker which down regulates T cell effector function 
when the cell is exposed to chronic viral infection (Sega et al., 2014). In the main study LAG-
3 displayed low levels of expression on the infected groups (approximately 2.7%) and 
highest levels of expression on the control group (3.3%) for both CD4+ and CD8+ T cells 
which is not in accordance with most of the literature. In favour of our current findings, 
Bertram et al., (2010), found that LAG-3 expression on CD8+ T cells exposed to chronic viral 
infection to be lower than 5%. Alternatively, Juno et al., (2015), reports that LAG-3 is highly 
expressed on the surface of exhausted CD8+ T cells and in healthy controls the expression 
is also negligible. Grosso et al., (2007), found that LAG-3 was expressed in low amounts on 
antigen naïve CD8+ T cells, and upon exposure to the antigen, LAG-3 was up-regulated. As 
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discussed earlier, cryopreservation and apoptosis of the most exhausted cells may be 
playing a role.   
 
In the current study, the co-expression of PD-1 and LAG-3 was significantly different on 
CD8+ T cells between the three group (p<0.05) with a positive correlation (r=0.3668, p= 
0.01) implying that as PD-1 expression increases, so does the expression of LAG-3. The 
expression of these markers together was 3.8 times higher in the infected groups than in the 
control group which is in line with the findings of the current literature which also found that 
co-expression of these two markers was up-regulated on exhausted CD8+ T cells (Grosso et 
al., 2007; Grosso et al., 2009; Wherry 2011). Hurst et al., (2015), found that co expression of 
PD-1 and LAG-3 to be 5% while in our study co-expression was 1.2%. In the main study, 
PD-1 single expression was 31.6% which is 26 times higher than co-expression with LAG-3. 
This could suggest that PD-1 is a marker that is best for characterising exhausted T cells.  
Similar to the main study, Hurst et al., (2015), found that PD-1 expression was highest when 
expressed singly with 15% on CD8+ T cells. Dual expression of these markers on CD4+ T 
cells did not differ significantly which could possibly be due to the initial questionable PD-1 
expression on these cells. Similar to our study, Khaitian and Unutmaz, (2011), found that 
while PD-1 was also highly expressed on exhausted CD4+ and CD8+ T, and both cell types 
were unable to elicit the correct effector function in the presence of chronic viral infection.  
 
2B4 is an inhibitory marker expressed on the cell surface of T cells which are experiencing 
stress due to chronic viral infection (Larsson et al., 2013). In the current study, 2B4 and PD-1 
were significantly co-expressed (27%) on CD8+ T cells in the infected groups (p<0.01). In 
support of our findings, Pombo et al., (2015), examined the co-expression pattern of PD-1 
and 2B4 and found that together the expression was almost 50% on CD8+ T cells of the HIV-
1 positive group. While there was no correlation between these two markers, 2B4 has been 
reported to co-express with PD-1, Tim-3 and LAG-3 on exhausted T cells (Wherry, 2011; 
Yamamoto et al., 2011). 2B4 single expression on CD8+ T cells was even higher than co-
expression with 75% expression on the co-infected group. Low expression of 2B4 on CD8+ T 
cells were found to be beneficial to the cell and increase proliferation while high expression 
of 2B4 was associated with a decrease in T cell effector function of HIV-1 positive individuals 
(Aldy et al., 2011). With 2B4 being so highly co-expressed with PD-1 on CD8+ T cells; it 
suggests that perhaps 2B4 is a strong marker for disease progression to AIDS.              
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5.9 Co-expression of LAG-3 and 2B4 as well as Tim-3 and 2B4 displayed 
unusual expression patterns on CD4+ T cells.  
In the literature, CD8+ T cells are well studied in relation to immune exhaustion. Conversely, 
CD4+ T cells are less well described and display unusual patterns of expression of all the 
exhaustion markers as also seen in the current study. Furthermore, marker expression is 
difficult to generalise due to low end stage CD4 count which is a hallmark of this disease and 
of many individuals in the current study. Nevertheless, expression of Tim-3 resulted in a 
positive correlation with 2B4 and there was dual expression of 3.5%. Similarly, LAG-3 and 
2B4 also resulted in a positive correlation and co-expression was found to be the highest on 
the control group. While it seems problematic to find high expression of a marker on the 
control groups, Costantini et al., (2003), also found that cryopreservation may significantly 
increase effector function related markers on T cells. Hurst et al., (2015), found that LAG-3 
alone was highly expressed on CD4+ T cells with almost 24% expression when compared to 
the current study of 1.3% in HIV-1 positive group. Additionally single marker expression of 
Tim-3 was found to be 50.2% which is drastically higher than the almost 20% found in the 
present study. Moreover, the main study showed that Tim-3 and LAG-3 displayed higher 
levels of expression when expressed independently than collectively, which was also found 
to be true for Hurst et al., (2015).  
 
5.10 Proliferation/ Functional responsiveness 
The proliferation assays were performed in an attempt to block Tim-3 and PD-1 
independently and simultaneously in order to improve T cell function. According to the 
literature, blocking PD-1 alone proved to be beneficial in improving T cell effector function by 
restoring proliferative and survival capabilities (Kulpa et al., 2013). Likewise, T cells which 
express high levels of PD-1 on the cell surface are also more likely to be associated with 
apoptosis (Nilsson et al., 2006). In the current study, it was found that blocking PD-1 alone 
did not significantly restore T cell proliferation ability with a low median proliferation value. 
Campbell et al., (2009), found that PD-1 and PD-L1 binding was significantly decreased on 
CD8+T cells which had been cryopreserved. In the current study, blocking Tim-3 alone 
appeared to have the greatest impact on proliferative ability for both CD4+ and CD8+ T cells 
groups, however this was statistically insignificant. Similar to our study, Kuchroo et al., 
(2014) found that by blocking Tim-3 alone there was some improvement in T cell 
capabilities.   
 
Conversely, blocking of both PD-1 and Tim-3 did not improve the proliferative capabilities of 
the CD4+ or CD8+T cells which was unexpected as blocking Tim-3 alone had a favourable 
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outcome. According to the literature Tim-3 and PD-1 co-expression on T cells is associated 
with an exhausted phenotype and blocking these surface markers has resulted in an 
increase in T cell function (Pauken and Wherry, 2015). Blocking antibodies may not have 
been optimally titrated in the current study or the cells were not preforming optimally due to 
cryopreservation procedures. Owen et al., (2007), found that T cells which have been 
exposed to long term cryopreservation have a loss in T cell responsiveness in both CD4+ 
and to a worse extent, CD8+ T cells. Furthermore, Owen et al., (2007), found that the T cells 
which had been stored for one year or longer displayed the worst T cell responses compared 
to T cells which had only been stored for a few months. According to the current study, the 
cells were cryopreserved for 36 months before these experiments were conducted which 
could perhaps explain why the cells preformed so poorly. However, there was slight change 
in T cell proliferation events which means that the assay worked to some extent and the 
proof of concept was achieved. In the future, fresh whole blood would be the preferred 
working sample to use in this type of proliferation assay.    
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5.11 Limitations and strengths of the study 
To the best of our knowledge, this study was the first to compare a broad and extensive 
range of activation and inhibitory surface markers simultaneously in chronically HIV-1 and 
HIV/TB co-infected South Africans. By conducting this study, we were able to observe 
marker expression patterns in the South African HIV-1 and HIV-1/TB infected populations. 
This could prove beneficial as a focus for further research into new therapeutic and 
treatment strategies to alleviate exhaustion phenotype and restore immune cell function. 
Despite the interesting findings, this study did have limitations. The co-infected group was 
small, and as such yielded some inconclusive data on the significant impact of TB co-
infection. In addition, in order to ascertain the contribution of TB alone to T cell activation and 
exhaustion, ideally a TB mono-infected group should have been included. 
The study involved two sub-studies – one utilizing fresh whole blood and the other 
cryopreserved PBMCs. The reason for this is that the earlier sub-study was a general survey 
study with insufficient material to cryopreserve the PBMC. The latter study was performed on 
material stored from another unrelated study. Were this study to be repeated - in order to 
fully understand the effects of cryopreservation on the cells a pre-experiment could have 
been included to ascertain marker variation on the cells found between the two sub-studies. 
This pre-experiment could consist of a small amount of blood collected from the HIV positive 
individuals (n=15) from the first pilot study as well as the main study (n=15) and exposed the 
cells to both fresh and frozen methodologies. By conducting this pre-experiment, a clearer 
understanding of the effects of cryopreservation on cell activation and cell death would be 
possible.  
 
In certain instances, frozen PBMCs expressed unusual marker patterns  which could be as a 
result of induced activation and/or cell death from exposing the cells to DMSO during the 
freezing and  thawing processes.    
 
The functional assay did not perform as well as expected, which could be due to the initial 
binding of the αCD3 antibody to CD3 receptor of the T cell while loading the cells into the 96 
well plates. While there were wash steps conducted, the CD3 receptors may have been 
saturated with αCD3 which could have resulted in the inability of the staining CD3 antibodies 
to bind to the respective receptors. Gating on CD45 instead of CD3 may have proven to be 
more beneficial surface marker in the monitoring of T cell proliferation ability.          
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In summary, the findings from this study also point to the importance of using fresh blood 
where possible for both phenotyping and functional profiling, and also standardized flow 
cytometry protocols throughout. 
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CHAPTER 6: CONCLUSION  
CD4+ T cells are responsible for defending the body against tuberculosis by means of 
activating infected macrophages and enhancing their bactericidal abilities. On infection with 
HIV-1, CD4+ cells are drastically diminished, as evidenced by falling CD4 count. In a TB 
situation, the impairment of the CD4+ T cell compartment, results in impaired macrophage 
function which in turn manifests in uncontrolled TB replication. This in turn would increase 
the antigenic stimulation of T-cells – promoting exhaustion and/or death. The two diseases 
thus amplify the overall morbidity – with dire consequences for the host.  
In this study we showed that chronic HIV-1 infection was accompanied by a significant 
increase in CD38 (p<0.0001), CD95 (p<0.01), PD-1 (p<0.01) and Tim-3 (p<0.1) expression 
on CD8+ T cells in fresh whole blood. TB co-infection led to significantly elevated expression 
of CD38, CD95 and Tim-3, but not PD-1 (all p<0.05).  
CD8+ T cell-associated CD38, CD95, and PD-1 displayed a similar trend in cryopreserved 
PBMCs in a separate cohort, with significant higher expression in the infected groups 
(p<0.0001, p<0.05, and p<0.0001, respectively), In contrast to the whole blood finding, Tim-3 
expression was consistently <10%, with no difference between the groups. The novel 
marker 2B4 showed high level baseline expression (median 59.2%) which was significantly 
increased in the HIV and HIV/TB groups (69.6% and 75.1% respectively, p=0.025). LAG-3 
was however poorly expressed. Co-expression of PD-1 and 2B4 as well as CD95 and CD38 
was also significantly increased (p<0.0001 for both). 
 
These findings suggest that immune dysfunction is apparent in both HIV-1 infection and HIV-
1/TB co-infection. Nevertheless, PD-1 and 2B4 single marker expression (on both CD4+ and 
CD8+ T cells) as well as co-expression on CD8+ T cells, suggests a potentially co-ordinated 
up-regulation pattern between these two markers. 2B4 is an exciting biomarker as its high 
level expression patterns, its correlation to LAG-3 expression and its significant PD-1 co-
expression, suggest it plays a major role in regulating T cell function. Although blocking Tim-
3 and PD-1 on CD4+ and CD8+ T cells did not appear to have beneficial effects on T cell 
proliferation in this study, the functional implications of manipulating these exhaustion 
pathways needs to be elucidated. Additional work is needed to ascertain conclusively 
whether blocking these markers plus 2B4 or LAG-3 could restore functional integrity.  
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Addendum B 
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Addendum C: 
Single and dual expression tables for CD4+ T cells 
Addendum C Table 1 Significance of Single Expression on CD4+ T cells (median 
values) 
  
 
Addendum C Table 2 Significance of Dual Expression on CD4+ T cells (median 
values) 
 p-value Control HIV+ HIV+/TB+ 
PD-1 and Tim-3 0.6 5.1 7.2 8.0 
LAG-3 and PD-1 0.9 0.7 0.5 0.2 
PD-1 and 2B4 0.7 3.9 5.4 3.8 
Tim-3 and LAG-3 0.2 1.6 0.5 0.3 
Tim-3 and 2B4* 0.01 7.3 3.5 2.4 
LAG-3 and 2B4* 0.01 1.0 0.2 0.2 
Surface markers indicated with an * denote significance 
 p-value Control HIV+ HIV+/TB+ 
PD-1 0.4 53.5 53.9 58.4 
Tim-3 0.6 26.6 19.6 18.8 
LAG-3 0.1 2.9 1.3 1.4 
2B4* 0.02 21.6 10.7 16.1 
CD38* 0.0001 16.7 42.8 41.7 
HLA-DR* 0.0001 1.9 5.7 5.9 
Fas* 0.4 53.5 52.9 58.4 
Surface markers indicated with an * denote significance 
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Addendum C Table 3 Significance of Dual Expression on CD4+ T cells (median values) 
 p-value Control HIV+ HIV+/TB+ 
PD-1 and Fas* 0.01 7.2 16.7 22.8 
PD-1 and CD38* 0.0001 0.5 7.5 4.9 
PD-1 and HLA-DR* 0.0001 0.2 1.6 1.2 
HLA-DR and CD38* 0.0001 1.4 4.4 4.9 
Fas and CD38* 0.0001 0.4 2.2 2.4 
Fas and HLA-DR* 0.0001 0.2 1.0 1.4 
Surface markers indicated with an * denote significance 
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Addendum D: 
Single and dual expression tables for CD8+ T cells 
 
Addendum D Table 1 Significance of Dual Expression on CD8+ T cells (median values) 
 p-value Control HIV
+
 HIV
+
/TB
+
 
PD-1 and Tim-3 0.2 1.5 2.6 1.9 
LAG-3 and PD-1* 0.01 0.4 1.2 1.1 
PD-1 and 2B4* 0.0001 8.3 27.2 25.6 
Tim-3 and LAG-3 0.9 0.5 0.4 0.1 
Tim-3 and 2B4 0.6 5.6 3.8 3.1 
LAG-3 and 2B4 0.6 1.9 2.6 1.8 
Surface markers indicated with an * denote significance 
Addendum D Table 2 Significance of Single Expression on CD8+ T cells (median 
values) 
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 p-value Control HIV+ HIV+/TB+ 
PD-1* 0.0001 9.5 31.6 34.9 
Tim-3 0.6 6.3 5.5 3.5 
LAG-3 0.9 3.3 3.2 2.2 
2B4* 0.01 59.2 69.6 75.1 
CD38* 0.0001 49.6 88.6 80.3 
HLA-DR 0.5 100. 99.98 100.00 
Fas* 0.01 15.9 34.0 43.9 
Surface markers indicated with an * denote significance 
Addendum D Table 3 Significance of Dual Expression on CD8+ T cells (median 
values) 
 p-value Control HIV+ HIV+/TB+ 
PD-1 and Fas* 0.01 6.0 14.9 22.0 
PD-1 and CD38* 0.0001 1.9 17.1 18.6 
PD-1 and HLA-DR* 0.01 32.7 37.8 43.9 
HLA-DR and CD38* 0.0001 5.9 38.6 25.4 
Fas and CD38* 0.0001 1.8 14.6 18.4 
Fas and HLA-DR* 0.01 14.9 31.9 43.5 
Surface markers indicated with an * denote significance 
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Addendum E: 
Correlation tables for CD4+ T cells 
Addendum E Table 1 Co-expression on CD4+ T cells correlations  
  r value star rating direction p-value 
PD-1 Fas 0.5791 **** + 0.01 
      
Tim-3 PD-1 0.4428 **** + 0.01 
 2B4 0.4918 **** + 0.05 
 LAG-3 0.9195 **** + 0.01 
 HLA-DR 0.3224 ** + 0.01 
 Fas 0.6437 **** + 0.01 
      
HLA-DR VL 0.2547 * + 0.05 
 PD-1 0.4743 **** + 0.01 
 Fas 0.3945 *** + 0.01 
 CD38 ON 4 0.6013 **** + 0.01 
      
2B4 PD-1 0.5977 **** + 0.01 
 LAG-3 0.5579 **** + 0.01 
 Fas 0.3990 *** + 0.01 
 CD38 ON 4 0.3269 ** - 0.01 
Stellenbosch University  https://scholar.sun.ac.za
129 | P a g e   
 
  
      
LAG-3 PD-1 0.4110 *** + 0.01 
 Fas 0.5327 **** + 0.01 
      
CD38 2B4 0.4130 *** - 0.01 
 LAG-3 0.2913 * - 0.05 
 HLA-DR 0.3871 *** + 0.01 
 CD4 COUNT 0.3588 ** - 0.01 
 VL 0.4104 *** + 0.01 
 Fas 0.1464 X X 0.21 
      
CD4 COUNT HLA-DR 0.3264 ** - 0.05 
      
VL HLA-DR 0.2547 * + 0.05 
 CD4 COUNT 0.4630 **** - 0.01 
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Addendum F: 
Correlation tables for CD8+ T cells 
Addendum F Table 1 Co-expression on CD8+ T cells correlations 
Fas PD-1 0.2808 * + 0.05 
 CD4 0.0196 X X 0.9 
 Tim-3 0.4386 *** + 0.01 
 2B4 0.2842 * + 0.05 
 LAG-3 0.5752 **** + 0.01 
 HLA-DR 0.4528 **** + 0.01 
 VL 0.0615 X X 0.6 
      
PD-1 Tim-3 0.3825 *** + 0.01 
 LAG-3 0.3668 ** + 0.01 
 2B4 0.2065 X X 0.1 
      
Tim-3 2B4 0.2722 * + 0.05 
 LAG-3 0.8799 **** + 0.01 
 CD4 COUNT 0.2366 * - 0.05 
      
HLA-DR LAG-3 0.2577 * + 0.05 
      
2B4 LAG-3 0.3695 ** + 0.01 
      
CD4 COUNT CD38 0.3588 ** - 0.01 
 VL 0.4630 **** - 0.01 
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